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ABSTRACT 
 
 
The role of class IA PI3K in cell growth and cell cycle entry is well described.  In 
addition to its activation in early G1 phase, PI3K is also activated in late G1 and is essential 
for G1/S phase transition.  The exact mechanism of PI3K activation and the role it plays in 
G1/S phase transition is nonetheless poorly understood.  Our observations indicate that 
activation of Ras and Tyr kinases is required for late G1 PI3K activation.  Inhibition of late 
G1 PI3K activity results in low c-Myc and cyclin A expression, impaired Cdk2 activity, and 
reduced loading of MCM2 (minichromosome maintenance protein) onto chromatin.  
Conditional activation of c-Myc in late G1 or expression of a stable c-Myc mutant 
counteracted PI3K inhibition in late G1 and restored S phase entry.  Based these findings, we 
concluded that Tyr kinases and Ras cooperate to induce the second PI3K activity peak in G1, 
which mediates initiation of DNA synthesis by inducing c-Myc stabilization. 
 
Class IA PI3K is reported to localise to the nuclei in various cell types.  We further 
studied the PI3K isoforms in the nucleus and their mode of translocation to the nucleus.  The 
work presented in this thesis indicates that, of the ubiquitously expressed p110  and p110  
class IA isoforms, p110  was mainly nuclear, whereas p110  was mostly cytoplasmic.  We 
also found that, of the regulatory subunits p85  and p85 , p85  was nuclear and p85  was 
mostly cytoplasmic.  In addition, we showed that p110  does not translocate to the nucleus on 
its own, but requires p85  association for nuclear translocation; this phenomenon is 
facilitated by a polybasic nuclear localization sequence in the p110  C2 domain.  
Nonetheless, the overexpressed p85 /p110  complexes did not show physiological nuclear 
staining as seen for the endogenous proteins.  We identified PCNA association to p110 , 
which further helps nuclear translocation of p85 /p110  complexes. 
To gain a better understanding of nuclear p110  function, we pulled down p110 -
associated proteins in the nucleus.  Mass spectra analysis showed DNA checkpoint proteins 
RAD17, RAD9, RAD50, among others.  Hence, we examined the role of p110  in DNA 
repair.  We observed activation of p110  following ultraviolet/ionizing radiation (UV/IR) 
exposure.  We found RAD17 association to p110  only after UV/IR exposure.  Using RNA 
interference in NIH3T3 cells, and knocked-out, immortalised murine embryonic fibroblasts, 
we demonstrate that p110 -deficient cells showed large numbers of chromosomes and 
aberrant chromosome breaks, implicating a p110  function in the maintenance of genomic 
integrity.  We identified defective ATR (inactive Chk1 and reduced accumulation of 
p-RAD17 at DSB foci) and ATM (reduced SMC1 and -H2AX phosphorylation) signalling 
pathways.  These defects were at the level of DNA sensor protein recruitment at the DNA 
damage sites, as we observed defective mobility of the DSB sensor protein NBS1 at damage 
sites.  We also found a direct role of p110  in the regulation of DNA repair; p110  activation 
and its colocalisation with -H2AX at the DNA damage area imply an integrative role for 
p110  in the aftermath of DNA damage responses.  In conclusion, we provide a molecular 
rationale as to how p110  integrates the regulation of different signalling pathways in 
response to DNA damage and show that depletion of p110  disrupts activation of DNA 
checkpoint proteins. 
 
Thesis Supervisor: Ana Clara Carrera 
Title: Professor 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated with respect to the man who inspired me, 
my grandfather 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGMENTS 
 
First of all, I would like to acknowledge my thesis advisor, Ana Carrera, for giving me an 
opportunity to perform my doctoral thesis under her guidance.  I am also grateful to her for 
unwavering support and sound advice as I embarked on new kinds of investigation in the lab.  
Her consistent encouragement and good judgement has resulted in a productive lab with a lot 
of good company.  Working in her lab has been an invaluable experience for me; she has 
taught us that a lot more than good data is needed to be a mature and successful researcher. 
 
For help, advice and their efforts, I sincerely thank the members of Ana’s lab, past and 
present, over the last five years.  In particular I would like to thank (past members) Zaira, 
Mónica, Domingo, Almira, Álvaro (now in lab 418) for helping me in adapting to the new 
change in my life.  Of the present members, I thank Miriam for being a good friend and 
colleague, Abel and Vicen for being wonderful guys and for the discussions we had during 
late evening stays in the lab; both have also been good friends inside and outside the lab.  
Thanks are also due to Ana González, Susana, Jesús, Vir, Isabela, Lorena, Carmen and Isa for 
their friendliness and collaboration. Vicen and Susana also helped me in Spanish translation 
of part of the thesis.   All these colleagues have made my stay in the lab both enjoyable and 
productive, and this work would not have been possible without such great support.  
 
I would like to acknowledge Oscar Fernández-Capetillo and his lab members, who helped in 
conducting DNA damage experiments.  In particular, thanks to Juan Lu for arranging and 
reserving the microscope facility at the CNIO, and Diego for performing the laser based DNA 
damage experiments. 
 
I also thank all the DIO members, the CNB personnel department, the Biosecurity division, 
the microcomputing facility, and the security guards for their kind support; I could not have 
asked for more.  From the department, I want to acknowledge in particular César (415), Sonia 
(415), Cristina (418/412/16), as well as Laura, Pilar, Bea, Borja and Oscar (all in 416), Quim 
(418), Jens (415), Valeria (413), Jesús Chamorro and Juanjo (413), Mohi (Genomics 
Facility), Antonio, Maria and Coral (Administrative department), as well as all past and 
current members of the DIO kitchen staff for their support and timely help.  I would also like 
to thank Sara and Mari Carmen for their help in conducting flow cytometry analysis.  Special 
thanks to Mario (416), Santos (415), Isabel Mérida (414) and Karel (411) for their sound 
advice and reagents at many junctures over the years. 
 
A very special thanks to Cathy, who has helped me throughout these years with her critical 
editing, or I should say simplifying our manuscript content to make our research clear for 
non-native-English speakers around the world.  Thank you, Cathy, for being such a wonderful 
person.  
 
Most importantly, I owe thanks to all my friends outside the world of science who made my 
stay easier and more fun over the last five years.  My biggest support has been my wife and 
lifeline, Rashmi.  Together we have navigated through some difficult times in research and in 
life.  Raising our daughter Tishya has been a challenging and rewarding experience.  Lastly, I 
cannot thank enough my parents and my late grandfather, to whom I owe everything I have. 
 
 
 
 
 
 
 
 
 
Articles Published 
 
 
1. Marqués M*, Kumar A*, Poveda AM, Zuluaga S, Hernández C, Jackson S, Pasero P 
and Carrera AC. 2009. Specific function of phosphoinositide 3-kinase beta in the 
control of DNA replication. Proc Natl Aacad Sci USA 106:7525-7530 *equal 
contribution 
2. Marqués M, Kumar A, Cortés I, Gonzalez-García A, Hernández C, Moreno-Ortiz 
MC and Carrera AC. 2008. Phosphoinositide 3-kinases p110alpha and p110beta 
regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell 
Biol 28(8); 2803-14. 
3. Alcázar I, Marqués M, Kumar A, Hirsch E, Wymann M, Carrera AC, Barber DF. 
2007. Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell 
activation. J Exp Med 204; 2977-87. 
4. Kumar A, Carrera AC. 2007. New functions for PI3K in the control of cell division. 
Cell Cycle, 6; 1696-8. 
5. García Z, Silio V, Marqués M, Cortés I, Kumar A, Hernandez C, Checa AI, Serrano 
A, Carrera AC. 2006. A PI3K activity-independent function of p85 regulatory subunit 
in control of mammalian cytokinesis. EMBO J 25; 4740-51. 
6. Kumar A, Marqués M, Carrera AC. 2006. Phosphoinositide 3-kinase activation in 
late G1 is required for c-Myc stabilization and S phase entry. Mol Cell Biol 26(23); 
9116-25. 
7. García Z, Kumar A, Marqués M, Cortés I, Carrera AC. 2006. Phosphoinositide 3-
kinase controls early and late events in mammalian cell division. EMBO J 25(4); 
655-61. 
8. Kumar A, Vaid A, Syin C, Sharma P. 2004. PfPKB, a novel protein kinase B-like 
enzyme from Plasmodium falciparum: I. Identification, characterization, and possible 
role in parasite development. J Biol Chem 279(23); 24255-64. 
9. Kumar A, Megías D, Fernadez-Capetillo O, Carrera AC. Phosphoinositide 3-kinase 
beta is essential for sensing DNA damage.  Manuscript in preparation. 
 
Patent Application: Carrera AC, Marqués M and Kumar A. Role of p110  in DNA 
repair. 
 
 
 
  1 
TABLE OF CONTENTS 
 
RESUMEN ESPAÑOL ………………………………………………………………………       7 
Resumen……………………………………………………………………... ..........       9 
Resumen Introducción………………………………………………………………    11 
Objetivos…………………………………………………………………… .............    15 
Resumen Resultados…………………………………………………………….…..    17 
Conclusiones…………………………………………………………………...........     19 
Resumen Discusión………………………………………………………………….    21 
 
INTRODUCTION………………………………………………………………………..     25 
SECTION 1. Growth Factor Receptos……………………………………….…...     27 
1.1)      Receptor tyrosine kinases 
1.2)      G protein-coupled receptor 
     
SECTION 2. Signal Transduction Proteins………………………………………      28 
2.1)      RAS 
2.2)      Mitogen Activated Protein Kinases 
 
SECTION 3. Phosphoinositides-3 Kinases………………………………………..      29 
3.1)      Class I PI3K 
3.1.1) Class IA PI3K 
3.1.1.1)      PDK1 
3.1.1.2)      Protein kinase B 
3.1.2) Class IB PI3K 
3.1.3) PTEN 
3.2)      Class II PI3K 
3.3)      Class III PI3K 
3.4)      Class IV PI3K 
 
SECTION 4. Nuclear Class IA Phosphoinositide-3-Kinase Signalling………….      34 
 4.1)      Role of nuclear Akt 
SECTION 5. Nuclear Regulatory Proteins………………………………………..     36 
5.1)        c-Myc 
SECTION 6. Cell Cycle…………………………………………………………….      37 
6.1) From G0 to S 
6.1.1) Progression through G1 phase 
6.1.2) Progression through late G1 to S phase 
6.2)       S phase entry and progression 
6.3)      G2 phase 
6.4)      Mitosis 
6.4.1) Prophase 
6.4.2) Metaphase 
6.4.3) Anaphase 
6.4.4) Telophase     
 
6.5)      Cytokinesis 
6.6)      Class IA PI3K and the cell cycle 
 
SECTION 7. DNA Damage Response…………………………………………….       45 
7.1) Sensors 
7.1.1) MRN complex 
7.1.2) Rad17-RFC and the 9-1-1 complex 
7.1.3) ATM and ATR 
7.2)      Mediators 
7.3)      Transducers 
  2 
 
AIMS OF THE STUDY………………………………………………………………...        49 
 
MATERIAL & METHODS…………………………………………………………...         51 
1. Antibodies and reagents……………………………………………………………...         53 
1.1)      Antibodies 
1.2)      Reagents 
2. Cell Culture……………………………………………………………………………        54 
2.1)      Cells and cell lines 
2.2)      Transfection and retroviral transduction 
2.3)      Synchronization of NIH3T3 cells 
2.4)      Cell cycle analysis 
2.5)      Pulse-chase assay 
2.6)      Inhibitor treatment 
3. DNAs, Northern blot, DNA damage, real time DNA damage……………………...        55 
3.1)       cDNA 
3.2)       mRNA analysis (Northern Blot) 
3.3)       Ultraviolet and Ionizing radiation treatment 
3.4)      Real-time recruitment of DNA repair proteins to the micro-laser   
generated sites of   DNA damage 
4. Biochemical Assays and Immunofluorescence………………………………………       57 
4.1)     Cell lysis, subcellular fractionation 
4.2)       Immunoprecipitation and Western blotting 
4.3)       PI3K assays 
4.4)       Cyclin/Cdk kinase assays 
4.5)     Pull-down assay 
4.6)        Immunofluorescence 
 
RESULTS……………………………………………………………………………….         61 
1. PI3K regulates G1/S phase transition…………………………………………….          63 
1.1)        Cell cycle progression  
1.2) PI3K activity in late G1 induces PKB activation that correlates with increased c-Myc 
protein   levels 
1.3)       Ras and Tyr kinases activate PI3K in late G1 
1.4) Late G1 PI3K inhibition reduces c-Myc and cyclin A levels as well as CDK2 activity 
1.5) Conditional c-Myc-ER activation rescues S phase entry in PI3K inhibitor-treated cells 
1.6) Expression of a GSK3-resistant c-Myc mutant rescues the cell cycle entry defects induced 
by inhibiting PI3K activity in late G1 
1.7) c-MycT58A expression rescues cyclin A expression, CDK2 activity, and MCM2 loading 
defects induced by PI3K inhibition in late G1 
1.8)        Conclusions 
 
2. Mechanisms controlling nuclear localisation of p110…………………………..        76 
2.1)      Class IA PI3K isoforms p110 and p110 have distinct intracellular localisation 
2.2)      p110 localisation in the nucleus is transient and activation-dependent 
2.3)      p110 overexpression results in cytoplasmic retention 
2.4)      p85 promotes p110 nuclear localisation 
2.5)      C2-domain in p110 conatins an nuclear localisatiob sequence 
2.6)      Preferential association of p110 with p85 compared to p85 
2.7)       p85 shuttling between nucleus and cytoplasm regulates p110 nuclear export 
  3 
2.8)       p85 N-terminal region contain a nuclear export signal 
2.9) p85/p110 associates with PCNA and translocates more efficiently to the nucleus 
2.10) Conclusions 
 
3. p110  
3.1)       Cells with reduced p110 levels undergo apoptosis following ultraviolet radiation 
3.2)       p110-deficient cells show genomic instability 
3.3)       p110 is activated by exposure to UV or ionising radiation 
3.4)       p110 associates with DNA repair protein in a radiation-dependent manner 
3.5)        p110 regulates the ATR pathway after UV exposure 
3.6)        p110 affects the ATR pathway by inactivation of its sensor protein 
3.7)       p110 also regulates activation of the ATM pathway 
3.8)       Rapid p110 translocation to the DNA damage sites 
3.9)        p110 controls NBS1 immobilisation at DNA damage sites 
3.10) p110 regulates 53BP1 loading at DNA damage sites 
3.11) PCNA a marker for DSB and requires p110 for loading at DNA damage sites 
3.12) PCNA and NBS1 translocates simultaneously to the DNA damaged areas 
3.13) Conclusions 
 
CONCLUSIONS……………………………………………………………………………..        95 
DISCUSSION…………………………………………………………………………………       97 
REFERENCES…………………………………………………………………………….......   109 
ARTICLES …………………………………………………………………………………….   133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  5 
ABBREVIATIONS 
 
 
Ab Antibody 
APC Anaphase-promoting complex 
ATP Adenosine-5'-triphosphate 
BCR Breakpoint cluster region 
BSA Bovine serum albumin 
BrDU Bromodeoxyuridine 
CAK CDK-activating kinase 
CDK Cyclin dependent kinase 
dCTP Deoxycytidine triphosphate 
CHK Check point kinase 
DTT Dithiothreitol 
DMSO Dimethyl sulphoxide 
DSB Double strand break 
DAPI 4',6-diamidino-2-phenylindole 
EGFR Epidermal growth factor receptor 
EDTA Ethylene diamine tetraacetic acid 
EGTA Ethylene glycol tetraacetic acid 
FBS Foetal bovine serum 
GFP Green fluorescent protein 
G1 Gap1 
GPCR G protein-coupled receptor 
G2 Gap2 
GTP Guanosine-5'-triphosphate 
GDP Guanosine diphosphate 
GST-tag Tag derived from glutathione S-transferase 
GF Growth factor 
HA-tag Tag derived from haemagglutinin 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IR Ionising radiation 
MAPK Mitogen-activated protein kinase 
MCM Minichromosome maintenance  
MEF Mouse embryonic fibroblast 
NLS Nuclear localisation sequence 
NES Nuclear export sequence 
NGF Nerve growth factor 
PAGE Polyacrylamide gel electrophoresis 
pol Polymerase 
PCR Polymerase chain reaction 
PH Pleckstrin homology 
PBS Phosphate-buffered saline 
PIP2 Phosphatidylinositol biphosphate 
PIP3 Phosphatidylinositol triphosphate 
PI Phosphatidylinositol 
PDGF Platelet-derived growth factor 
RFP Red fluorescent protein 
RPM Rotations per minute 
RTK Receptor tyrosine kinase 
RC Replication complex 
RBD Ras-binding domain 
SH3 Src homology 3 
SH2 Src homology 2 
SSC Saline-sodium citrate buffer 
SDS Sodium dodecyl sulphate 
S phase Synthesis phase 
TX-100 Triton X-100 
TyrK Tyrosine kinase 
TF Transcription factor 
UV Ultraviolet 
 
 
  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESUMEN ESPAÑOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  9 
RESUMEN 
 
El papel de la PI3K de clase IA  en crecimiento y entrada en ciclo celular está bien descrito. 
Además de su activación en fase G1 temprana, la PI3K   también se activa en fase G1 tardía y 
resulta esencial para la transición G1/S. Sin embargo, el mecanismo de activación y el papel que 
juega en la transición G1/S no se conoce y parte de nuestro trabajo ha sido estudiar la activación y 
función de PI3K en este proceso. Nuestras observaciones indican que Ras y Tyr- quinasas inducen 
la activación de  PI3K en la fase G1 tardía. La inhibición de la actividad de PI3K en este estadío 
provoca una disminución en la expresión de c-Myc y ciclina A, alteración de la actividad Cdk2 y 
reducción en el reclutamiento de MCM2 a la cromatina. La activación condicional de c-Myc en 
fase G1 tardía o la expresión de un mutante de c-Myc resistente a degradación contrarresta la 
inhibición de PI3K en fase G1 tardía y restaura la entrada en fase S. Por ello concluimos que las 
Tyr quinasas y Ras colaboran para inducir el segundo pico de activación de PI3K en fase G1, el 
cual media el inicio de la síntesis de ADN estabilizando la expresión de c-Myc. 
Además de su papel esencial en ciclo celular, la PI3K de clase IA ha sido descrita en el 
núcleo de diferentes tipos celulares. Por ello, estudiamos que isoformas localizan en el núcleo y su 
modo de translocación. El trabajo presentado en esta tesis indica que de las dos isoformas 
expresadas de manera ubicua, p110 y p110, solo p110 se localiza en gran parte en el núcleo 
mientras que p110 es mayoritariamente citoplásmica. Hemos encontrado también que de las 
subunidades reguladoras p85 y p85, p85 posee una mayor localización nuclear mientras que 
p85  es esencialmente citoplásmica. Además, observamos que p110 no es capaz de translocarse 
al núcleo por si misma necesitando de la asociación de p85 para la correcta translocación al 
núcleo y que dicho translocación se facilita por una secuencia de localización nuclear polibásica 
presente en el dominio C2 de p110. Sin embargo, la expresión de p85/p110 exógenos fue 
insuficiente para promover la traslocación al núcleo completa de p85/p110, sugiriendo que otras 
proteínas se asocian fisiológicamente a estos complejos para inducir su localización nuclear. 
Hemos identificado que la asociación de PCNA a p110 favorece la translocación nuclear de 
p85/p110.  
Con objeto de tener alguna pista la función de p110 nuclear, hemos analizado que proteínas 
se asocian a p110 en el núcleo. Mediante análisis de espectroscopia de masas hemos encontrado 
entre otras, proteínas relacionadas con el control de la reparación del ADN como RAD 17, RAD9, 
RAD50.  Hemos estudiado el posible papel de p110 en reparación del ADN. Tras exposición a 
radiación UV/IR observamos activación de p110. También observamos asociación de RAD17 a 
p110. Mediante ARN de interferencia y MEFs inmortalizadas p110-/- encontramos que células 
deficientes para p110 presentan aneuploudía observándose células con un número elevado de 
cromosomas y roturas cromosómicas aberrantes, deduciéndose una función de p110 en el 
mantenimiento de la integridad genómica. Encontramos que p110 regula las vías de señalización 
ATR (Chk1 y p-RAD17) y ATM (SCM1 y H2AX). También identificamos que los defectos se 
producen a nivel de reclutamiento de las proteínas al lugar del daño en el ADN como por ejemplo 
la movilidad reducida de la proteína sensor de rotura doble NBS1  a los lugares de daño. En 
conjunto hemos determinado un papel directo de p110 en la regulación de la reparación del ADN; 
la activación de p110 y su colocalización con -H2AX en las zonas dañadas del ADN implican un 
papel integrador de p110 en las respuestas a daño en el ADN. Por todo ello, proporcionamos una 
explicación (justificación) molecular de cómo p110 es integradora  en la regulación de las 
diferentes vías de señalización implicadas en la respuesta al daño en el ADN y que su depleción 
afecta a la activación de las proteínas de control del ADN (checkpoint proteins). 
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INTRODUCCIÓN 
 
En eucariota superiores, la división celular es un proceso fundamental para el desarrollo, el 
crecimiento y la renovación de células. La regulación del número de células viene determinada por 
un equilibrio entre división celular y muerte. Existen múltiples proteínas encargadas del  control de 
la división celular, que pueden incluirse en cuatro categorías: factores de crecimiento y sus 
receptores (sección 1), transductores de señales (sección 2) y por último proteínas reguladoras 
nucleares. De entre las moléculas implicadas en la transducción de señales nos centraremos en la 
familia de las PI3K, por ser el objeto de nuestro estudio (sección 3), así como las rutas de 
señalización nucleares (sección 4). 
La unión de los factores de crecimiento a sus respectivos receptores desencadenan la 
activación de estos últimos. Como consecuencia, se estimula la actividad de transductores de 
señales, que actúan como segundos mensajeros intracelulares. Son éstos los que regulan la función 
de proteínas reguladoras nucleares, impulsando la expresión génica y contribuyendo a la entrada en 
ciclo (sección 6). Por último se incluye una sección (7) acerca de las vías implicadas en la respuesta 
a daño en el DNA, ya que una parte de nuestra investigación se centra en desentrañar el posible 
papel de PI3K en este proceso. 
 
SECCIÓN 1. RECEPTORES DE FACTORES DE CRECIMIENTO 
1.1) Receptores con actividad tirosina-quinasa 
Los  Receptores con actividad tirosina-quinasa (RTK) constituyen una amplia familia de 
proteína quinasas, que actúan a través de su unión a una gran variedad de factores de crecimiento y 
catalizan la fosforilación en residuos de tirosina en distintas moléculas diana. Los RTKs contienen 
un dominio extracelular de unión a sus respectivos ligandos, un dominio hidrofóbico 
transmembrana y una porción citosólica con actividad tirosina quinasa (Hupfeld et al., 2007). Se 
han identificado 58 de estos receptores, clasificados en 20 subfamillias distintas, en función de las 
secuencia de su dominio quinasa (Robinson et al., 2000). 
1.2) Receptores acoplados a proteínas G 
Otro grupo de receptores pertenecientes a los receptores integrales de membrana lo forman 
los receptores acoplados a proteínas G (GPCRs), que se unen a proteínas G heterotriméricas tras su 
estimulación con factores de crecimiento. El resultado consiste en el cambio conformacional de las 
proteínas G, lo que permite su interacción con GTPasa, estimulando la liberación de GDP. 
SECCIÓN 2. PROTEÍNAS TRANSDUCTORAS DE SEÑALES 
Las proteínas transductoras de señales forman redes complejas de vías de señalización 
interconectadas, que permiten integrar las señales extracelulares recibidas en la membrana, 
regulando múltiples procesos celulares. A continuación se detallan algunas de estas proteínas: 
2.1) Ras 
Las proteínas Ras son pequeñas GTPasas ubicadas en el centro de la membrana plasmática, 
donde actúa como un interruptor que permite la transducción de señales extracelulares al 
citoplasma. 
2.2) Proteína quinasas asociadas a microtúbulos (MAPKs) 
Las MAPKs son capaces de desencadenar cambios en la expresión génica provocados por la 
unión de una señal extracelular a su receptor de membrana, mediante la fosforilación de diversos 
sustratos (Seger & Krebs, 1995). Dentro de este grupo destacan tres clases diferentes de MAPKs 
(Gallo & Jonhson, 2002). 
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a- ERK1/2 
b- JNK1,2-3  
c-  p38 () 
Las MAPKs actúan regulando la actividad de múltiples proteínas, tales como PI3K, 
fosfolipasa C (Rhee, 2001), proteína quinasa C (Griner & Kazanietz, 2008), así como la 
formación de diacilglicerol (Irving, 2003) y la liberación de Ca
2+
 (Roderick & Cook, 2008). 
SECCIÓN 3. FOSFOINOSITOL-3 QUINASA (PI3K) 
Las PI3K pertenecen a una familia de las lípido quinasas que fosforilan la posición 3´ del 
grupo hidroxilo de distintos fosfoinosítidos y regulan numerosas respuestas entre las que se 
incluyen la división celular, la migración etc (Serunian et al., 1990; Ling et al., 1992). 
3.1) PI3K de clase I 
Las PI3K de clase I son proteínas heterodiméricas formadas por una subunidad catalítica y 
otra reguladora, que median la producción de PI(3,4,5)P3 y PI(3,4)P2 in vivo, que actúan como 
segundos mensajeros intracelulares. La Clase I se divide en dos subgrupos: clase IA y clase IB 
(Stoyanov et al., 1995). Las isoformas catalíticas p110,  y  pertenecen al primer grupo, 
mientras que el segundo estaría constituido únicamente por la subunidad p110 (Hiles et al., 1992; 
Hu et al., 1993; Vanhaesebroeck et al., 1997). Mientras que la clase IA es activada por receptores 
con actividad tirosina quinasa, p110 se activa por medio de receptores acoplados a proteínas G. 
3.2) Vías de señalización controladas por PI3K de clase IA 
La formación de PI(3,4,5)P3 y PI(3,4)P2 en la membrana plasmática desencadenada por la 
activación de PI3K conduce a la translocación a la membrana de distintas proteínas con dominio de 
homología con la pleckstrina (PH). Entre ellas encontramos a PDK1, PKB/Akt, P70S6K, PKC, 
cuya activación va a regular una amplia gama de funciones, tales como la captación de glucosa, el 
tráfico de membranas, la adhesión celular, la reorganización de actina y la proliferación. 
Habitualmente, la señalización intracelular de PI3K viene mediada por PDK1, una serina/treonina 
quinasa cuyo principal sustrato es PKB (Cohen et al., 1997; Anderson et al., 1998). 
3.2.1) PKB 
PKB pertenece a la familia AGC de proteínas quinasas (Peterson et al., 1999). Es el análogo 
en mamíferos del oncogén v-Akt (Staal, 1987). Debido a la variedad y especificidad de sus 
sustratos, PKB tiene un papel central en muchas de las respuestas mediadas por PI3K de clase IA, 
entre las que destacan el crecimiento, la supervivencia y el metabolismo. El primer sustrato de PKB 
identificado fue la glicógeno sintasas quinasa (GSK, Brazil et al., 2001; Datta et al., 1999), de 
modo que su fosforilación por parte de PKB desencadena la estabilización de c-Myc, un oncogen 
que regula en rutas de proliferación, supervivencia y tumorogénesis (Sears et al., 2000). 
 
3.2.2) PTEN 
PTEN es el antagonista de la señalización de PI3K de clase I, puesto que es capaz de 
desfosforilar la posición 3´ del anillo inosítido reduciendo los niveles de PI(3,4,5)P3 y PI(3,4)P2 
(Maehama & Dixon, 1998). PTEN fue descubierta por dos grupos independientes como una 
molécula supresora de tumores, codificada por un gen ubicado en el locus 10q23. Estudios 
posteriores demostraron que se encuentra mutado frecuentemente en distintos tipos de tumores 
humanos (Li & Sun, 1997; Steck et al., 1997). 
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SECCIÓN 4. SEÑALIZACIÓN NUCLEAR MEDIADA POR PI3K 
Mientras que la vías de señalización reguladas por PI3K en el citosol han sido ampliamente 
estudiada, se sabe menos de su papel en el núcleo, en el que PI3K podría funcionar 
independientemente de las vías citosólicas (Neri et al., 2002). Por un lado PI3K se expresa 
constitutivamente en el núcleo de hepatocitos de rata (Martelli et al., 1999), Neri y colaboradores 
detectaron por inmunohistoquímica e “immunobloting” la subunidad reguladora p85 y demostraron 
que la inducción de conduce a una rápida translocación de PI3K al núcleo (Neri et al., 1994). Más 
aún, el análisis microscopía inmunoelectrónica utilizando un anticuerpo anti-p85 mostraron 
marcaje en la membrana nuclear y el nucleoplasma, en consonancia con otro trabajo que 
demostraba la presencia de PI3K en el núcleo de las células de osteosarcoma humano SAOS-2 
(Zini et al., 1996). Basándose en su reactividad inmunológica, Lu y colaboradores encontraron que 
la cantidad de PI3K existente en el núcleo de las células derivadas de hígado de rata constituía un 
5% del total (Lu et al., 1998). La activación de PI3K en el citosol necesita de receptores con 
actividad tirosina quinasa o de GTPasas como Ras, pero ninguna de esas moléculas parece estar 
presente en el núcleo. Por el contrario, al menos en células neuronales, se ha descrito la existencia 
de una GTPasa nuclear (PIKE), que es capaz de interaccionar con PI3K estimulando su actividad 
Ye et al., 2002).  El tratamiento de estas células con NGF estimularía la translocación de PLC-1 al 
núcleo, donde actuaría como un GEF fisiológico de PIKE-S (Ye et al., 2002), de este proceso 
depende la entrada de PI3K al núcleo, de una manera aún desconocida. Uno de los objetivos de este 
estudio es determinar el mecanismo de entrada de PI3K al núcleo celular. 
SECCIÓN 5. Proteínas Nucleares 
c-myc se halla entre los primeros proto-oncogenes. Forma parte de una familia a la que 
también pertenecen los genes N- y L-myc. Las proteínas derivadas de estos genes se localizan 
principalmente en el núcleo y su expresión, generalmente, se correlaciona con la proliferación 
celular. Las células que expresan constitutivamente elevado niveles de c-myc reducen sus 
requerimientos de factores de crecimiento (Kaczmarek et al., 1985; Sorrentino et al., 1986; Stern 
et al., 1986), presentas una fase G1 más corta y no entran en G0 tras deprivación de suero (Kohl & 
Ruley, 1987). c-myc regula la expresión de múltiples genes, alguno de los cuales son esenciales 
durante el intervalo G0/S (Ponzielli et al., 2005; Dang et al., 1999). Se trata de un gen de respuesta 
rápida indispensable para una rápida progresión de G0 a G1 y a través de esta última fase (Schorl 
2003; Mateyak et al., 1997; Amati et al., 1998). 
c-myc es una proteína muy inestable, de modo que su expresión se encuentra muy controlada 
a lo largo del ciclo celular. La regulación de su estabilidad se lleva a cabo por medio de su 
fosforilación, siendo los residuos implicados en este proceso la Thr58 y la Ser62. El primero es 
fosforilado por MAPK y el segundo por GSK3La proteína fosforilada es susceptible de 
degradación por el proteasoma (Yeh et al., 2004). 
SECCIÓN 6. CICLO CELULAR 
El ciclo celular es uno de los procesos biológicos estudiados con mayor profundidad, debido 
a su relevancia en el crecimiento celular y el desarrollo de los procesos fisiológicos normales de un 
individuo y también en muchas de las enfermedades humanas (Fig. 1). Los eventos clave del ciclo 
celular, tales como la replicación del DNA y la división del citosol, ocurren durante interfase y 
citoquinesis respectivamente. La interfase se puede dividir en cuatro etapas: G1, S, G2 y fase M. 
Durante G1 tiene lugar un aumento de la masa y una serie de eventos moleculares que permiten a la 
célula estar preparada para la replicación del DNA. En G1, la célula determina si puede seguir 
adelante (en presencia de factores de crecimiento y nutrientes), o si entra en fase de quiescencia 
(G0). Una vez que la célula pasa del punto de restricción en G1 avanzado (Pardee, 1989) ésta se 
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vuelve refractaria a las señales extracelulares que regulan el crecimiento y queda comprometida a 
completar el ciclo celular (Garcia et al., 2006). 
A lo largo de la fase S se desencadenan una serie de complejos eventos que permiten la 
duplicación de los cromosomas, Tras la replicación del DNA la célula transita a través de la fase 
G2, una etapa en la que la célula se prepara para la división nuclear (mitosis) y la citoquinesis. En 
mitosis tiene lugar la separación de los cromosomas en dos núcleos diferentes, tras este proceso se 
divide el citosol, formándose dos células separadas. Una vez terminada la citoquinesis, la 
exposición a factores de crecimiento determinará si las células hijas continúan dividiéndose o salen 
del ciclo, para entrar en un estado especial, denominado G0. 
El ciclo celular está controlado por las CDKs (cyclin dependent kinases). Se trata de 
serina/treonina quinasas que forman complejos con unas subunidades reguladoras denominadas 
ciclinas, que se expresan transitoriamente a lo largo del ciclo. La constitución de los complejos 
ciclina D (D1, D2 y D3)/Cdk6 o Cdk4 es necesaria para la progresión de G1; mientras que para la 
entrada en fase S se requiere la constitución de complejos ciclina E/Cdk2 y ciclina A/Cdk2. En 
mitosis son esenciales la formación de complejos ciclina A/Cdk1 y ciclina B/Cdk1 (Ekholm et al., 
2000). La formación de diferentes complejos a lo largo del ciclo permite la activación de sustratos 
específicos implicados en su regulación temporal. En la fase G2 se sintetiza una serie de proteínas 
que permite a la célula asegurarse de que la copia del DNA realizada carece de errores en su 
secuencia y responde al daño en el DNA. Cuando se produce este daño se puede desencadenar 
varios procesos, como la parada del ciclo, la iniciación de la reparación del DNA, la activación de 
un programa de transcripción, la entrada en senescencia o la muerte por apoptosis (Khanna & 
Jackson, 2001; Zhou & Bartek, 2004). Los puntos de restricción no sólo paran el ciclo en 
respuesta a daño en el DNA, sino que también controlan la activación de rutas de reparación y 
regulan el movimiento de estas proteínas al sitio adecuado en el DNA (Rouse & Jackson, 2002). 
SECCIÓN 7.  RESPUESTA A DAÑO 
Existen distintos tipos de daño en el DNA que pueden conducir a la activación de proteínas 
de control del DNA. Producen una parada temporal del ciclo que permite la reparación del DNA. 
Las proteínas ATM y ATR pertenecientes a la clase IV de las PI3K se activan rápidamente en 
respuesta a radiación UV e ionizantes, dando paso a la reparación del DNA. 
Las proteínas implicadas en respuesta a estrés genotóxico se pueden dividir en sensores, 
transductores y mediadores. Parte de nuestro trabajo se centra en examinar el efecto de eliminar las 
isoformas de PI3K de clase IA en las respuestas a estrés por radiación.  
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OBJECTIVOS DEL ESTUDIO 
 
La activación de la PI3K de clase IA tras activación de receptores para factores de 
crecimiento es necesaria para el crecimiento celular (aumento de la masa) y la entrada en ciclo 
celular. Además, la expresión de mutaciones activadoras y la sobre expresión de las isoformas 
PI3K de clase IA produce una aumento en la señalización de la vía PI3K, lo cual se asocia con 
transformación celular y cáncer. La activación de PI3K mediada por factores de crecimiento ocurre 
a dos tiempos diferentes durante la fase G1 del ciclo celular. El primer pico de activación se 
observa rápidamente tras la adición de los factores de crecimiento, mientras que el segundo pico de 
activación se produce en la fase G1 tardía, justo antes de la entrada en fase S. Este segundo pico de 
activación es esencial para la replicación del ADN. Sin embargo, los mecanismos y la función de la 
activación de PI3K en la entrada de fase S son desconocidos. 
Recientemente se ha encontrado que una fracción de la PI3K de clase IA se encuentra en el 
núcleo. El papel de PI3K nuclear está relacionado con supervivencia celular, mitosis, 
diferenciación, etc. a través de su principal efector PKB. Sin embargo, se desconoce que isoformas 
de PI3K se localizan en el núcleo. Las isoformas de clase IA ubicuas p110 y p110 exhiben 
distintas y importantes funciones en la división celular, por tanto es importante estudiar cual es la 
localización intracelular de las distintas subunidades catalíticas y reguladoras de clase IA. Además, 
es también necesario determinar el modo de su translocación al núcleo. 
La delección genética de p110a y p110b en ratones provoca letalidad embrionaria. Además, 
p110a ha sido claramente implicada en cáncer ya que se han descrito distintas mutaciones que 
provocan un incremento en su actividad quinasa y están presentes en tumores humanos. La sobre 
expresión de p110b también ha sido descrita en diferentes tipos de tumor, sin embargo, no hay 
mutaciones funcionales descritas en el gen PIK3CB. El ratón deficiente condicional para p110b 
mostró un papel independiente de la actividad quinasa en desarrollo, de cualquier forma, la función 
de p110b está poco clara. 
Para abordar estas cuestiones, los principales objetivos de mi tesis fueron: 
1) Investigar los mecanismos de  activación y el papel de la actividad de PI3K de 
clase IA en fase G1 tardía 
2) Identificar que isoformas de PI3K de clase IA localizan en el núcleo y investigar 
los mecanismos implicados en su translocación al núcleo 
3) Investigar la participación de p110 en las respuestas a daño en el ADN 
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RESULTADOS 
 
La fosfoinosítido 3-quinasa (PI3K) es una de las moléculas de señalización temprana 
inducida por estimulación de receptores para factores de crecimiento, la cual es necesaria para el 
crecimiento celular y entrada en ciclo celular. La activación de PI3K ocurre a dos tiempos 
diferentes durante la fase G1. El primer pico de activación tiene lugar inmediatamente tras la 
adición de los factores de crecimiento, y el segundo en la fase G1 tardía, antes de la entrada en fase 
S. Este segundo pico de actividad es esencial para la transición desde G1 a S; sin embargo, el 
mecanismo por el cual este pico de actividad se induce y regula la entrada en fase S se desconoce. 
En este trabajo hemos estudiado el mecanismo de activación y la función de la actividad PI3K en 
fase G1 tardía. La activación de PI3K en G1 induce activación de PKB y expresión de c-Myc (Fig. 
2). Nosotros hemos observado la activación de TyrK y Ras en la fase G1 tardía (Fig. 3) es esencial 
para la activación de PI3K y de su efectores en la fase G1 tardía (Fig. 4, 5). 
La inhibición de la actividad PI3K en dicha fase produce una baja expresión de c-Myc, 
ciclina D2, Cdk4 (Fig. 6). Para estudiar por que se produce esta reducción de los niveles proteicos 
de c-Myc tras la inhibición de la actividad de PI3K en G1 tardía, realizamos Northern blot  
analizando el efecto sobre los niveles de mRNA y ensayos de pulso y caza para ver  el efecto sobre 
estabilidad de la proteína c-Myc (Fig. 7, 8).  Observamos mayor bajada de niveles de proteína que 
de ARNm cuando inhibimos la actividad PI3K en G1 tardía. La Inhibición de la actividad PI3K en 
G1 tardía también provoca una bajada de niveles de ciclina D3, ciclina A, e hipo-fosforilación de 
Rb (Fig. 9) alterando además, la actividad Cdk2 debida a la presencia de mayores niveles del 
inhibidor p27
Kip1
 (Fig. 10). Esta bajada de Cdk2 produjo un descenso en el reclutamiento del 
complejo MCM (mantenimiento de minicromosoma) a la cromatina (Fig. 11). 
La consecuencia más importante de inhibir PI3K en fase G1 tardía fue la desestabilización 
de c-Myc. Para demostrar esto usamos un vector condicional de c-myc fusionado a ER que 
responde a 4-OHT y  induce el desplazamiento de c-Myc al núcleo. También usamos un mutante c-
MycT58A, que no depende de GSK3 . La activación condicional de c-Myc en fase G1 avanzada o 
la expresión estable del mutante c-Myc rescataron los defectos de la inhibición PI3K y restaurando 
la entrada en fase S (Fig. 12, 14); corrigiendo los niveles de cyclin A, actividad de ciclina E/CDK2, 
ciclina A/CK2 y el reclutamiento de MCM2 a cromatina (Fig 15, 16, 17, 19). Estos resultados 
muestran que las tirosina quinasas y Ras cooperan a la hora de inducir el segundo pico de actividad 
PI3K en G1 que induce la iniciación de la síntesis de ADN por estabilización de c-Myc. 
La localización nuclear de la PI3K de clase IA se ha descrito con anterioridad. Sin embargo, 
que isoformas se localizan en el núcleo se desconocen. Comparando la localización de las 
isoformas ubicuas p110 y p110,  determinamos que la mayoría de p110 localiza en el núcleo 
mientras que p110 es mayoritariamente citoplásmica (Fig. 20).  También observamos la 
localización de p110 en el  núcleo de otras líneas celulares (Fig. 21). Por otro lado, hemos 
observado que durante la progresión del ciclo celular p110 se desplaza entre el núcleo y el 
citoplasma y que se produce una gran concentración nuclear durante la fase S (Fig. 22A). El 
incremento en la localización nuclear coincidió con la activación de p110 en el núcleo (Fig. 22B). 
Estas observaciones nos permiten concluir que la actividad quinasa de p110 es importante para su 
translocación nuclear, un aspecto que requiere futuros análisis. 
Para estudiar la función de p110 en núcleo, transfectamos p110 en varias líneas celulares 
y observamos que el p110  sobreexpresado no se localiza correctamente, dando lugar a una 
expresión citoplásmica (Fig. 23). Nosotros describimos parte de los mecanismos implicados en la 
translocación de p110. Concluimos que p110 no se transloca al núcleo por si misma y que 
necesita de la asociación con p85 y no con p85. Dicha asociación facilita la localización 
nuclear de p110. Cuando transfectamos p110 con p85 o p85, p110 permaneció en el 
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citoplasma  al igual que p85 y al igual que la mayoría de p85Fig. Además, hemos 
identificado una  secuencia de localización nuclear en el dominio C2 de p110, que cuando se muta 
inhibe la translocación al núcleo del complejo p85/p110. Estos resultados fueron inesperados; 
aunque se considera que  ambas subunidades reguladoras tienen papeles similares, ya que solo 
p85 (no p85) facilitó de manera reproducible la translocación nuclear de p110. Una posibilidad 
es la unión preferencial de p110 a p85 y de p110 a p85. Para examinar esta posibilidad 
fusionamos el NLS a p85 y cotransfectamos p110 o p110 con p85-NLS (“nuclear localization 
signal”). p85 mostró una completa localización nuclear debido a la secuencia NLS (de SV40), lo 
cual también se tradujo en la localización de p110 en el núcleo; sin embargo, en el caso de p110 
una gran fracción permaneció en el citoplasma (Fig. 26). 
A parte del papel de p85 en la translocación nuclear de p110, p85 también controla su 
exclusión nuclear (Fig. 27). Identificamos que los primeros 41 aminoácidos en la región N-terminal 
de p85 regulan la exportación nuclear de esta proteína (Fig.28). Observamos que p85 no fue 
suficiente para completar la translocación nuclear de p110 a niveles semejantes al endógeno. 
Hemos observado que la unión de PCNA a p110(Fig. 29) incrementa la localización nuclear de 
p110Fig3. 
Tras determinar la localización nuclear de p110 y su papel en la regulación de la 
replicación del ADN, estudiamos su función en el núcleo. La exposición de células con niveles 
reducidos de p110 a UV, indujo apoptosis (Fig. 31). p110 KO MEF mostraron un número de 
cromosomas muy superior a lo normal y roturas cromosómicas aberrantes, implicando una función 
de p110 en el mantenimiento de la integridad genómica (Fig 32). 
Posteriormente analizamos dos vías de señalización de reparación activadas tras daño al 
ADN como son las iniciadas por ATR y ATM. Se observó una señalización defectuosa a través de 
ATR, una menor activación de Chk1 y una acumulación reducida de p-RAD17 (Fig. 35, 36). 
Además, también encontramos que la delección de p110 provoca defectos en la vía ATM donde 
se producen alteraciones en la activación de ATM y sus efectores p-SMC1, p-Chk2 y -H2AX (Fig 
37). La colocalización de p110 con H2AX, en los puntos de daño al el ADN implica un papel 
integrador de p110 en las respuestas a daño en el ADN (Fig. 38). Por otro lado, encontramos que 
p110 regula la movilidad de la proteína “sensor” NBS1 a los puntos de daño. p110-/- MEF 
presentan defectos en la movilización de NBS1 y 53BP1 en respuesta a daño en el ADN inducido 
por láser UV (Fig. 39, 40). Estas observaciones nos llevan a concluir que p110 actúa antes que las 
proteínas “sensor” de daño en el ADN. Dado que anteriormente identificamos que p110 asocia 
con PCNA, examinamos si PCNA localiza en las áreas dañadas y observamos inmovilización de 
PCNA con cinéticas similares a las de NBS1(Fig. 41), infiriendo por tanto que PCNA puede tener 
un papel como proteína sensor además de su papel en la replicación de AND y que es dependiente 
de p110 
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CONCLUSIONES 
 
 
Objetivo 1. Investigar el mecanismo de activación y función de PI3K en G1 tardía 
1,1) La activación de Ras y Tyr quinasas son necesarios para la activación de PI3K en G1 tardía.  
1,2) La actividad PI3K en G1 tardía regula los niveles de c-Myc y en consecuencia los niveles de 
ciclina A, la actividad Cdk2 y la unión de MCM2 a la cromatina. La expresión de c-Myc 
rescata los defectos provocados por la inhibición de PI3K en G1 tardía y la entrada en fase S. 
 
 Objetivo 2. Investigar el mecanismo de localización de p110en el núcleo 
2,1) La mayoría de p110 es nuclear mientras p110 es principalmente citosólico. Además, 
p110 se mueve entre el núcleo y el citosol durante la progresión del ciclo celular y es   
principalmente nuclear en la fase S; el aumento de la localización nuclear de p110 coincide 
con la activación de PI3K nuclear.  
2,2) La localización nuclear de p110 requiere de su asociación con p85 . La subunidad 
reguladora p85 también determina la salida del núcleo de p110, los primeros 41 aa p85 
contienen una región que actúa como secuencia de exporte nuclear.  
2,3)  p110 contiene una señal de localización nuclear en el dominio C2. 
2,4)  p110 se asocia con PCNA; este complejo aumenta la localización nuclear de p110  
 
Objetivo 3. Investigar la participación de p110 en la reparación del ADN.  
3.1)  La reducción de los niveles p110 celulares interfiere con los mecanismos de reparación del 
ADN provocando inestabilidad genómica.  
3.2) La radiación ionizante y la luz ultravioleta activan p110.  
3,3) p110 asocia RAD17 de forma dependiente de la radiación. p110 también regula la 
activación de ATR y de ATM. 
3,4) p110 transloca a las roturas de ADN; la deficiencia en p110 impide el posterior 
reclutamiento de NBS1, 53BP1 y PCNA al sitio de daño al ADN. 
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DISCUSIÓN 
 
La activación de  PI3K de clase IA en fase G1 tardía se requiere para la estabilización de 
c-Myc y la entrada en fase S 
 
La activación de PI3K en la fase G1 tardía es esencial para la entrada en fase S (García et 
al., 2006; Jones et al., 2001). En este trabajo examinamos las señales implicadas en la activación 
de PI3K en la fase G1 tardía y los mecanismos por lo cuales PI3K controla la transición G1/S. 
Encontramos que las tirosina quinasas y Ras también se activan en fase G1 tardía. De hecho, la 
inhibición simultánea de las tirosina quinasas y Ras en fase G1 tardía anuló por completo el 
segundo pico de activación de PI3K. Estos resultados sugieren que la activación de PI3K en la fase 
G1 tardía es dependiente de la actividad tirosina quinasa y es además controlada por Ras. 
También demostramos que la estabilización de c-Myc es la principal función de la activación 
de PI3K en la fase G1 tardía, basándonos en  la observación de que la inhibición de PI3K en fase 
G1 tardía reduce los niveles de c-Myc y ciclina A. La inhibición de PI3K en este momento también 
incrementó la expresión de p27kip y redujo la actividad quinasa asociada a ciclinaE/CDK2 y 
ciclinaA/CDK2. Nuestros resultados son consistentes con lo observado en células deficientes para 
c-Myc, las cuales muestran defectos similares (Vlach et al., 1996;Mateyak et al., 1999). Nosotros 
demostramos esto usando un mutante de c-Myc (MycT58A, Hemann et al., 2005) resistente a la 
acción de GSK3, o alternativamente, expresando una forma inducible de c-Myc en fase G1 tardía 
se restaura la entrada en ciclo celular contrarrestando la inhibición de PI3K en todos los parámetros 
estudiados. Estos incluyen la síntesis de ADN, la expresión de ciclina A, la actividad de ciclina 
E/CDK2 y ciclina A/CDK2, así como la separación de p27kip de ciclinaE/CDK2. La activación de 
PI3K en fase G1 tardía por lo tanto regula los niveles de la proteína c-Myc. 
Un aspecto muy interesante de nuestras observaciones es que aunque la actividad de PI3K en 
fase G1 tardía es casi paralela a la de c-Myc y de hecho la activación de PI3K puede sustituirse por 
la expresión de una forma estable de c-Myc, en la transición G0 a G1, c-Myc y PI3K tienen 
funciones bien distintas y ambas son necesarias para inducir el paso a fase G1 (Jones et al., 2001), 
sugiriendo distintas funciones de PI3K en fase G1 temprana y tardía. La activación de PKB 
mediada por PI3K es también requerida para la inactivación del factor de transcripción (FT) FoxO. 
En un estado desfosforilado, FoxO inhibe la inducción de varias dianas de c-Myc, proporcionando 
un mecanismo para la acción sinérgica de c-Myc y PI3K en la progresión del ciclo celular 
(Bouchard et al., 2004). La activación inmediata de PI3K tras estimulación de receptores de 
factores de crecimiento podría explicar esta aparente contradicción, ya que la actividad PI3K en 
fase G1 temprana es esencial para el crecimiento celular (Álvarez et al., 2003) y para la 
inactivación de FoxO (Álvarez et al., 2001). 
Las proteínas de mantenimiento del minicromosoma (MCM) están implicadas en la 
replicación y forman un complejo del cual se piensa que es la helicasa replicativa en organismos 
eucariota. El complejo MCM se mantiene con el complejo de replicación hasta que dicho proceso 
de replicación se completa, y varias proteínas MCM están reguladas a través de fosforilación CDK 
(Tye, 1999). Nosotros hipotetizamos que, desde que la inhibición de la actividad PI3K en fase G1 
tardía provocó un descenso en la actividad ciclina/CDK2 (Geng et al., 2003), esta inhibición podría 
afectar al reclutamiento del complejo MCM a la cromatina. Hemos examinado el reclutamiento a la 
cromatina cerca de la transición G1/S mientras inhibimos la actividad PI3K. Encontramos que la 
actividad PI3K en fase tardía G1 es requerida para un correcto reclutamiento de MCM2, otro 
evento crucial para una correcta inducción de la síntesis de ADN. 
Después de examinar el papel de la PI3K en la fase G1 tardía, identificamos la isoforma de 
clase IA PI3K responsable de la transición G1/S. Nuestro grupo recientemente describió que tanto 
p110 y p110 se activan en fase G1 tardía, aunque a tiempos distintos (Marques et al., 2008). 
p110 se activa a mitad de fase G1, mientras que p110 se activa más tarde en G1 (en la entrada 
en fase S) concluyéndose que p110 tiene un papel diferente de p110, dado que p110 regula la 
progresión de la fase S. 
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La asociación a p85 media la translocación nuclear de p110 
Se exploraron las bases del papel de p110 en progresión de la fase S. Usando 
inmunomarcaje (immunostaining) y inmunofijación (immunoblotting) de la subunidad reguladora 
p85, Neri y colaboradores mostraron que la PI3K de clase IA localiza en el núcleo de diferentes 
tipos celulares (Neri et al., 2002). Nosotros encontramos distintas localizaciones intracelualres para 
p110 y p110 en  células NIH3T3; mientras que p110 se concentraba principalmente en el 
citoplasma, la mayoría de p110 se localizó en el núcleo. En células HeLa y en fibroblastos 
embrionarios de ratón (MEF), también observamos la localización nuclear de p110. Estas 
observaciones sugieren que p110 aparece en el núcleo como un fenómeno general, 
indistintamente del tipo celular y de la especie de mamífero. Algunos trabajos recientes 
documentan la aparición de PI3K en núcleo y un posible  papel diferente de PI3K en núcleo y 
citoplasma (Martelli et al., 2007). El mecanismo por el cual p110 se transloca al núcleo se 
desconocía. 
Mostramos que tras re-estimular células paradas en G0 en medio sin suero, una fracción de 
p110 se desplaza entre el citoplasma y el núcleo durante la fase G1. Además, la cinética de 
activación nuclear de PI3K fue en paralelo a las translocación de p110 al núcleo. p110 nuclear 
fue máxima cerca de la transición de fases G1/S. También, encontramos p85 nuclear, mientras 
que p85 se localizó mayoritariamente en el citoplasma. 
Mientras estudiábamos el papel de p110 nuclear, observamos que su sobreexpresión 
inducía una localización citoplásmica. Por ello consideramos que la transcripción y traducción 
continua de ADNc en las células podría provocar la acumulación del p110 sintetizado de novo en 
los polisomas del retículo endoplásmico. En este sentido, la inhibición de la expresión de proteínas 
con ciclohexamida durante 3 h antes del análisis de inmunofluorescencia no cambió la localización 
citosólica de p110 recombinante. Una posibilidad alternativa es que p110 requiere asociación 
con otros proteínas celulares para su translocación nuclear. 
p110 y p110 son considerados compañeros obligados de sus subunidades reguladoras p85 
(Geering et al., 2007). Nosotros determinamos que la expresión de p85, y no la de p85, facilita 
la localización nuclear de p110, y no la de p110. Cuando p85 fue expresado solo, provocó un 
ligero marcaje nuclear en las células transfectadas. Cuando las células son cotransfectadas con 
p85/p110, el marcaje nuclear de p85 fue observado en el 22% de las células. Además p110 
también se localizó en el núcleo en estas células, mostrando que p85/p110 es el heterodímero 
que se localiza en el núcleo. Cuando p110 fue cotransfectada con p85 o p85, p110 
permaneció en el citoplasma  al igual que p85 y la mayoría de p85. Estos resultados fueron 
inesperados; ya que se considera que  ambas subunidades reguladoras tienen papeles similares y 
solo p85 (no p85) facilitó de manera reproducible la translocación nuclear de p110 (no p110). 
La unión de p85 a p110 podría provocar cambios conformacionales en el complejo, o en 
la activación del complejo; cualquiera de estos eventos podría promover la translocación nuclear. 
Otra posibilidad es la unión preferencial de p110 a p85 y de p110 a p85. Examinamos esta 
posibilidad fusionando  el NLS a p85 y cotransfectando p110 y p110 con p85 y p85-NLS 
(Fig. 26). p85NLS mostró una completa localización nuclear  debido a la SV40 NLS, lo cual 
también se tradujo en un p110 nuclear; sin embargo, en el caso de p110 una gran fracción 
permaneció en el citoplasma al igual que p85. Con estos datos parece que existe una unión 
preferencial de p110 a p85 aunque el análisis bioquímico (futuro) es necesario para confirmar 
esta posibilidad. 
Tras determinar la localización de estos complejos en el núcleo, buscamos si existían NLS 
clásicos en p85 o en p110. Encontramos una región potencial polibásica NLS en p85 y la 
mutamos reemplazando dichos residuos básicos por los correspondientes en la misma región de 
p85. Sin embargo no observamos una localización de los complejos mutantes distinta de la de los 
complejos control p85/p110. De estas observaciones concluimos que la potencial polibásica en 
p85 no funciona como un NLS. 
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Además, detectamos tres NLS potenciales en p110, las cuales fueron mutadas con residuos 
no básicos. Dos de estas mutaciones no tuvieron efecto en la localización nuclear de los complejos 
mutantes p85/p110, mientras la mutación en el NLS putativo en el dominio C2 de p110 inhibió 
la translocación nuclear del complejo p85/p110. Estas observaciones nos permitieron hipotetizar 
que la conformación del complejo p85/p110 abre la región polibásica en el dominio C2 para 
asociar la maquinaria de importación nuclear para su translocación como complejo (Fig. 2). 
Para determinar si p85 o p110 tienen una señal de exportación nuclear (NES), 
examinamos el efecto del tratamiento con Leptomicina B en la localización de p85, p110 o 
p85/p110. Dicho tratamiento resultó en una localización nuclear constitutiva  de p85 
transfectada y en una retención parcial nuclear del p110 cotransfectado con p85. Estos 
resultados sugieren la presencia de un NES en p85. De hecho, identificamos una región NES en 
sus N-41 aminoácidos (NT41aa). 
Incluso cuando p85 fue coexpresada con p110, no todas las células que coexpresaron estas 
dos subunidades mostraron un fenotipo de localización nuclear tan completo como el exhibido por 
los complejos endógenos. Nosotros identificamos  asociación de p110 con PCNA, la cual podría 
ayudar en la translocación de p85/p110. Aunque PCNA no tiene un NLS, se trata de una 
proteína constitutivamente nuclear. Se ha sugerido que CDK2 controla la translocación de PCNA 
al núcleo (Koundrioukoff et al., 2000). Se requieren estudios futuros que ayuden a identificar 
proteínas que contribuyen a en la translocación de p110. En cualquier caso nuestros datos 
sugieren que la asociación de PCNA a p85/p110 incrementa su localización nuclear. 
p110 es necesaria para la estabilidad genómica y activación de la respuesta a daño del ADN 
tras exposición a UV e IR 
p110 regula la reparación del ADN. Esta hipótesis fue confirmada por la observación de 
células transfectadas con shARN de p110 y exposición a UV lo que provocó muerte celular (en 
fase sub-G1). Nuestros resultados también indicaron que la delección de p110 en celulas con 
defectos en apoptosis (defectos en la ruta de p53) provoca inestabilidad genómica, con roturas 
cromosómicas y alteración de los cromosomas debido a uniones aberrantes. Además, encontramos 
aneuploidias en MEFs p110-/-/DNp53 con una media de 100-150 cromosomas. Esto nos permitió 
examinar el papel de p110 en reparación del ADN. Aquí mostramos que p110 es esencial para la 
correcta activación de los mecanismos de reparación del ADN inducidos por UV e IR. La 
activación de dichos mecanismos implica a una compleja red de proteínas de control que ejercen 
distintas funciones en reparación de DNA y son activadas por ATM o ATR. Los diferentes 
requerimientos para la activación de ATM y ATR, así como otras proteínas relacionadas con estas 
vías de señalización permanecen por esclarecer. Nosotros observamos asociación de p110 con 
RAD17 dependiente de radiación, sugiriendo un papel específico para los complejos 
p110/RAD17 en reparación del ADN. 
Un incremento en la actividad quinasa de p110 tras exposición a UV o IR muestra que el 
daño en el ADN induce actividad de p110. Recientemente Bouzic et al describieron activación de 
PKB en respuesta a DNA DSB (Bozulic et al., 2008). Ellos concluyeron que PKB actúa en 
niveles inferiores de la vía de señalización de DNA-PK en DDR (DNA Damage Response), donde 
DNA-PK fosforila PKB en Ser473; además, ellos observaron un incremento en la fosforilación de 
Thr308 que es estrictamente dependiente de PI3K. Por tanto es posible que la activación de p110 
regula la activación de PKB tras DSB. 
Nuestros estudios indican activación defectuosa de la vía ATR en células deleccionadas de 
p110; hubo una disminución en la fosforilación de Chk1 y RAD 17  en dichas células tras 
exposición a UV o IR. Nosotros también observamos una disminución en la acumulación de p-
RAD17 y formación de focos tanto en células depleccionadas de p110 y células tratadas con 
inhibidores de p110, aunque el efecto fue mucho más fuerte en células p110-/-. Esto podría 
deberse a la activación ya descrita de ATR mediada por RAD17/9-1-1, donde el complejo 
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RAD17-9-1-1 recluta a la proteína activadora de ATR, TopBP1 a los lugares de daño en el ADN 
(Kumagai et al., 2006; Delacroix et al., 2007; Lee et al., 2007). 
Por otro lado, se observó que p110 regula la autofosforilación de ATM, la cual a su vez 
controla la DDR tras exposición IR. Después de exponer células p110-/- a radiación gamma, 
observamos activación defectuosa de ATM, Chk2 y SMC1, como resultado de la disminución de 
los eventos superiores en la vía de señalización de ATM. También identificamos que los defectos 
se produjeron a nivel del reclutamiento de las proteínas sensor al daño en el ADN como así ocurrió 
en el caso de la proteína sensor NBS1. También observamos inmovilización defectuosa a los 
lugares de daño del ADN en el caso de GFP-53BP1 tras inducción de daño en el ADN mediante 
láser UV lo cual corresponde con una defectuosa DDR, pues 53BP1 está implicada en la respuesta 
celular temprana a DSB (Schultz et al., 2000) y contribuye a la activación de los puntos de control 
tras su reclutamiento (Wang B. et al., 2002). 
También hemos determinado un papel directo de p110 en la regulación del proceso 
reparación del ADN; la activación de p110 y su colocalización con gamma-H2AX en las áreas de 
daño del ADN, implican un papel integrador de p110 en las respuestas a daño. 
Holmes y colaboradores sugirieron que PCNA es un requerimiento para el reclutamiento de 
proteínas de recombinación a los puntos de reparación del ADN (Holmes MA, and Haber JE, 
1999). De acuerdo con esta idea, nuestros análisis de imágenes in vivo tras exposición a UV-láser 
en células vivas, mostraron movilización simultánea de PCNA y NBS1 a los lugares de daño del 
ADN. Examinamos el efecto de p110 en la translocación de PCNA al punto de daño del ADN, y 
encontramos que la inhibición de la actividad quinasa de p110 retardó la movilidad de PCNA; la 
delección de p110 alteró mas aún la localización de PCNA en los puntos de daño. Concluimos 
que p110 actúa como andamio molecular regulando el reclutamiento de PCNA a la cromatina en 
los lugares de daño en el ADN. Por tanto, concluimos que p110 regula ambas ramas de las vías de 
señalización relacionadas con DSB. Como la PI3K tiene actividad proteína y lípido quinasa 
(Dhand et al., 1994; Foukas et al., 2004; Foukas & Shepherd, 2004), estudios futuros ayudarán a 
esclarecer el papel de p110 (como proteína o lípido quinasa) tras activación inducida por IR/UV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  25 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
  26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 27 
In higher eukaryotes, cell division is a fundamental process for development, growth, 
and replacement of worn-out cells.  A balance is always maintained between cell division and 
cell death to regulate cell number. In a normal setting, division and death are tightly 
regulated through complex mechanisms, as deregulation of either can result in unrestrained 
cell proliferation, leading to tumourigenesis.  Such deregulation can be due to the changes in 
cell cycle machinery caused by hyperactive proto-oncogenes or by tumour suppressor genes 
that no longer respond to normal control of cell proliferation. Cell cycle deregulation 
associated with hyperproliferation occurs through the overexpression or mutation of proteins 
with a pivotal role in different cell cycle phases.  These proteins exploit the mechanisms they 
regulate to shorten cell cycle length, and to bypass checkpoint and DNA replication defects. 
These cell division regulatory proteins can be grouped into four classes:  growth 
factors, growth factor receptors (section 1), signal transducers (section 2), and nuclear 
regulatory proteins.  Among signal transducers, we will introduce in more detail the PI3K 
signalling pathway, which constitutes the objective of our study (section 3), as well as 
signalling pathways in the nucleus (section 4).  Receptor activation by growth factors (GF) 
triggers signal transducers, which act on secondary messengers.  These secondary messengers 
control nuclear regulatory proteins (section 5) to initiate gene expression, which contributes 
to the triggering of cell cycle entry (section 6).  An introduction to DNA damage response-
mediated pathways is included (section 7), as part of our research refers to the role of the 
PI3K pathway in DNA damage repair. 
SECTION 1.  GROWTH FACTOR RECEPTORS 
Addition of growth factors stimulates GF receptors, some of which are described below. 
1.1)  Receptor tyrosine kinases 
The receptor tyrosine kinases (RTK) form a large family of protein kinases, which act upon 
extracellular signals through a variety of growth factors and catalyse the phosphorylation of 
tyrosines on various target molecules.  RTK comprise an extracellular ligand-binding domain, a 
transmembrane hydrophobic  helix, and a cytosolic domain with protein-tyrosine kinase activity 
(Hupfeld et al., 2007).  Of 90 known tyrosine kinases, 58 are RTK; they are further classified into 
20 subfamilies, depending on the sequence of the kinase domain (Robinson et al., 2000).  Some of 
these subfamilies are EGF (epidermal GF), insulin, PDGF (platelet-derived GF), FGF (fibroblast 
GF), VEGF (vascular endothelial GF), and HGF (hepatocyte GF). 
Following GF stimulation, distinct protein ligands bind to their respective receptors on the 
extracellular domain, triggering dimerisation with adjacent homologous RTK.  This dimerisation 
leads to activation of the cytoplasmic side of the receptor by autophosphorylation of its tyrosine 
residues or through cytoplasmic tyrosine kinases, such as Src kinases, that phosphorylate the 
receptor.  The resulting phosphotyrosines serve as docking sites for adaptor proteins containing Src 
homology 2 (SH2) or PTB (phosphotyrosine-binding) domains (Schlessinger, 2000; Hubbard & 
Till, 2000). 
Adaptor proteins can act in two different ways:  they either directly phosphorylate effector 
molecules following activation or, if they lack kinase activity, they facilitate the association of 
activated tyrosine receptors to their partners.  These SH2- and PTB-containing signalling proteins 
are modular in nature (Schlessinger
 
& Lemmon, 2003).  A large family of SH2 domain-containing 
proteins have intrinsic enzymatic activities such as protein tyrosine kinases (PTK; examples are the 
Src kinases), protein tyrosine phosphatase (PTP; Shp2), phospholipase C (PLC), or Ras-GAP.  
Another family of proteins that have only SH2 or SH3 domains use these domains to mediate the 
interaction of different proteins involved in signal transduction (Pawson, 1995).  Whereas RTK are 
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signal transduction initiators, adaptor proteins act to transmit the signal induced by GF addition to 
the cell. 
1.2)  G protein-coupled receptors 
Another prominent group of receptors belongs to the integral membrane receptors family.  
These are the G protein-coupled receptors (GPCR), which bind to heterotrimeric G proteins and are 
activated following stimulation (for example, by growth factors) to transduce extracellular signals 
into intracellular changes through secondary messenger cascades.  GPCR act on the heterotrimeric 
G proteins as guanine-nucleotide exchange factors.  Stimulation thus results in conformational 
changes in the G protein complex, which allow it to interact with GTPases, leading to GDP release.  
The GTP-bound form of the G protein -subunit dissociates from the receptor and from the stable 
-dimer, initiating a signalling cascade.  Hydrolysis of -subunit-bound GTP through its intrinsic 
GTPase activity results in its inactivation (Dupré et al., 2009). 
Many reports suggest that RTK can use proximally located G protein/GPCR signalling 
components in an integrated manner to induce activation of key regulatory pathways linked to 
cellular processes such as proliferation and differentiation.  RTK (e.g., receptors for PDGF, insulin, 
EGF) appear to form associated complexes with GPCR, which in some cases supply G protein for 
use by the RTK for downstream signalling.  In addition, certain RTK (e.g., IGF-1R) appear to 
associate directly with and activate heterotrimeric G protein (Malbon, 2004; Alcántara-
Hernández et al., 2008). 
SECTION 2.  SIGNAL TRANSDUCTION PROTEINS 
Signal transduction proteins form complex networks of highly interconnected and redundant 
signalling pathways to implement intra- and extracellular signals for distinct cell processes.  Many 
proteins participate in signal transduction pathways downstream of GF receptors to mediate various 
cell responses; we will introduce a few of these below. 
2.1)  RAS 
Ras proteins are G proteins (small GTPases) positioned at the inner leaflet of the plasma 
membrane, where they serve as binary molecular switches to transduce extracellular ligand-
mediated stimuli into the cytoplasm.  Ras shuttles between two conformations – an active (RAS-
GTP) and inactive form (RAS-GDP).  Guanine nucleotide exchange factors (GEF) activate Ras by 
releasing GDP from Ras and allowing GTP to bind to it.  Allosteric changes in Ras after GTP 
binding increase its affinity for its effectors, to generate intracellular signals, whereas Ras is 
inactivated by GTPase-activating proteins (RAS-GAP), which hydrolyse the RAS-bound GTP to 
GDP while releasing an inorganic phosphate.  This activation/inactivation cycle is associated with 
the transduction of an upstream signal to downstream effectors to regulate Ras-mediated cell 
processes. 
In addition to the regulation of Ras family proteins by their GTP- or GDP-bound status, Ras 
GTPases undergo post-translational modifications that regulate protein-protein interactions, 
stability, as well as membrane attachment and thus, subcellular localisation and function (Fig. 1).  
The Ras carboxy terminus has a membrane targeting sequence (CAAX motif), which is a substrate 
for a series of post-translational modifications that create a lipidated hydrophobic domain; this 
mediates attachment to specific proteins and membranes (Karnoub et al., 2008).  Post-
translationally modified active Ras translocates to the plasma membrane, where Ras interacts and 
activates its downstream effector proteins. 
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Figure 1.   Prenylation and post-prenylation reactions of RAS GTPases.  Newly synthesized RAS is a cytosolic 
protein.  HRAS, NRAS and KRAS4A are prenylated (HRAS is only farnesylated, whereas NRAS and KRAS4A can be 
farnesylated or geranylgeranylated) before proteolytic removal of the AAX tripeptide by RAS-converting enzyme 1 
(RCE1) and carboxymethylation by isoprenylcysteine carboxymethyltransferase (ICMT) in the endoplasmic reticulum.  
They are subsequently palmitoylated in the Golgi and transferred to the plasma membrane, to which they attach through 
their farnesyl (F) or geranylgeranyl (GG), and palmitoyl moieties. (Adapted from Konstantinopoulos et al., 2007). 
2.2) Mitogen-activated protein kinases 
The mitogen-activated protein kinase (MAPK) pathway regulates cell processes by 
transmitting extracellular signals from cell surface receptors to downstream factors in the nucleus 
to regulate gene expression through phosphorylation (Seger & Krebs, 1995).  The MAPK 
signalling cascades are composed of a wide array of specialized molecules that include 
transmembrane receptors, guanosine triphosphatase (GTPases), adaptors, kinases, phosphatases, 
scaffolds, and transcription factors (Gaestel, 2006).  There are three major classes of MAPK: 
extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK1, JNK2 and 
JANK3; often called the stress-activated protein kinase) and p38 kinases (, , , ) (Gallo & 
Johnson, 2002). 
Activation of these kinases requires phosphorylation by upstream kinases.  The ERK MAP 
kinases are activated by the MAPK kinases (MKK) MKK1 and MKK2; the p38 MAPK are 
activated by MKK3, MKK4, and MKK6, and the JNK pathway is activated by MKK4 and MKK7.  
These MAPK kinases are activated in turn by several different MAPK kinase kinases (MKKK).  
Activation of ERK1/2 has been linked to cell survival, whereas JNK and p38 are associated 
primarily to apoptosis induction, although some studies report a role in cell survival (Alvarado-
Kristensson et al., 2004; Gallo & Johnson, 2002).  JNK phosphorylate Jun proteins, thereby 
enhancing their ability to activate transcription without affecting DNA binding.  The role of p38 
MAPK signalling in cell responses is diverse, depending on cell type and stimulus. 
Signalling pathways vital for a variety of cellular responses include phosphoinositide-3-
kinase (PI3K), phosphoinositide-specific phospholipase C (PLC) (Rhee, 2001), protein kinase C 
(PKC) (Griner & Kazanietz, 2007), diacylglycerol (DAG) (Irvine, 2003), and Ca
2+
 release 
(Roderick & Cook, 2008).  Of these, the PI3K constitute the centre of our research; a detailed 
description of this pathway is presented in section 3. 
SECTION 3.  PHOSPHOINOSITIDE-3-KINASES 
The PI3K family of lipid kinases are one of the signal transducers required for 
transformation of mammalian cells (Serunian et al., 1990; Ling et al., 1992).  PI3K belongs to the 
family of lipid kinases that phosphorylate the 3´-hydroxyl group of phosphoinositides (PI, PI4P, 
PI5P, PI(4,5)P2).  In normal cells, PIP3 {phosphatidylinositol (3,4,5)-triphosphate} can be detected 
transiently after stimulation by a variety of growth factors (Whitman et al., 1988; Varticovski et 
al., 1989).  PIP3 levels can increase by more than 50-fold, peaking between 10-60 sec after PDGF 
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stimulation and lasting for 30-60 min (Auger et al., 1989).  The PDGF receptor was the first 
receptor shown to associate with (Kaplan et al., 1987) and activate PI3K (Auger et al., 1989). 
PI3K was discovered as a Rous sarcoma virus protein associated with polyoma middle-T 
transformation (Whitman et al., 1985).  Later, Whitman et al. (1988) identified that the D-3 site 
on the inositol ring is phosphorylated by type I PI3K.  With time, many PI3K homologues were 
found and grouped into four classes according to sequence homology and substrate specificity.  All 
PI3K isoforms have similar Ras-binding (except class III), C2, PIK and catalytic domains, with 
maximum similarity in these last.  These four classes contribute to a variety of cell responses such 
as division (Garcia et al., 2006), survival, migration (Katso et al., 2001; Datta et al., 1999), 
polarity (Wang F. et al., 2002), cytoskeletal organisation (Sasaki et al., 2004; Reif et al., 1996; 
Toker & Cantley, 1997), vesicle trafficking (Siddhanta et al., 1998), glucose transport (Toker & 
Cantley, 1997), platelet function (Jackson et al., 2004), autoimmunity (Katso et al., 2001), 
angiogenesis (Katso et al., 2001; Graupera et al., 2008), apoptosis (Franke et al., 2003) and 
DNA repair (Sancar et al., 2004).  A brief introduction to the four PI3K classes is given below. 
3.1)  Class I PI3K 
The class I PI3K are heterodimeric proteins consisting of one catalytic and one associated 
regulatory subunit, which catalyze the in vivo production of PI (3,4,5) P3 and PI(3,4)P2, which act 
as second messengers for the activation of many PI3K effectors.  The regulatory subunits modulate 
the kinase activity of the enzyme and its subcellular localisation (Garcia et al., 2006).  In addition 
their role as lipid kinases, class I PI3K also exhibit limited protein kinase activity. 
Depending on their mode of activation and their association to different receptors, class I 
PI3K are further divided into two subgroups, class IA and class IB PI3K (Stoyanov et al., 1995).  
Class IB PI3K is composed of a single gene product, PIK3G (PI3K), and is activated by GPCR.  In 
mammals, three genes have been identified that code for the class IA catalytic isoforms, namely 
p110, p110 and p110 (Hiles et al., 1992; Hu et al., 1993; Vanhaesebroeck et al., 1997), 
encoded by PIK3CA, PIK3CB and PIK3CD, respectively.  There are five p85-related regulatory 
subunits (p85, p85, p55, p50 and p55), of which p55and p85 are encoded by PIKR3 and 
PIKR2, whereas p85, p55 and p50 are encoded by PIK3R1 through alternative splicing 
(Koyasu, 2003).  Of the three class IA catalytic subunits, p110 and p110 are expressed 
ubiquitously, whereas p110 is abundant in haematopoietic cells. 
While class IB PI3K is activated by GPCR, class IA PI3K are activated mainly by RTK 
growth factor receptors.  This subfamily is also activated through cytosolic tyrosine kinases such as 
Src family members, which phosphorylate the p85 subunit of the heterodimer.  Ras can further 
enhance class IA activity after initial activation through RTK (Downward, 2003).  As an exception, 
the p110/p85 complex can also be activated through GPCR and can function redundantly in the 
absence of class IB to mediate GPCR signals (Garcia et. al., 2006). 
The p85 regulatory subunits  and , which are encoded by different but related genes, have 
two carboxy-terminal SH2 domains separated by an inter-SH2 region that forms the binding site 
for the catalytic subunits p110, p110 and p110.  In addition, p85 and p85 have an amino-
terminal proline-binding SH3 and a breakpoint cluster region (BCR) homology domains.  Finally, 
the BCR homology domains are flanked by two proline-rich domains (Fig. 2A) (Wymann & 
Pirola, 1998). 
The p110 catalytic subunits are also organized in a modular manner, containing an N-
terminal p85-binding domain (25-173), a Ras-binding domain, a membrane-binding C2 domain, a 
helical region and catalytic subunit at the C-terminal (Fig. 2B).  The ribbon crystal structure of 
p110 with the p85 region is shown in Fig. 2C. 
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Figure 2.  Domain structure of class IA PI3K catalytic and regulatory isoforms.  A) Structure of the catalytic subunit 
p110 with the N-terminal p85-binding domain, Ras-binding region, a C2 domain, PIK domain and a C-terminal catalytic 
domain.  B) Structure of p85 proteins with SH3, polyproline, BCR region, polyproline, N-terminal SH2 followed by an 
iSH2 p110-binding region and a C-terminal SH2 domain.  C) Ribbon structure of p110 binding to p85 inter-SH2 
domain while in subsequent association with Ras (figure adapted from Huang et al., 2007). 
3.1.1)  Signalling pathways controlled by class IA PI3K 
The class IA PI3K are activated by a variety of RTK such as PDGF-R, IGF and Ras.  In 
vitro studies using PI3K-binding mutants of the PDGF receptor show that PI3K is responsible for 
PDGF-induced cell proliferation, survival and migration (Valius & Kazlauskas, 1993; Bazenet & 
Kazlauskas, 1994; Joly et al., 1994) (Fig. 3).  Active PI3K catalyzes production of the 
phospholipid messenger PIP3.  Production of PIP3 results in membrane translocation of some of its 
effectors through the specific pleckstrin homology (PH) domain, which following activation 
transduces PI3K signals to many downstream effectors.  The finding that RTK activation of PKB 
(protein kinase B) is blocked by the PI3K inhibitors wortmannin and LY294002 indicates that 
PI3K activity is necessary for PKB activation (Chan et al., 1999).  The many proteins that bind to 
these lipids, such as phosphoinositide-dependent kinase 1 (PDK1), PKB, p70S6k, Bruton‟s tyrosine 
kinase, protein kinase C (PKC) have diverse physiological functions (Toker & Cantley, 1997) 
including glucose uptake, cell trafficking, adhesion, actin rearrangement, and proliferation. 
Activation of PI3K downstream kinases in the cytosol is often mediated by PDK1, a 
serine/threonine kinase originally identified as critical for PKB activation loop phosphorylation and 
its activation (Cohen et al., 1997; Anderson et al., 1998). 
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Figure 3.  Activation of class IA PI3K after growth factor-mediated stimulation.  In response to extracellular stimuli, 
the catalytic subunit of PI3K (p110) is recruited through its regulatory subunit (p85) to RTK or GPCR at the membrane 
where it phosphorylates PIP2 to generate PIP3. 
3.1.1.1)  PDK1 
PDK1 is a 63 kDa protein kinase, which consists of an N-terminal kinase domain and a 
C-terminal PH domain.  The PH domain of PDK1 binds to the PI3K products PIP3 and PIP2, which 
target PDK1 to the plasma membrane; for this reason, it was termed 3-phosphoinositide-dependent 
kinase-1 (Alessi et al., 1997).  PDK1 is activated by phosphorylation in the activation loop (Ser241 
in human and Ser244 in the mouse) (Casamayor et al. 1999; Wick et al., 2002; Wick et al., 2003).  
In addition to phosphorylation, PDK1 function is regulated by protein-protein interactions (Makris 
et al., 2002), and it regulates many AGC super family protein kinases, including protein kinase A 
(PKA), PKC and RAC-PK (Williams et al., 2000; Dutil et al., 1998; Le Good et al., 1998), the 
ribosomal S6kK, and S6K1 kinases (Toker & Newton, 2000; Vanhaesebroeck & Alessi, 2000). 
3.1.1.2)  PKB 
PKB belongs to the AGC family of protein kinases (Peterson et al., 1999).  Mammalian 
PKB is a homologue of the v-Akt oncogene (acute transforming retrovirus in mice) (Staal, 1987).  
Following PI3K activation, the PKB PH domain binds to PIP2 and PIP3, which induces 
translocation of cytoplasmic PKB to the plasma membrane (Frech et al., 1997; Franke et al., 
1997).  After membrane translocation, PKB is phosphorylated at Thr308 by PDK1, which 
facilitates Ser473 phosphorylation by the mTOR complex 2 or by DNA-PK (Fig. 4).  
Phosphorylation at Ser473 results in fully activated PKB (Alessi et al., 1996). 
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Figure 4.  PKB structure and mechanism of activation.  The N-terminal PH domain of PKB is followed by the 
catalytic domain.  Active PDK1 phosphorylates Thr308, making Ser473 available for phosphorylation by mTOR or 
DNA-PK.  After phosphorylation at Ser473, PKB is fully activated. 
Due to the variety and specificity of its substrates, PKB has a central role in many PI3K 
class IA-mediated cell responses such as growth, survival and metabolism.  PKB substrates have a 
common consensus sequence, RXRXXS/T, where X is any amino acid and S/T are the 
phosphorylation sites.   Glycogen synthase kinase (GSK) was the first substrate identified for PKB 
and the consensus substrate sequence was derived from it (Brazil et al., 2001; Datta et al., 1999).  
GSK inactivates glycogen synthase after stimulation and regulates glycogen synthesis.  PKB 
phosphorylates GSK3- at Ser9 and indirectly regulates the stability of c-Myc, an oncogene 
implicated in a number of cell growth, survival and tumourigenic pathways (Sears et al., 2000).  
PKB has been implicated in regulating the apoptotic pathway specifically through control of the 
phosphorylation and inhibition of apoptotic mediators such as the FOXO family (Brunet et al., 
1999), the Bcl-2 family, BAD (Datta et al., 1997), GSK3- and IKK-, and through inhibition the 
apoptosis-promoting JNK pathway.  PKB is also important in neurobiology, as it modulates 
neuronal synapse activity and neurodegeneration (Dudek et al., 1997). 
3.1.2) Class IB PI3K 
The class IB subgroup is a heterodimer composed of one catalytic p110 subunit (Fig. 5) that 
associates with p101 or p87 regulatory subunits of class IB PI3K (Walker et al., 1999; Pacold et 
al., 2000).  GPCR are major activators of class IB PI3K; as one more exception, this class can be 
activated by tyrosine kinases (Alcazar et al., 2008). 
 
 
Figure 5.  Domain structure of the class IB p110 catalytic subunit.  Ras-binding domain, C2 domain, PIK region and 
catalytic domain. 
3.1.3)  Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 
PTEN is an antagonist of class I PI3K signalling that directly opposes the activity of PI3K by 
dephosphorylating the third position of the inositol ring of poly-phosphoinositols (Maehama & 
Dixon, 1998).  PTEN was first discovered by two independent groups and recognized as a tumour 
suppressor gene on human chromosome 10q23, a locus that is highly susceptible to mutation in 
primary human cancers (Li & Sun, 1997; Steck et al., 1997). 
3.2)  Class II PI3K 
These enzymes mainly catalyse the production of PI(3)P, but to a lesser extent can also 
produce PI(3,4)P2 after activation. Class II PI3K have roles in regulating cytoskeleton organization, 
cell migration, membrane trafficking and exocytosis (Gaidarov et al., 2001; Engelman et al., 
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2006).  This class is comprised by three isoforms, PI3KC2, PI3KC2 and PI3KC2.  Class II PI3K 
are catalytic subunit monomers, as they do not associate with a regulatory subunit (Fig. 6).  PI3K 
C2 is located in the nucleus of some cell types, and can regulate mRNA transcription 
(Didichenko & Thelen, 2001). 
  
 
Figure 6.  Domain structure of the class II catalytic subunit.  Ras-binding domain, C2 domain, PIK region, catalytic 
domain, PX , C-terminal C2 domain. 
3.3)  Class III PI3K 
This PI3K class comprises only one isoform, the vacuolar protein-sorting defective 34 
(Vps34).  It is a heterodimer of the 101 kDa catalytic subunit (Fig. 7) and a 150 kDa regulatory 
subunit (Vps15p/p150).  Vps15p/p150 has an N-terminal myristylation signal, a serine/threonine 
kinase domain, a series of leucine-rich repeats, and C-terminal WD motifs (tryptophan-aspartate 
repeat).  Vps34 preferentially catalyzes phosphorylation of PI to produce PI3P.  The primary 
function of Vps34 was shown to be vesicle trafficking, but it might have additional roles in 
controlling cell growth, as it is reported to regulate the mammalian target of rapamycin (mTOR) 
(Nobukuni et al., 2005), and in autophagy (Wurmser & Emr, 2002; Vieira et al., 2001). 
 
 
Figure 7.  Domain structure of the Vps34 catalytic subunit.  C2 domain, PIK region and catalytic domain. 
3.4)  Class IV PI3K 
This is a distinct class of the PI3K family, which act as serine/threonine kinases and lack 
lipid kinase activity.  This class comprises four isoforms:  ataxia telangiectasia mutant (ATM), 
ataxia telangiectasia and Rad3-related (ATR), DNA-PK and mTOR (Engelman et al., 2006).  
ATM, ATR and DNA-PK are implicated in DNA repair, where they recruit DNA damage sensor 
proteins to the site of DNA damage and induce the cell cycle checkpoint through various means 
(Sancar et al., 2004).  Of these isoforms, ATR and ATM are activated by cell exposure to 
ultraviolet (UV) light or ionizing radiation (IR), after which they are recruited to the DNA damage 
sites.  Activation of ATM (by autophosphorylation at Ser1981) or ATR kinases activates 
checkpoint kinases 1 (Chk1) and 2 (Chk2) through phosphorylation.  Activated Chk1 and Chk2 
regulate several proteins that promote DNA repair, some of which cause cell cycle arrest due to 
DNA damage (Su, 2006). 
SECTION 4.  NUCLEAR CLASS IA PI3K SIGNALLING 
Whereas PI3K signalling in the cytosol is well documented as an essential pathway for 
transducing signals from the plasma membrane to the nucleus, evidence suggests that the nucleus-
specific phosphoinositide signalling pathway works independently of the cytoplasm (Neri et al., 
2002).  PI3K and its effectors involved in PI3K signalling, such as PDK1 (Lim et al., 2003), PKB, 
and PTEN are localised partially to the nucleus (Chan et al., 1999; Neri et al., 2002; Planchon et 
al., 2008).  The purpose of these signals is thought to be the activation of specific chromatin-
remodelling complexes (Rando et al, 2002; Zhao et al, 1998), specific gene transcription, and 
inhibition of apoptotic pathways (Martelli et al., 1999). 
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Whereas PI3K is constitutively expressed in the nucleus of rat hepatocytes (Martelli et al., 
1999), Neri et al. used immunostaining and immunoblotting of the p85 regulatory subunit to show 
that nerve growth factor (NGF) stimulation of PC-12 rat pheochromocytoma cells results in rapid 
PI3K translocation to the nucleus (Neri et al., 1994).  PI3K activity was identified in isolated rat 
liver nuclei (Lu et al., 1998).  Furthermore, analysis with an antibody to the regulatory subunit 
(p85) and immunoelectron microscopy demonstrated immunolabelling of both the nuclear 
membrane and the nucleoplasm, in agreement with a report showing the intranuclear presence of 
PI3K in Saos-2 human osteosarcoma cells (Zini et al., 1996).  Based on its immunological 
reactivity, nuclear rat liver PI3K was found to constitute approximately 5% of total cellular PI3K 
(Lu et al., 1998). 
Cytoplasmic PI3K activation requires activated RTK or GTPase proteins such as Ras.  
Nevertheless, none of these PI3K activators is known to be present in the nucleus.  A novel brain-
specific nuclear GTPase, phosphoinositide 3-kinase enhancer (PIKE), interacts with PI3K to 
stimulate its lipid kinase activity (Ye et al., 2000) in neurons.  NGF treatment elicits PIKE-S 
activation by triggering the nuclear translocation of PLC-1, which acts as a physiological GEF for 
PIKE-S through its SH3 domain (Ye et al., 2002); this effect is independent of its lipase catalytic 
activity.  Nuclear PI3K is also implicated in RNA processing and transport (Boronenkov et al., 
1998; Bunney et al., 2000).  NGF elicits the translocation of PI3K and its downstream effectors 
into the nucleus, although the mode of nuclear PI3K translocation and its biological functions in 
the nucleus remain elusive.  One goal of this study was to determine the mechanism of PI3K 
translocation to the nucleus. 
4.1) Role of nuclear PKB 
In NIH3T3 cells, v-Akt is distributed equally between cell membrane, cytosol, and the 
nucleus (Ahmed, 1993).  Both v-Akt and PKB localize in the nucleus (Chan et al., 1999).  After 
insulin stimulation in 293T cells, PKB translocation to the plasma membrane was followed by its 
nuclear translocation (Andjelkovic et al., 1997; Meier et al., 1997).  Nuclear phosphorylated PKB 
has been reported in lung, breast, prostate, and thyroid cancers, as well as in acute myeloid 
leukaemia (Lee et al., 2002; Brandts et al., 2005; Nicholson et al., 2003; Vasko et al., 2004; 
Capellini et al., 2003; Van de Sande et al., 2005).  All three PKB isoforms (PKB-1, -2, -3) have a 
classic leucine-rich, leptomycin-sensitive nuclear export sequence (NES) (Saji et al., 2005).  
PKB-1 overexpression with a non-functional NES results in constitutive nuclear localisation of 
PKB-1 and enhanced in vitro migration of PKB-1
-/-
 fibroblasts (Saji et al., 2005).  These findings 
suggest that PKB nuclear localisation is involved in tumourigenesis.  It was also reported that in 
PC12 cells, PIP3 generated in the nucleus by PI3K after NGF stimulation regulates the nuclear 
translocation of PKC- (Neri et al., 1999); following nuclear translocation, PKC- phosphorylates 
nucleolin (Zhou et al., 1997) involved in rRNA synthesis, metabolism and transport (Ginisty et 
al., 1999) (Fig. 8).  Nucleolin also acts as a stabilizing agent for the anti-apoptotic protein Bcl-2 
(Sengupta et al., 2004; Kito et al., 2003).  Recent reports propose that nuclear PKB activity 
promotes cell survival (Lee et al., 2008). 
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Figure 8.  Nuclear PI3K signalling.  NGF binding to its receptor stimulates translocation of both PI-PLC- and PI3K 
class I (p85/p110) to the nucleus.  Catalytically inactive PI-PLC- acts as a GEF and activates a nuclear GTPase called 
PIKE.  PIKE stimulates the activity of the nuclear PI3K, which phosphorylates PtdIns(4,5)P2 into PtdIns(3,4,5)P3.  
PtdIns(3,4,5)P3 attracts PKC- and p-PKB that, after activation, translocate from cytoplasm to the nucleus and 
phosphorylate their nuclear substrates.  The nuclear PI3K pathway inhibits the DNA fragmentation activity of caspase-
activating DNAse (CAD), promotes cell differentiation and assists mRNA export through Aly, a recently identified 
targets of the activated nuclear PI3K pathway. 
SECTION 5.  NUCLEAR REGULATORY PROTEINS 
A number of nuclear proteins are intimately involved in the sequential expression of genes 
that regulate variety of cellular processes.  Many have the ability to bind DNA and thereby 
influence the expression of other genes.  Of these, c-Myc constitutes the main interest of our study 
and is introduced below. 
5.1)  c-Myc 
c-Myc was one of the first proto-oncogenes discovered; it belongs to the MYC family that 
also includes N- and L-myc genes, which encode related proteins.  The proteins (c-Myc) encoded 
by MYC family genes localize predominantly to the cell nucleus, and their expression generally 
correlates with cell proliferation.  The c-myc gene was first isolated as the chicken cellular 
homologue of v-myc (Vennstrom et al., 1982).  c-Myc is frequently elevated in human cancers 
(Little et al., 1983; Mariani-Costantini et al., 1988; Munzel et al., 1991; Erisman et al., 1985); 
its overexpression is strictly dependent on mitogenic signals and is suppressed by growth-
inhibitory signals (Alexandrow et al., 1995). 
c-Myc is important for proliferation and apoptosis in response to appropriate stimuli, and 
itself acts as a strong mitogenic and apoptotic stimulus (Grandori et al., 2000).  Mouse embryos in 
which both c-myc alleles have been deleted by homologous recombination lack primitive 
haematopoiesis and die early in development (Davis et al., 1993).  Targeted gene replacement of 
endogenous c-myc with N-myc during embryogenesis allows normal development, indicating that 
N-myc has functional activities largely equivalent to those of c-myc (Malynn et al., 2000; Landay 
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et al., 2000).  L-myc-null mice are healthy and do not have a phenotype distinct from their wild-
type littermates, suggesting that L-myc is not required for embryogenesis (Hatton at al., 1996).  
Downregulation of c-Myc expression leads to a marked decrease or absence of proliferation and 
cell viability (Shi et al., 1993). 
The study of the proteins that interact with c-Myc led to identification of the Max protein.  
Max interacts specifically with all MYC family proteins, and the resulting heterocomplexes 
recognize the hexameric DNA sequence CACGTG (belonging to the larger class of sequences 
known as E-boxes, CANNTG) (Prendergast & Ziff, 1991).  c-Myc requires Max to activate 
transcription of genes containing E-box-binding sites (Amati et al., 1992).  c-Myc-Max binding to 
E-boxes is associated predominantly with gene activation, a finding consistent with c-Myc‟s ability 
to recruit multiple co-activator complexes (Grandori et al., 2000; Adhikary & Eilers, 2005; Cole 
& Nikiforov, 2006).  c-Myc has also been associated with transcriptional repression.  While there 
are several modes of Myc repression, at least one mechanism involves specific binding and 
inhibition of the transcriptional activator Miz-1 (Kleine-Kohlbrecher et al., 2006).  Deregulated 
ARF, p53, and Bcl-xL interact with c-Myc to increase cell growth by inhibiting c-Myc-induced 
pro-apoptotic pathways (Seoane et al., 2002; Lawlor et al., 2006).  c-Myc also regulates 
expression of genes that block cell cycle progression (e.g., cyclin-dependent kinase inhibitors 
(CKI) (Knoepfler et al., 2002; Staller et al., 2001; Herold et al., 2002), inhibit signal transduction 
pathways (Berwanger et al., 2002), and reduce cell contact and adhesion (Frye et al., 2003; 
Wilson et al., 2004; Gebhardt et al., 2006).  The ability of mammalian c-Myc to abrogate the 
influence of proliferation arrest genes is a crucial aspect of c-Myc function in normal development 
(Zindy et al., 2006) and in tumourigenesis (Seoane et al., 2002; Oskarsson et al., 2006).  Proteins 
of the Mxd family (formerly known as the Mad family) of transcriptional repressors contain 
c-Myc-related bHLHZ domains, heterodimerise with Max, and bind E-box sequences to restrict 
c-Myc binding and antagonize c-Myc function (Grinberg et al., 2004; Hooker and Hurlin 2006; 
Rottmann and Luscher, 2006). 
In general, c-myc expression correlates with the proliferative potential of the cell.  Cells that 
constitutively express high c-Myc levels have reduced requirements for GF (Kaczmarek et al., 
1985; Sorrentino et al., 1986; Stern et al., 1986), spend less time in G1 phase (Karn et al., 1989), 
and cannot become quiescent (Kohl & Ruley, 1987).  c-Myc regulates expression of a large 
number of genes, some of which play an essential role in the G0/S interval (Ponzielli et al., 2005; 
Dang et al., 1999).  c-myc is an early response gene whose rapid induction is essential for cell 
progression from G0 to G1 and for progress through early G1 (Schorl 2003; Mateyak et al., 1997; 
Amati et al., 1998).  c-Myc expression is induced within minutes of cell exposure to GF, and 
contributes to control of cyclin D and cyclin E expression.  Moreover, c-Myc is essential for 
cyclin-A expression (Vlach et al., 1996, Mateyak et al., 1999).  c-Myc also regulates CDK kinase 
activity by controlling p27
Kip1
 expression, and in addition, can restrain p27
Kip1
 association to 
cyclinE/CDK2 and cyclinA/CDK2 (Vlach et al., 1996, Perez-Rogers et al., 1997).  c-Myc levels 
also increase in two waves that coincide temporally with PI3K activation (Ponzielli et al., 2005; 
Jones et al., 2001).  c-Myc is a very unstable protein; regulation of its stability is therefore 
controlled temporally throughout the cell cycle.  Phosphorylation-dependent regulation of c-Myc 
stability involves two key residues, Thr58 and Ser62; the former is mediated by MAPK and the 
latter by GSK3, which targets c-Myc for degradation (Yeh et al., 2004). 
SECTION 6.  CELL CYCLE 
The cell cycle is one of the most comprehensively studied biological processes, given its 
importance for cell growth and development in normal physiology and in many human disorders.  
Research on yeast, mammals, flies, worms and frog reveals a universal picture of the regulation of 
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basic cell cycle machinery.  The time required to complete one cell cycle is organism-specific.  For 
example, bacteria require as little as 20 min for cell division, single-celled yeast take 90-120 min, 
whereas mammalian cells need about 24 h to complete the cell cycle.  The fundamental cell cycle 
events such as DNA replication and cell division occur during interphase and cytokinesis, 
respectively.  In interphase, the cell‟s mass increases, followed by duplication of cytoplasmic 
components and of chromosomes.  The interphase can be further classified into four primary 
stages, G1, S, G2 and M phases (Fig. 10).  A brief review of the different interphase stages is given 
below, followed by a detailed description of each phase. 
The G1 phase represents the collective events needed by the cell to prepare for the process 
of DNA replication.  In G1, the cell also determines its fate to stop, proceed or exit the cell cycle, 
depending on mitogen or growth inhibitory signals.  After proceeding to a state in G1 termed the 
“restriction point” (Pardee, 1989), the cell becomes refractory to extracellular growth regulatory 
signals and is committed to completion of the cell cycle (Garcia et al., 2006).  After completion of 
DNA replication, cells transit to G2 or Gap 2 phase, an interval in which a cell prepares itself to 
undergo successful nuclear division, termed mitosis.  The mitosis or M phase represents the group 
of complex events through which the replicated chromosomes are segregated into separate nuclei, 
after which the cell proceeds to cytokinesis for cytosolic division into two independent daughter 
cells.  Following successful cytokinesis, growth factors determine whether the daughter cells 
continue the cell cycle process or leave the cycle to enter the specialized resting phase known as 
G0.  Defects in G1 control are universal in tumours.  Appropriate stimulation leads cells to leave 
G0 (quiescence), and re-enter the cell cycle through the G1 phase; hence, the division program is 
cyclical (Vermeulen et al., 2003; Norbury & Nurse 1992; King
 
& Cidlowski, 1998). 
 
 
 
Figure 10.  Cell cycle image illustrating different phases of the cell cycle.  The cell cycle is composed of four distinct 
phases:  the first gap phase (G1); the DNA synthesis phase (S); the second gap phase (G2); and finally, mitosis (M).  A 
normal cell requires approximately 24 h for duplication, and the daughter cells generated re-enter the cell cycle in G1 
(figure adapted from Alberts et al., 2004). 
A model system widely used to study cell proliferation and cell cycle progression is the 
stimulation of serum-starved cells with growth factors, after which the events leading to transition 
and progression from one phase into another are followed. 
6.1)  From G0 to S 
In many cell types, serum starvation results in quiescence (G0).  The quiescent state 
represents the total inactivation and stalling of the machineries that promote cell proliferation, 
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through elevated expression and activation of various cell cycle inhibitors (Deng et al., 2004).  To 
proliferate, these cell types must first begin the cell cycle by entering G1 phase.  In G0 phase, 
however, cells express limited numbers of receptors for their ligands and low levels of cyclins.  
After stimulation, these ligands bind to and activate their respective receptors, which become 
competent to respond to further stimuli following the expression of new receptors.  Expression and 
activation of new growth factor receptors also results in expression and activation of cell cycle 
regulatory proteins, leading to the G0/G1 transition, which is accompanied by an increase in 
cellular metabolism (Sherr, 1994). 
6.1.1)  Progression through G1 phase 
Mitogen stimulation leads to G1 entry by activating RTK, GPCR and Ras, which use various 
means to control G1 phase-regulating proteins at the level of transcription and translation, and 
downstream signalling pathways (Jones & Kazlauskas, 2000). 
In unicellular eukaryotes, cell cycle progression is governed mainly by CDK (cyclin-
dependent kinase) Ser/Thr kinases that pair with cell cycle-specific regulatory subunits known as 
cyclins, due to their transient expression during cell cycle progression.  There is a series of critical 
criteria that must be met during G1 for cells to proceed to S phase.  These criteria, and those for 
cell re-entry into the cell cycle through G1, are governed by the sequential assembly and activation 
of different sets of cyclin-Cdk complexes.  Although initially discovered in yeast, cyclins are now 
known to be the universal cell cycle regulators in all eukaryotes.  In multicellular eukaryotes, cell 
cycle control is more complex; several CDK and cyclins are required for cell cycle progression.  
The D cyclins (D1, D2, D3) and Cdk4 or Cdk6 are needed for G1 progression; cyclin E and Cdk2, 
or cyclin A and Cdk2 are necessary for entering S phase, and cyclinA/CDK2 as well as 
cyclinA/CDK1 and cyclinB/CDK1 for progression through mitosis (Ekholm et al., 2000).  
Different cyclins impart distinct substrate specificity to CDK for temporal regulation of cell 
division.  G1 events can be further subdivided into early, mid and late G1 phase. 
Growth factor addition initiates the first wave of signalling in G0/G1 transition and early G1, 
which continues for 60-90 min post-stimulation and then returns to basal levels.  The first wave of 
GF mediates signalling through activation of tyrosine kinases, GPCR, and Ras.  This results in a 
substantial increase in cyclin D1, D2 and D3 expression, which is strictly GF stimulation-
dependent (Assoian & Zhu, 1997).  These cyclins interact with their catalytic partners CDK4 and 
CDK6 to form cyclinD/CDK4 and cyclinD/CDK6 complexes; they can phosphorylate many 
substrates to activate or inactivate them, and are essential for G1 entry (Sherr, 1994).  In contrast 
to cyclin D proteins, CDK protein levels remain relatively stable throughout the cell cycle.  In 
addition to cyclin-dependent CDK activation, the catalytic activity of CDK can be counteracted by 
phosphorylation on tyrosine and threonine residues (Tyr15 and Thr14) or through binding to the 
inhibitory subunit INK4 family of CKI (cyclin kinase inhibitor).  These CKI form stable complexes 
with CDK before cyclin binding, preventing association with cyclin D (Carnero & Hannon, 
1998).  In contrast, the other class of cell cycle inhibitors, p21
Cip1
 and p27
Kip1
, although they bind 
and inhibit CDK2, also bind to cyclinD/CDK4 or cyclinD/CDK6 complexes, but do not inhibit 
their kinase activity (Blain et al., 1997; LaBaer et al., 1997).  Indeed, association of p21
Cip1
 and 
p27
Kip1
 contribute to the formation of stable cyclinD/CDK4 or cyclinD/CDK6 complexes during 
early cell cycle phases (Blain et al., 1997; LaBaer et al., 1997; Cheng et al., 1999) and target 
them to the nucleus.  CyclinD/CDK complexes can also be activated by threonine phosphorylation 
(Thr177 in CDK6 and Thr172 in CDK4) by CDK-activating kinase (CAK). 
In addition to the biochemical modulation through different cell cycle inhibitors, continuous 
stimulation is required to maintain cyclin D levels, which sustains CDK kinase activity, as these 
proteins have short half-lives.  When cyclinD/CDK4 or cyclinD/CDK6 complexes are active, the 
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target proteins are phosphorylated on CDK consensus sites.  A critical target of cyclinD/CDK4 and 
cyclinD/CDK6 is the product of the retinoblastoma tumour suppressor gene (Rb).   Rb is a 110 kDa 
nuclear phosphoprotein that belongs to the family of pocket proteins, due to its pocket-like 
structure; it binds to cell proteins in G1 and blocks cell cycle progression (Tamrakar et al., 2000; 
Harbour & Dean, 2000; Lukas et al., 1995).  Growth suppression by Rb is considered to be a 
consequence of its ability to bind E2F and HDAC (histone deacetylase protein); Rb acts as a 
transcriptional repressor of the E2F target genes needed for cell cycle progression.  During early 
G1, Rb is phosphorylated at Ser795, leading to its partial dissociation from HDAC and E2F, which 
then transcribes proteins needed for later cell cycle phases. 
In addition to inducing cyclinD-associated CDK kinase activity, early G1 signals also 
inactivate the FOXO transcription factors.  These factors negatively regulate cell cycle progression 
by inhibiting cyclin D1 and D2 expression (Brunet et al., 2002) and by promoting transcription of 
cyclin inhibitors such as p18
INK4c
, p27
Kip1
 and p21
Cip1
 (Schmidt et al., 2002; Dijkers et al., 2000; 
Medema et al., 2000).  Cell cycle-promoting signals also stimulate downregulation and 
degradation of cell cycle inhibitors such as p27
Kip1
 and p16
INK4a
.  In these conditions, expression of 
D-type cyclins activates the CDK kinase activities, which inhibit transcription of cell cycle 
inhibitor proteins and activate other transcription factors. 
6.1.2)  Progression through late G1 to S phase 
While D type cyclins, in association with CDK4 and CDK6, regulate early and mid-G1 
phase progression, cyclinE/CDK2 acts in the G1-to-S phase transition.  The progression from G1 to 
S phase requires the de novo expression of genes that encode proteins and enzymes involved in 
DNA replication.  Regulation of these S phase genes is therefore an important component of the 
biological program during late G1 progression.  S phase genes are silenced in quiescent and early 
G1 cells, and are activated at the G1/S transition.  Indeed, late G1 signalling mechanisms require 
induction of a second wave of activation of signalling molecules in late G1 (Jones & Kazlauskas, 
2000; Jones & Kazlauskas, 2001).  The two waves of GF-dependent signalling events are 
necessary for a proliferative response.  The first is an acute burst of signalling that takes place 
immediately after GF stimulation, lasts for 60-90 min, and is essential to trigger cell growth and 
cyclin D synthesis; the second occurs in late G1 (7-12 h post-stimulation) and the mechanism that 
triggers its induction is unknown.  RTK and Ras are activated during the second signalling wave, 
and inhibition of either of these abrogates cell cycle progression (Jones et al., 1999; Takuwa & 
Takuwa, 1997, 2001).  The second signalling wave in late G1 induces cyclin E expression, which 
in turn increases its associated CDK2 protein kinase activity.  The active cyclinE/CDK2 complex 
hyperphosphorylates pRb at various positions, inactivating it completely.  CyclinE/CDK2 kinase 
activity is negatively regulated by the Cip/Kip family of cell cycle inhibitor proteins.  p21
Cip1
 
(Harper et al., 1995), p27
Kip1
 and p57
Kip2
 (Nakayama & Nakayama, 1998) form inactive 
complexes with cyclinE/CDK2, which no longer allow CAK phosphorylation of CDK2 at Thr160.  
In addition, p21
Cip1 
and p27
Kip1
 have separate binding sites for cyclins and CDK, which regulate 
cyclinE/CDK2 complex formation and interfere with the ATP binding site in the catalytic cleft of 
the complex.  p27
Kip1
 appears to be a primary negative regulator during normal cell proliferation in 
a variety of cell types (Sherr & Roberts, 1999). 
At the G1/S boundary, pools of cyclinE/CDK2 are liberated from the inactive ternary 
complex and phosphorylate p27
Kip1
 at Thr187; this phosphorylation provides a recognition motif 
for an E3 ligase (SCFSkp2) that targets phosphorylated p27
Kip1
 for ubiquitination.  Ubiquitinated 
p27
Kip1
 is targeted for proteosomal degradation (Elledge and Harper 1998; Bloom & Pagano 
2003).  p27
Kip1
 is phosphorylated only when the cyclinE/CDK2 concentration exceeds that of 
p27
Kip1
 (Vlach et al., 1997; Sheaff et al., 1997).  As p27
Kip1
 is degraded, positive-feedback 
dynamics lead to rapid phosphorylation and destruction of the remaining p27
Kip1
 pool.  There are 
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additional mechanisms by which p27
Kip1
 binding to the cyclin/CDK complex is regulated; these 
include MAPK and direct c-Myc-mediated inhibition of p27
Kip1
 binding (Vlach et al., 1996).  
Sequential pRb phosphorylation by many cyclin/CDK complexes in late G1 results in complete 
activation of E2F and chromatin-remodelling proteins following their release from the Rb complex, 
promoting entry into S phase.  This pRB inactivation is also considered the sensor of restriction 
point.  In other words, the restriction point switch from GF-dependent early G1 to the subsequent 
mitogen-independent phases reflects the induction of broad transcriptional programmes that are 
regulated by the parallel Rb and c-Myc pathways, which regulate genes critical for G1/S transition 
and initiation of S phase progression.  Activated E2F contributes to both the silencing and the 
activation of S phase genes.  E2F1 positively regulates the transcription of genes whose products 
are required for late G1 progression and S phase entry, including cyclin A, cyclin E and Cdc25 
(Buchkovich et al., 1989; Brehm et al., 1998).  A schematic diagram of G1-to-S progression, the 
temporal relationship between the two G1 control points, and the components that influence cell 
cycle, with their approximate position, is shown in Fig. 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
Figure 11.  G1 progression with cyclins, cyclin inhibitors and restriction point clearance.  Quiescent cells (G0) 
entering the cell cycle after growth factor addition are driven by the activities of different cyclin/CDK complexes, which 
hyperphosphorylate Rb and p27Kip1, thereby blocking their growth-inhibitory functions and permitting cell cycle 
progression. Progression through G1 phase is facilitated by cyclinD/CDK4, cyclinD/CDK6 and cyclinE/CDK2.  
CyclinD/CDK4 and cyclinE/CDK2 complexes are active after phosphorylation by CAK.  Following activation, the 
cyclinE/CDK2 complex mediates p27Kip1 proteosomal degradation and release of E2F transcription factors from the Rb 
complex.  Released E2F induces expression of cyclinA and induces cyclinA/CDK2 activity, promoting S phase entry and 
DNA replication. 
6.2)  S phase entry and progression 
The function of cyclinE/CDK2 is not completely restricted to G1 phase regulation.  In S 
phase, the E-type cyclins and their catalytic partner CDK2 phosphorylate substrates directly 
involved in cell duplication, such as replication origin components and proteins involved in origin 
firing, thereby participating in establishment of the pre-replication complex (pre-RC) and its 
licensing, which is determined by the binding of the minichromosome maintenance protein 
complex (MCM) to the replication complex (Yu & Sicinski, 2004).  The cyclinE/CDK2 complex 
is considered indispensable for S phase initiation.  At the G1/S boundary, cyclin A is expressed, 
binds to CDK2, and regulates S phase progression.  CyclinA/CDK2 is activated in late G1; this 
activation increases steadily as cells begin DNA replication, and it is required for S phase 
INTRODUCTION 
 42 
completion (Girard et al., 1991).  The increased activities of cyclinE/CDK2 and cyclinA/CDK2 
maintain p27
Kip1
 levels low in S phase through phosphorylation-triggered proteolysis (Malek et al., 
2001). 
Replication in eukaryotic cells is initiated from many replication origins, and a large network 
of proteins is required to regulate DNA replication.  A two-step mechanism governs the initiation 
of DNA replication, ensuring that the entire genome is precisely duplicated in each cell cycle.  In 
the first step, Cdc6 and Cdt1 collaborate with the origin recognition complex (ORC) to load the 
replicative hexameric helicase MCM2-7 complex, which has ATPase activity, into pre-RC at 
replication origins (Fig. 12, Cvetic & Walter, 2006).  Once the MCM proteins have been loaded 
on chromatin, ORC and Cdc6p can be removed from chromatin without preventing subsequent 
DNA replication, which suggests that the primary role of the pre-RC is MCM loading (Rowles et 
al., 1999; Hua & Newport, 1998).   CyclinE/CDK2 is crucial for MCM2 loading onto chromatin,
 
as it cooperates with Cdc6 in pre-RC assembly.  Cells lacking
 
cyclin E fail to load MCM2 
replicative helicase onto replication origins while re-entering the cell cycle from quiescence (Geng 
et al., 2003).  Inhibition of the MCM2-7 complex causes its dissociation from chromatin, resulting 
in a rapid halt of DNA replication. 
 
 
 
 
 
 
 
 
 
 
Figure 12.  A model for pre-replicative complex formation.  Current information concerning pre-RC formation in 
eukaryotes.  The stoichiometry of the components is unknown.  The apparent overabundance of MCM2–7 relative to 
other components is illustrated as additional MCM2–7 complexes associated with adjacent chromatin (figure adapted 
from Bell & Dutta, 2002). 
DNA duplication occurs once per cell cycle due to pre-RC assembly only in late mitosis and 
G1; once cells enter S phase, pre-RC can no longer assemble.  Cell cycle regulation is critical to 
ensure that origins fire once and only once during each cell cycle.  CDK2- and CDK1-associated 
activity thus prevents pre-RC formation by phosphorylating pre-RC components (ORC, Cdc6p and 
the MCM), although the mechanism by which it prevents re-initiation is unknown (Nguyen et al., 
2001).  Cdc6 phosphorylation leads to its degradation (Calzada et al., 2000; Drury et al., 2001).  
Phosphorylation of the MCM2-7 complex leads to its export from the nucleus once released from 
the chromatin (Labib et al., 1999; Nguyen et al., 2000).  Although Cdt1 itself may not be 
phosphorylated, it is exported with MCM (Tanaka & Diffley, 2002).  Whereas the same proteins 
are regulated by CDK phosphorylation in all organisms, the details differ.  Metazoans have a CDK-
independent mechanism to control re-replication, the Cdt1 inhibitor protein geminin (Wohlschlegel 
et al., 2000; Tada et al., 2001).  Geminin is present from S through M phase, and is degraded by 
the anaphase-promoting complex (APC) at the metaphase-to-anaphase transition (McGarry & 
Kirschner, 1998).  Pre-RC formation marks potential sites for the initiation of DNA replication; 
hence, the regulation of complex formation at origins is essential to ensure that large eukaryotic 
genomes are faithfully duplicated.  These proteins include regulatory factors as well as components 
of the DNA replication fork. 
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The next step in the process of DNA duplication is activation of the origins through 
formation of a replication fork. Cdc7/ASK protein kinase complex then convert pre-RC  into 
bidirectional replisomes at each origin.  The MCM helicase is activated at this point, unwinds the 
DNA duplex, and the resulting single-stranded DNA is stabilized through binding of multiple 
copies of the heterotrimeric single-strand binding protein RPA. This results in formation of a 
bidirectional replication fork.  DNA strands are replicated continuously through the 5´ 3´ 
polymerase activity of DNA polymerases.  After the initiation of DNA replication by the formation 
of small newly synthesised oligonucleotides by DNA polymerase-, replication factor C (RFC, 
chaperone-like complex) specifically bind to the template primers at the 3´ ends and catalyzes the 
subsequent binding of the ring-shaped homotrimer replication factor PCNA that encircles DNA, 
displacing DNA polymerase- and recruiting polymerase- to replace RFC in the replicative 
complex; this enables rapid, progressive synthesis of both leading and lagging strands at the 
replication fork (Fig. 13) (Johnson & O'Donnell, 2005; Barsky & Venclovas, 2005). 
PCNA belongs to the family of DNA sliding clamps (-clamps), which are structurally and 
functionally conserved (Kelman, 1997).  They form ring-shaped complexes with pseudohexameric 
symmetry, which encircle the DNA and are able to slide freely in both directions. On the verge of 
DNA replication completion, the DNA Plo or  holoenzyme meets the 5‟ end of the RNA portion 
of the
 
previously synthesised fragment, specialised proteins are recruited that
 
remove the RNA part, 
fill the gap. Finally, Lig1 associates with PCNA and performs
 
the final ligation step, sealing the 
nick and finishing the process (Moldovan et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  DNA replication. During S phase, DNA replication begins with local decondensation and separation of the 
double DNA helices, so that the DNA molecule becomes accessible for enzymes to make a complementary copy of each 
strand. (figure from M. Ruiz, Wikepedia [accessed 22-04-09]). 
6.3) G2 phase 
Similar to G1, G2 is an intermediate gap phase.  After genome duplication in S phase, cells 
transit through G2, where they prepare for mitosis.  In this phase, cell cycle regulatory proteins 
ensure that the copied DNA is error-free (Lukas et al., 2004), and respond to DNA damage 
(similar checkpoints are found in other cell cycle phases).  The DNA damage response results in 
one of several possible cell fate decisions:  induction of cell cycle arrest, initiation of DNA repair, 
activation of transcription programs, and either apoptosis or cell senescence (Khanna & Jackson, 
2001; Zhou & Bartek, 2004). The DNA damage response causes a delay to allow DNA repair 
before entry into mitosis.  The DNA damage checkpoints are not unique pathways activated by 
DNA damage, but rather are biochemical pathways that operate under normal growth conditions 
that are amplified by an increase in damage.  These checkpoints not only arrest the cell cycle in 
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response to DNA damage, but also control activation of DNA repair pathways and regulate the 
movement of DNA repair proteins at the damage site (section 7). 
Apart from checking and correcting potential DNA errors, proteins that are needed for 
mitosis are synthesised and assembled during the G2 phase, including mitotic cyclins, Plk, and the 
Aurora kinases. 
6.4)  Mitosis 
Mitosis is the final phase of the cell cycle.  Mitosis can be further divided in four stages:  
prophase, metaphase, anaphase and telophase. 
6.4.1)  Prophase 
Prophase is the beginning of mitosis, in which the cyclinA/CDK1 and cyclinB/CDK1 
complexes are activated to drive events, such as chromosome condensation and resolution, nuclear 
envelope breakdown, and assembly of the mitotic spindle (composed of cytoplasmic microtubules 
and other proteins).  In prophase, microtubules move one pair of centrioles to the opposite poles of 
the cell. 
6.4.2)  Metaphase 
The prophase to metaphase transition involves the cyclinA,B/CDK1-mediated bi-orientation 
of all sister chromatid pairs on the spindle.  The sister chromatids are pulled towards the poles, but 
held together by sister chromatid cohesion.  When all the chromosomes are aligned at the cell 
equator halfway between the poles in metaphase, the anaphase-promoting complex (APC) activates 
and promotes degradation of the cohesins, permitting progression to anaphase.  Cyclin A is 
destroyed during prometaphase and cyclin B promotes the completion of chromosome 
condensation and spindle assembly: cyclin B is destroyed later in anaphase. 
6.4.3)  Anaphase 
CDK activity drives cell cycle progression until metaphase, when its inactivation coincides 
with dephosphorylation of CDK substrates and activation of the APC, cohesions degradation 
permits chromosome separation and movement and spindle stability (Nigg, 2001; Miel, 2004).  
Progression into anaphase and beyond therefore depends on the ubiquitin-protein ligase called the 
anaphase-promoting complex (APC) or cyclosome, which ubiquitinates several regulatory proteins, 
thereby targeting them to the proteosomes for destruction.  APC activity oscillates in response to 
changes in APC association with the activating subunits CDC20 or CDH1. In anaphase, sister 
chromatids separate and move toward opposite poles of the cell through the spindle apparatus. At 
the end of anaphase, each pole of the spindle located has a complete set of chromosomes and the 
cell is ready to transit to telophase. 
6.4.4) Telophase 
Telophase begins when chromosomes arrive at the poles and begin to decondense.  The 
nuclear envelope forms from the fusion of small vesicles. At this point DNA division (mitosis) is 
complete. 
6.5) Cytokinesis 
Cytokinesis is the final stage in eukaryotic cell division.  It is achieved by the equatorial 
constriction of the mother cell through an actomyosin-based contractile ring, dividing the 
cytoplasm into the daughter cells.  This process is precisely regulated in space and time. 
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6.6) Class IA PI3K and the cell cycle 
The early embryonic lethality of p110- or p110-null mice indicates that these isoforms 
have distinct, essential functions in embryonic development and possibly in cell division (Bi et al., 
1999; Bi et al., 2002).  In normal cells, PIP3 can be detected transiently following stimulation with 
growth factors (Whitman et al., 1988; Varticovski et al., 1989).  Class IA PI3K mediates the GF-
stimulated pathways, such as PKB activation, that initiate cell division.  Enhanced PIP3 production 
after GF receptor binding accelerates cell cycle entry, whereas PIP3 reduction diminishes this 
process (Álvarez et al., 2003).  PI3K activity increases within minutes of GF receptor stimulation 
(first peak), with a second PI3K peak in mid-G1, which is essential for transition to S phase (Jones 
& Kazlaukas, 2001).  Neutralizing PI3K antibodies block S phase entry when they are 
microinjected in mid- to late G1 (Roche et al., 1994).  Indeed, inhibition of PI3K activity abrogates 
cell cycle progression (Garcia et al., 2006).  A role for PKB in cell cycle regulation was observed 
in the phenotype of MyrPKB-expressing cells, in which increased c-Myc and Bcl-2 expression 
were found even in the absence of GF (Brennan et al., 1997).  PKB helps to transduce PI3K-
dependent GF signals that end in Rb hyperphosphorylation, thereby promoting E2F activation.  
PKB also phosphorylates FOXO transcription factors, inducing their sequestration in the cytosol 
and reducing FOXO TF-mediated expression of cyclin G2 and p27
Kip1
, which in turn inhibit CDK 
and regulate p53 intracellular levels through MDM2 (Medema et al., 2000).  PI3K also controls 
the G0/G1 transition through PKB, promoting cyclin D synthesis through the PI3K effectors Rac 
and Cdc42; cyclin D then activates CDK4 or CDK6 in G1. Phosphorylation of Rb by PKB-
transduced signals could result from a combination of mechanisms, including downregulation of 
the cyclin-dependent kinase inhibitor p27
kip1
 by directly phosphorylation of p27
Kip1
 on Thr157; this 
results in nuclear exclusion of p27
Kip1
 and later degradation through ubiquitination (Sheaff et al., 
1997; Nguyen et al., 1999).  PKB also inhibits c-Myc and cyclin D degradation by inactivating 
GSK-3. Therefore, all these mechanisms contribute to explain how PI3K regulate G0>G1 
transition. Nevertheless, the mechanism involved in PI3K activation
 
in late G1 and its role in S 
phase entry remains unknown.  Here we used an alternative approach, inhibition of late G1 PI3K 
activity, to address the precise requirements for PI3K activation in late G1, and we analysed the 
effect of this inhibition on cell cycle. 
PI3K also influences the G2/M phase.  There is an additional minor PI3K activity peak at M 
phase entry.  Release of epithelial cell lines from S phase arrest shows a basal PI3K activity during 
S phase and activity peak at M phase entry (Garcia et al., 2006).  This second activation peak is 
not as strong as that observed during cell cycle entry, but PI3K inhibition in late S phase blocks 
mitosis entry in MDCK cells, whereas it delays this transition in HeLa and NIH3T3 cells 
(Shtivelman et al., 2002).  These studies show that PI3K regulates mitosis entry with a distinct 
relative contribution depending on cell type.  Finally, PI3K activity must be downregulated for 
completion of mitosis, as fibroblasts expressing constitutive active PI3K/PKB forms show delayed 
G2/M progression and defective cell cycle exit (Álvarez et al., 2001). 
7.  THE DNA DAMAGE RESPONSE 
Several types of DNA damage can trigger activation of the DNA checkpoint proteins.  
Activation of these checkpoint proteins temporarily blocks cell cycle progression to allow repair of 
the damaged DNA.  The class IV PI3K proteins ATM and ATR are among the most proximal 
players triggered by IR- and UV-induced DNA damage that initiate a rapid response, allowing 
DNA repair.  The proteins that participate in the cell response to genotoxic stress can be grouped as 
sensors, mediators and transducers (Fig. 14). 
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7.1) Sensors 
Three groups of proteins are known as checkpoint-specific damage sensors:  the MRN 
complex (MRE 11-Rad50-Nbs1 complex) (Lee & Paull, 2005), the RFC/PCNA (clamp 
loader/polymerase clamp)-related Rad17-RFC/9-1-1 complex (Melo & Toczyski, 2002) and the 
two phosphoinositide 3-kinase-like kinase (PIKK) or class IV PI3K family members, ATM and 
ATR (Durocher & Jackson, 2001). 
7.1.1)  Mre11-Rad50-Nbs1 complex 
The MRN complex is a heterotrimeric complex consisting of Mre1, Rad50 and Nbs1 
proteins.  After formation of DSB (double-strand break), this complex binds to DNA and resects 
the double strand, exposing ssDNA to proteins involved in repair (Falck et al., 2005; Mirozoeva et 
al., 2001; Carney, 1998).  MRN complexes can activate ATM by independently promoting both 
monomerisation and autophosphorylation. 
7.1.2)  Rad17-RFC and the 9-1-1 complex 
The Rad17-RFC complex is a checkpoint-specific structural homologue of the RFC 
replication factor, where Rad17 interacts with four RFC subunits (Rfc2, Rfc3, Rfc4 and Rfc5) to 
form a pentameric complex.  After checkpoint activation, the 9-1-1 (Rad9-Rad1-Hus1) complex 
functions as a clamp loader, similar to PCNA (Bartek J et al., 2004; Parrilla-Castellar et al., 
2004; Bartek & Lukas, 2003).  In vitro experiments suggest that Rad17 recruits the 9-1-1 complex 
to DNA damage sites (Bermudez et al., 2003).  After DNA damage, however, phosphorylation of 
Rad17 by ATR is necessary for the DNA damage checkpoint response (Bao et al., 2001).  
Replication protein A (RPA) mediates the recruitment of ATR/ATRIP, Rad17, and 9-1-1 
complexes to ssDNA and stimulates the kinase activity of ATR toward Rad17 (Zhou & Elledge, 
2000; Zou et al., 2003).  When IR induces the DNA damage, Rad 17 phosphorylation relies more 
heavily on ATM activation (Bao et al., 2001). 
7.1.3)  ATM and ATR 
ATM and ATR are among the most proximal proteins that carry out a variety of cell 
processes in response to DNA damage (Sancar et al., 2004; Tibbetts et al., 1999; de Klein et al., 
2000).  ATM is a 350 kDa oligomeric protein, whereas ATR (ATM- and Rad3-related) is a 
303 kDa protein.  Both ATM and ATR show considerable sequence similarity to PI3K family 
proteins (Engelman et al., 2006), although ATM and ATR lack lipid kinase activity and are 
protein kinases activated following DNA DSB formation. 
After cell exposure to ionizing radiation, ATM, which is normally found in the nucleus as a 
resting homodimer, is activated through intermolecular autophosphorylation on Ser1981.  This 
results in the dissociation of ATM homodimers and localisation of monomeric ATM to damage 
sites on the DNA (Bakkenist & Kastan, 2003).  Activated ATM in turn phosphorylates many 
proteins, including Chk2 at Thr68 (Matsuoka et al., 2000; Zhou et al., 2000; Bartek & Lukas, 
2003), p53 at Ser15 (Caspari, 2000), NBS1 (Lim et al., 2000) and BRCA1 (Cortez et al., 1999). 
ATR must associate with ATRIP (ATR-interacting protein) for its function, and is activated 
preferentially after generation of single strand breaks (UV irradiation) (Cortez et al., 2001; Sancar 
et al., 2004).  Following activation, ATR phosphorylates the same proteins as ATM, as well as 
another set of substrates after UV irradiation.  ATR is also activated in response to IR, although 
probably later and not as strongly as ATM.  In the absence of ATM, ATR can partially compensate 
for ATM function by phosphorylating and activating common downstream targets (Cliby at al., 
1998; Kim et al., 1999).  In the absence of ATR, ATM is unable to compensate, and ATR
-/-
 
mutants are embryonic lethal (de Klein et al., 2000).  DNA synthesis defects induce mainly the 
ATR pathway. 
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7.2) Mediators 
Mediator proteins associate simultaneously with damage sensors and help to provide signal 
transduction specificity. Mediator proteins include histone 2AX (H2AX), Rad9, p53-binding 
protein (53BP1) (Schultz et al., 2000; Wang et al., 2002), the topoisomerase-binding protein 
(TopBP1) (Yamane et al., 2002), mediator of DNA damage checkpoint 1 (MDC1) (Goldberg et 
al., 2003; Stewart et al., 2003), and structural maintenance of chromatin 1 (SMC1).  These 
proteins interact with damage sensors such as ATM, ATR, RAD17 and the MRN complex, signal 
transducers such as Chk2, and effector molecules such as p53.  H2AX phosphorylation is one of 
the first measurable responses to DSB (Fernandez-Capetillo et al., 2003).  It is phosphorylated on 
Ser139 and is loaded into a 2 Mb region surrounding a break and can be visualized (Burma et al., 
2001; Banath & Olive, 2003; Friesner et al., 2005).  The DNA damage checkpoint response is 
abrogated in cells that have decreased levels of or lack of these proteins. 
7.3) Transducers 
Two kinases, Chk1 and Chk2, have a strict signal transduction function in cell cycle 
regulation and checkpoint responses; both are Ser/Thr kinases with limited substrate specificity.  In 
mammalian cells, the DSB signal sensed by ATM is transduced by Chk2 (Hirao et al., 2000), and 
the UV damage signal sensed by ATR is transduced by Chk1 (Abraham, 2001); there is 
nonetheless some functional overlap between these two proteins. 
A part of our research examined the consequences of knockdown of the class IA PI3K 
isoform on checkpoint responses following radiation stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  The DNA damage response (DDR). The DDR is robustly activated by DNA double strand breaks (DSB) 
and/or exposure of RPA-coated single-stranded DNA (ssDNA).  DSB are sensed by MRN complex, and the C terminus 
of NBS1 recruits the apical protein kinase ATM, which undergoes autophosphorylation.  Chk2 localizes transiently at 
DNA damage sites to be phosphorylated and activated by ATM.  The exposure of modified histone residues further 
boosts accumulation of the DNA damage mediator 53BP1 at the damage site.  In the case of single strand breaks, once 
ssDNA forms, RPA-coated ssDNA recruits the heterodimeric complex that comprises ATR (a paralogue of ATM), its 
DNA-binding subunit ATRIP, and the RAD17-9-1-1 complex.  ATR activity is boosted by the 9-1-1 and RAD17-RFC 
complexes.  In addition, ATR activity is stimulated by TOPBP1, which is necessary for CHK1 phosphorylation.
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AIMS OF THE STUDY 
 
Activation of class IA PI3K is necessary for cell growth and cell cycle entry downstream of 
growth factor receptors.  Moreover, mutational activation or overexpression of class IA PI3K 
isoforms result in enhanced PI3K signalling, which is associated with cell transformation and 
cancer.  Growth factor-mediated PI3K activation occurs at two distinct time points during the G1 
cell cycle phase.  The first activation peak is observed immediately after growth factor addition, 
whereas the second peak of activation occurs in late G1, before S phase entry.  This second activity 
peak is essential for DNA replication; nonetheless, the mechanism and function of PI3K activation 
at the onset of S phase entry is poorly understood. 
A fraction of class IA PI3K was recently described to reside in the cell nucleus.  The role of 
nuclear PI3K is linked to cell survival, mitogenesis, and differentiation through its principle 
effector, PKB.  Which PI3K isoforms are nuclear nonetheless remains unclear.  The different 
class IA PI3K isoforms p110 and p110 exhibit distinct, important functions in cell division.  It is 
therefore necessary to study the intracellular localisation of the class IA PI3K catalytic and 
regulatory subunits, as well as the mode of their nuclear translocation. 
Genetic deletion of p110 and p110 in mice leads to embryonic lethality.  In addition, 
p110 has been clearly implicated in cancer, as multiple mutations lead to an increase in its kinase 
activity.  Overexpression of p110 is also reported in various types of tumours, although no 
functional mutations are known in the PIK3CB gene.  A recent study of conditional knockout mice 
for p110 showed a kinase-independent role in development; nonetheless, the p110 function is 
presently unclear . 
 
To address these issues, the main objectives of my thesis work were:  
 
1) Investigate the mechanism of activation and the role of class IA PI3K activity in late G1 
2) Identify which isoforms of class IA PI3K localise in the nucleus and study the mechanism 
for their nuclear translocation 
3) Investigate p110 involvement in DNA damage responses 
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1. Antibodies and reagents 
1.1) Antibodies 
 
Antibody Supplier 
c-Myc (C-19) Santa Cruz Biotechnology 
Cyclin E (M-20) Santa Cruz Biotechnology 
Oestrogen receptor alpha (ER) (MC-20) Santa Cruz Biotechnology 
Pan-Ras Oncogene Research 
Tubulin Oncogene Research 
p-PKB(473) Cell Signaling Technologies 
Cyclin D3 BD Biosciences 
p27Kip BD Biosciences 
MCM2 BD Biosciences 
Rb Zymed Laboratories 
Phospho(T58/S62)-c-Myc Cell Signaling Technologies 
Myc-tag (9B11) Cell Signaling Technologies 
Cyclin A Upstate Biotechnology 
Phosphotyrosine Upstate Biotechnology 
-actin Sigma 
Histone Chemicon International 
Cyclin D2 Santa Cruz Biotechnology 
CDK4 Santa Cruz Biotechnology 
p110 (for immunofluorescence) Santa Cruz Biotechnology 
p110 (WB, IP) Cell Signaling Technologies 
p110 (immunofluorescence) Klippel et al., 1998 
p110 (WB, IP) Cell Signaling 
p-Chk1 (Ser345) Cell Signaling 
Chk1 Novocastra 
Chk2 Upstate 
p-ATM (1981) Rockland Immunochemicals, Inc 
p85 Donated by Isabel Cortes, DIO, CNB 
PCNA BD transduction Lab. 
RAD17(IP) Santa Cruz Biotechnology 
RAD17(WB) Abcam 
p-RAD17 Abcam 
p-p38 Cell Signaling Technologies 
p38 Cell Signaling Technologies 
p-SMC1 Abcam 
-H2AX Millipore 
HRP-conjugated second antibodies Dako 
Anti-rabbit second Ab-Alexa 488 Molecular Probes 
Anti-rabbit second Ab-Cy3 Jackson Laboratories 
Anti-rabbit second Ab-Cy5 Jackson Laboratories 
Anti-mouse second Ab-Alexa 488 Molecular Probes 
Anti-mouse second Ab-Cy3 Jackson Laboratories 
Anti-mouse second Ab-Cy5 Jackson Laboratories 
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1.2)  Reagents 
Enhanced
 
chemiluminescence, L-[
35
S]methionine, [-
32
P]dCTP, and [-
32
P]ATP
 
were from 
Amersham Biosciences.  Lovastatin, herbimycin, and
 
Ly294002 were from Calbiochem.  PIK75 
and TGX221 (Knight et al. 2006;Jackson et al. 2005)
 
were synthesised in the Australian Centre 
for Blood Diseases (Melbourne, Australia). Hoechst 33258 was purchased from Molecular Probes.  
Cyclohexamide, leptomycin B, and all remaining reagents were bought from Sigma 
2. Cell Culture 
2.1) Cells and Cell lines 
The different cell lines were maintained in Dulbecco's modified
 
Eagle's medium (DMEM; 
Gibco-BRL) supplemented with 10% (vol/vol)
 
foetal bovine serum (FBS), 2 mM glutamine, 10 
mM HEPES, 100 U/ml
 
penicillin, and 100 µg/ml streptomycin in a humidified
 
atmosphere (5% 
CO2, 37°C).  
Cell lines used: 
 NIH 3T3 mouse fibroblast line 
 HeLa epithelial cell line derived from human cervical cancer 
 Saos-2 human epithelial-like osteosarcoma cell line 
 Phoenix cells are second-generation retrovirus producer lines for the generation of helper 
free ecotropic and amphotropic retroviruses 
 293T cells expressing gag-pol and envelope protein (for ecotropic and amphotropic 
viruses) were also used in some retroviral infections 
Mouse embryonic fibroblasts (MEF): 
MEF were isolated from mouse embryos at day 14 of gestation, and maintained in tissue 
culture medium with 20% FBS.  Immortalized p110 KO, KR and WT MEF were donated by Drs. 
JJ Zhao and TM Roberts (Dana Farber Cancer Institute, Boston, MA). 
2.2)  Transfection and retroviral transduction 
We used JetPei (Genycell) to transfect cell lines. In some cases, transfected cells (p110 
shRNA) were selected for 2 days in medium containing 2 g/ml puromycin (Sigma).  For retroviral 
transduction, Phoenix cells were transfected using JetPei-NaCl (Polyplus
 
transfection) according to 
manufacturer's protocols; after
 
10 h, cells were washed and placed in DMEM-10% FBS.  At 48 h 
post-transfection, the supernatant from transfected phoenix cells was filtered through a 0.45m 
filter and polybrene added to a final concentration of 5 g/ml.  Cells to be infected were 
supplemented with viral supernatant and polybrene, and were centrifuged (1800 rpm, 90 min, 
37ºC).  To improve infection, the procedure was repeated 3 times at 8-10 h intervals.  Infected 
NIH3T3 (c-MycER) cells were selected for 2 days in
 
medium containing 2 g/ml puromycin. 
2.3) Synchronization of NIH3T3 cells 
Synchronization in G0.  To monitor the G0-to-S transition
 
accurately, we established a standard 
time course protocol for
 
all experiments (Martinez-Gac et al. 2004).  Exponentially growing cells 
were seeded into
 
dishes and rendered quiescent by incubation in DMEM-0.1% FBS
 
(19 h).  Under 
these conditions, cells showed a G0 phenotype,
 
examined as described (Martinez-Gac et al. 2004). 
Synchronization in metaphase.  NIH3T3 cells were arrested in mitosis by maintaining cells in 
medium containing 75 ng/ml colcemid (KaryoMAX, 12 h). 
2.4) Cell cycle analysis 
Propidium iodide staining for cell cycle analysis.  Quiescent cultures were
 
rinsed with serum-free 
medium and synchronous cell cycle entry
 
was stimulated by serum re-addition (10% final 
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concentration). 
 
Some samples were harvested immediately before serum addition
 
(time zero); other 
cells were harvested at various times after serum
 
stimulation.  DNA synthesis was studied by DNA 
staining with
 
propidium iodide and analysed in a flow cytometer (Beckman-Coulter)
 
as described 
(Álvarez et al., 2001). 
BrdU incorporation. Cells were incubated with 10 M BrdU (90 min) and harvested at indicated 
time points using trypsin-EDTA (see Fig. 4).  Cells were washed twice with phosphate-buffered 
saline (PBS)-1%
 
FBS and fixed in ice-cold 80% methanol overnight.  Cells were
 
then washed twice 
and resuspended in PBS containing 1% FBS and
 
0.1 mg/ml RNase (30 min, room temperature).  To 
extract histones
 
and denature cellular DNA, we incubated cells with 1.5 N HCl
 
and 0.5% Triton X-
100 (30 min, room temperature).  For direct
 
immunofluorescence staining, cells were incubated 
(1 h) with
 
fluorescein isothiocyanate-conjugated anti-BrdU antibody (Becton
 
Dickinson).  After 
washing (PBS-1% FBS), cells were resuspended
 
in 500 l PBS (with 0.1 mg/ml RNase, 0.1% 
NP-40,
 
5 g/ml propidium iodide). DNA synthesis was studied as percent BrdU incorporation and 
analysed by flow cytometry (Beckman-Coulter). 
2.5) Pulse-chase assay 
NIH3T3 cells were incubated in DMEM-0.1% FBS for 19 h (as above); medium was then 
replaced with Met-free RPMI
 
(Gibco) containing 10% dialyzed FBS (9 h), with 0.75
 
mCi [
35
S]Met 
(per p100 dish) included for the last 6 h.  At
 
8.5 h after serum addition, some samples were treated
 
with Ly294002 (10 M).  After the 9-h pulse, the [35S]Met-containing medium was washed and 
replaced by DMEM-10% FBS containing 200 M cold Met and Cys alone, or with Ly294002 
(10 M) and maintained until 12 h and 16 h after serum addition (chase). 
2.6) Inhibitor treatment 
To activate c-MycER, we added 4-hydroxytamoxifen (4-OHT; 200
 
nM, Sigma) 6.5 h after 
serum stimulation.  In some cases, cells
 
were treated with 0.1% dimethylsulphoxide (control), 
lovastatin
 
(10 M), herbimycin (2 M), or Ly294002 (10 M).  When samples were collected at 
time zero, inhibitors were added
 
30 min before serum addition; otherwise, inhibitors were added
 
4, 
6, or 7 h after serum stimulation.  Cycloheximide (20 g/ml) was used to inhibit translation in 
intact cells.  In DNA repair experiments, cells were TGX221-treated (indicated) to inhibit 
p110kinase activity. 
3. DNA, Northern blot, DNA damage, real-time DNA damage 
3.1) cDNA 
The table below shows the different constructs used for experiments.  Myc-tagged-p110, 
originally cloned in pCMV, was subcloned into the PSG5 EcoRI site using the restriction enzyme 
EcoRI at both ends.  pEBG-GST-p110 was generated by inserting p110 in the C-terminus of 
GST in pEBG. To construct pEBG-GST-p110-NLS, the SV40 NLS sequence PKKKRKV was 
inserted 3‟ of p110.  pSG5-p85-NLS was generated in a similar manner, where amplified p85-
NLS was inserted in pSG5.  pEGFP-C1-p110 was generated by amplifying p110 and inserting it 
in pEGFP-C1.  The mutants pSG5-p110 Mut1, pSG5-p110 Mut2 and pSG5-p110 Mut3 were 
generated using the Quik site-directed mutagenesis kit (Stratagene) with primers described below. 
For preparation of the p85 chimera, the p85 fragment from amino acids 77 to 343 was 
replaced by the corresponding amino acids from p85. 
1-p85  amino acids by PCR amplification and 
was subcloned in the pSG5 vector.  100-p85  was 
purchased from Origene Technology. 
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Plasmid Reference 
pSG5-Myc-p110 bovine Jiménez et al., 1998 
pCDNA3-His-p110 human B. Vanhaesebroeck (Ludwig Inst Cancer Research, UK) 
pSG5-Myc-p110 human Described in above 
pEBG-GST-p110 Described in above 
pEBG-GST-p110-NLS Described above 
pSG5-p110 Mut1 Described above 
pSG5-p110 Mut2 Described above 
pSG5-p110 Mut3 Described above 
pSG5-HA-p85 I. Cortés, DIO, CNB, Madrid 
pSG5-HA-p85 I. Cortés, DIO, CNB, Madrid 
pSG5-HA-p85-NLS Described above 
pSG5-HA-p65 I. Cortés, DIO, CNB, Madrid 
pSG5-1-p85 Described above 
pSG5-2-p85 Described above 
pCMV-c-Myc-WT/T58A S. Lowe (Cold Spring Harbor Laboratory, NY) 
pBabe puro c-Myc-ER G. Evan (Cancer Research Institute, UCSF, CA) 
pEGFP-NBS1 O. Fernández Capetillo, CNIO, Madrid 
pEGFP-53BP1 O. Fernández Capetillo, CNIO, Madrid 
RFP-PCNA M.C. Cardoso, MDC, Berlin   
3.2)  mRNA  analysis (Northern blot) 
Total RNA was isolated from serum-starved, 9 h-serum stimulated, or LY-treated cells using 
the Trizol reagent kit.  Total RNA (20 g) was separated by electrophoresis in denaturing 
formaldehyde-1% agarose gels and transferred overnight
 
to a nylon membrane (Zeta-Probe; Bio-
Rad) followed by UV crosslinking.  The c-Myc probes were [
32
P]dCTP-labelled by random
 
priming with the Prime-It II labelling kit (Stratagene).  Hybridization was performed with 
ExpressHyb solution
 
(BD Biosciences; 1 h, 60°C) in the presence of 10 g/ml sheared salmon 
sperm DNA (Sigma).  The membrane was washed three
 
times in 2x SSC (150 mM NaCl, 15 mM 
sodium citrate, pH 7.0) with 0.05% sodium dodecyl sulphate (SDS) at room temperature,
 
and once 
in 0.1x SSC plus 0.1% SDS (52°C).  Murine c-Myc (1.4 kb) was used as probe. 
3.3)  Ultraviolet and ionizing radiation treatment 
NIH3T3 cells were transfected with p110 shRNA or control plasmid.  After 30 h 
transfection, cells were selected for 2 days in
 
medium containing 2 g/ml puromycin and exposed 
to ultraviolet or ionizing radiation at the doses given in Results.  IR was delivered by the X-ray 
generator (MARK 1-30, Shephard & Associates).  
3.4)  Real-time recruitment of DNA repair proteins to microlaser-generated DNA damage sites 
NIH3T3 cells transfected with p110 shRNA or control plasmid were incubated with 2 
g/ml puromycin after 30 h transfection.  After selection for 12 h, transfected cells were seeded on 
6-well Petri plates with puromycin-containing medium. At 10 h post-plating, cells were transfected 
with fluorescent-tagged plasmids (indicated) using the JetPei/NaCl method.  After 24 h, cells were 
again seeded on Petri plates for live study using confocal microscopy (Leica).  Some control plates 
were incubated with TGX221.  Before laser treatment, medium was changed to phenol red–free 
DMEM (Invitrogen). DNA intercalating dye Hoechst 33258 was added at 10 µg/ml and incubated 
for 20 min at 37°C. Cells were irradiated with a 351-nm laser along a user-defined path to generate 
localized DSBs. The UV laser output was set to 50%, the minimum dose required to generate a 
clearly detectable DSB response (in a Hoechst-dependent manner) strictly within the laser-exposed 
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nuclear compartments.  The total time of single-cell exposure to the laser beam did not exceed 1 
sec.  In these conditions, cells showed no morphological or cytotoxic effects.  Immediately after 
microirradiation, the same field was subjected to repeated image acquisition via the confocal unit 
integrated into the microscope using LCS software version 2.61.  The first images were 
consistently recorded ~5 - 6 sec after DSB generation with a gap of 1.6 sec. per image . 
4. Biochemical assays and immunofluorescence 
4.1) Cell lysis, subcellular fractionation 
Cell lysis. Total cell lysates were prepared in RIPA lysis buffer (20 mM Tris-HCl pH 8.0, 137 mM 
NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS and protease inhibitors (1 mM PMSF, 1 mM Na3VO4, 10g/ml leupeptin, 10 g/ml aprotinin, 
5 mM NaF, 10 mM okadaic acid, 1 mM EDTA). 
Subcellular fractionation. For analysis of MCM2 loading onto chromatin, cells were fractionated 
into cytosol, nucleosol and chromatin using the lysis buffers in the following sequence. 
 For extraction of the cytoplasmic fraction, cells were resuspended in buffer A (10 mM 
Hepes pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 340 mM sucrose, 10% glycerol, 1 mM DTT, 
0.1% TX-100 with protease inhibitors mentioned above) for 5 min on ice, then centrifuged 
(3500 rpm, 5 min).  The supernatant constitutes the cytoplasmic fraction. 
 The remaining pellet contains the intact nuclei of the lysed cells, which were washed once 
in buffer A without TX-100 and centrifuged as above.  Pellets were then resuspended in 
buffer B (3 mM EDTA, 0.2 mM EGTA with protease inhibitors) and incubated (30 min, on 
ice, with mixing every 10 min).  The lysates were then centrifuged (3500 rpm, 5 min).  The 
supernatant constitutes the nuclear soluble fraction and the pellet contains the chromatin 
fraction. 
 Pellets were resuspended in 2x Laemmli sample buffer for electrophoresis and boiled (5 
min, 95ºC).  These samples were sonicated to resuspend DNA aggregates. 
To examine protein-protein interactions, cells were fractionated into cytosolic and nuclear 
fractions using the lysis buffers below sequentially (NP-40 protocol). 
 For extraction of the cytoplasmic fraction, cells were resuspended in buffer A (10 mM 
Hepes pH 7.5, 10 mM KCl, 5 mM MgCl2 with protease inhibitors mentioned above) and 
incubated (15 min, on ice), after which NP-40 was added to a final concentration of 0.3%, 
followed by incubation (10 min, on ice).  Lysates were centrifuged (3500 rpm, 5 min).  The 
supernatant constitutes the cytoplasmic fraction. 
 Pellets (nuclear fraction) were resuspended in buffer B (20 mM Hepes pH 7.5, 200 mM 
NaCl, 1% NP-40 containing protease inhibitors and DNAse 2-3U/l) and incubated (30 
min, 37ºC).  Lysates were then centrifuged (14000 rpm, 20 min) and the supernatant was 
collected as total nuclear extract. 
4.2).  Immunoprecipitation and Western blotting 
For PCNA association with p110 and p110, NIH3T3 cells were co-transfected either with 
pSG5-Myc-p110 plus pSG5-HA-p85-NLS or pSG5-Myc-p110 plus pSG5-HA-p85-NLS.  
Transfected cells were fractionated into cytoplasmic and nuclear fractions using the NP-40 
protocol.  Total protein concentration was measured
 
with the Micro BCA kit (Pierce).  
Immunoprecipitation was performed
 
by incubating lysates (4ºC, 3-4 h) with the appropriate 
antibody, followed
 
by incubation with 30 l of 50% protein A-Sepharose slurry (Amersham 
Biosciences) for 1 h.  Protein (800 g) from the nuclear fraction was used to immunoprecipitate 
p110, and 200 g nuclear lysate was used for control immunoprecipitations.  Immunoprecipitates 
were washed three times with
 
lysis buffer, twice with 50 mM Tris-HCl, pH 7.5.  
MATERIAL & METHODS 
 58 
Immunoprecipitated
 
proteins were resolved by SDS-PAGE, then transferred to nitrocellulose
 
for 
Western blot analysis. 
RAD17 association with p110 was examined in control cells or cells irradiated with UV or 
IR; at 1 h post-exposure, cells were harvested and fractionated as cytoplasmic and nuclear extracts 
using the NP40 protocol. Anti-p110 Ab (Cell Signaling) was used to immunoprecipitate p110 
from 800g nuclear lysate, whereas RAD17 was immunoprecipitated from 200 g (control) using 
anti-RAD17 Ab (Santa Cruz).  Western blot to analyse associations were developed with anti- 
RAD17 and anti-pan p85 for controls. 
4.3) PI3K assays 
Different PI3K isoforms were immunoprecipitated from the distinct subcellular fractions 
using appropriate antibodies (see Results). Immunopurified PI3K was resuspended
 
in 20 l 50 mM 
Hepes containing phosphoinositide4,5-bisphosphate (PIP2; 10 mg/ml; Sigma) as substrate.  The 
kinase reaction
 
was initiated by adding 5 l of kinase buffer containing 10 Ci [32P]ATP, 100 mM 
MgCl2, and 100 M cold ATP (37ºC, 5 min).  The reaction was terminated by adding 100 l 1 M 
HCl and 200 l of methanol/chloroform (1:1 v/v).  The extracted phospholipids were resolved by 
thin layer chromatography (Silica Gel 60; Merck)
 
on 1% potassium oxalate-coated plates and 
developed in glacial
 
acetic acid/H2O/n-propyl alcohol (4:31:65 v/v/v).  The radioactive
 
products 
were visualized by autoradiography. 
4.4) Cyclin/Cdk kinase assays 
NIH 3T3 cells were incubated in DMEM-0.1% FBS for 19 h (see
 
above), after which 
medium was replaced with DMEM containing 10% FBS for 9, 12 and 16 h.  At 7 h post-serum 
addition, some samples were treated
 
with Ly294002 (20 M).  Cells were harvested at indicated 
times (see Results) and lysed.  We used 200 g of total lysate to immunoprecipitate cyclin E or 
cyclin A using appropriate antibodies.  Antibodies were incubated with total lysates overnight 
(4ºC) followed by protein A (blocked with 3% milk in 1x PBS) incubation (2 h, 4ºC).  Bead-bound 
immunoprecipitated protein was washed three times with lysis buffer, twice with 50 mM Tris/HCl 
pH 7.5 and twice with kinase buffer.  The kinase reaction was performed in kinase buffer (20 mM 
Tris/HCl pH 8.0, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 5 Ci -ATP with protease inhibitors) 
and incubated (30 min, 30ºC).  Reactions were terminated by boiling the reaction mixture in 
1x Laemmli buffer (10 min, 95ºC), resolved in SDS-PAGE, and the radioactive
 
products were 
visualized by autoradiography. 
4.5)  Pull-down assay 
Ras pull-down assay.  Ras-GTP
 
was purified from cell extracts on Sepharose-Gex2T-RBD (the
 
Ras-binding domain of Raf-1).  Briefly, NIH3T3 cells were harvested,
 
lysed with glutathione 
S-transferase fluorescent in situ hybridization
 
buffer (50 mM Tris-HCl, pH 7.5, 2 mM EDTA, 
100 mM NaCl, 2 mM
 
MgCl2, 1% [vol/vol] NP-40, 5 mM NaF, 10% [vol/vol] glycerol,
 
1 mM 
phenylmethylsulphonyl fluoride, 1 g/ml aprotinin, and 10 g/ml leupeptin).  Protein 
concentration, determined
 
using the Micro BCA kit, was normalized
 
and lysates were incubated (1 
h, 4ºC) with glutathione-Sepharose
 
beads coupled with glutathione S-transferase-RBD.  Beads were
 
washed three times in lysis buffer, and bound Ras-GTP was solubilised
 
in 30 l Laemmli buffer.  
Ras-GTP levels were analysed
 
by Western blot 
GST-p110 pull-down.  NIH3T3 cells were transfected with pEBG-GST or pEBG-p110-NLS.  
Cells were harvested and fractionated into cytoplasmic and nuclear extracts.  Lysates (1 mg) were 
incubated (2 h, 4ºC) with glutathione beads.  Beads were washed twice with lysis buffer, once with 
50 mM Tris/HCl pH 7.5, bound p110 was resuspended in 2x Laemmli buffer and resolved in 
SDS-PAGE.  The gel was stained using a silver staining kit (Amersham).  Stained proteins were 
cut into small pieces and analysed by mass spectrometry.  p110-associated proteins was identified 
MATERIAL & METHODS 
 59 
by comparison of peptide sequences with the database. 
4.6)  Immunofluorescence 
Cell lines and MEF were fixed with 4% formaldehyde (1x PBS; 10 min, room temperature) 
after the indicated treatments.  The cells were then blocked using 1x PBS staining solution and 
permeabilised with 0.3% TX-100 PBS (10 min).  Cells were incubated with appropriate primary 
antibodies (1 h, room temperature, with end-to-end rocking), followed by three washes with 
blocking buffer.  Appropriate secondary antibodies were added to samples and incubated (1 h, 
room temperature), followed by three washes with blocking buffer.  Cells were then mounted using 
mounting medium containing DAPI (VectaShield) and visualized under the microscope the 
confocal or fluorescence microscope. 
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1. PI3K REGULATES G1/S TRANSITION 
1.1) Cell cycle progression 
There are several methods to study cell division, such as monitoring the increase in cell 
number over time or examining cells visually under a microscope.  The use of specific analysis in 
flow cytometry (such as staining of phospho-histone H3 for mitosis detection) provides additional 
means of estimating cell division, as does determination of the cell doubling time and of the 
percentage of cells in different phases of the cell cycle. For this last method we measure DNA cell 
content with propidium iodide. NIH3T3 cells, used here to study the cell cycle, were arrested in 
G0-phase by serum starvation (Martinez et al., 2004).  Serum-starved cells were stimulated with 
10% FBS to trigger cell cycle entry, after which they progressed synchronously through the distinct 
phases of the cell cycle.  Following stimulation, cells were harvested at different time points to 
determine by FACS the time needed to reach a specific cell cycle phase.  NIH3T3 cells showed a 
smooth progression through the cell cycle after stimulation of serum-starved cells (Fig. 1).  The 
G1-to-S phase transition occurred at ~9 h, and progressed through S phase until 16 h post-
stimulation.  At 18 h, cells showed a synchronized transition into G2/M phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
Figure 1.  Quiescent NIH3T3 cells enter S phase between 9 to 12 h post-stimulation.  DNA content in cell cycle 
profiles of NIH3T3 cells arrested in G0 by serum deprivation, then released for different periods (indicated) to allow 
synchronous cell cycle entry.  Percentage of cells in G0/G1, S (in bold) and G2/M phases is indicated. 
1.2)   PI3K activity in late G1 induces PKB activation that correlates with increased c-Myc protein levels 
Initiation of cell division requires exposure of resting quiescent cells to growth factors (GF) 
(Sherr, 1994). Cells cultured in the continuous presence of GF undergo two waves of intracellular 
signalling molecules activation, the first occurs within one hour after GF addition and the second at 
7-to-9 h after serum addition; the two signalling waves include activation of PI3K, Ras and MAPK 
(Jones et al., 1999). PI3K is activated in late G1 (Jones et al., 2001); this activity peak is essential 
for S phase entry, since PI3K inhibition in late G1 blocks S phase entry, and PIP3 addition in late 
G1 induces cell cycle entry in the absence of serum (del Real et al., 2004; García et al., 2006). 
Prolonged and continuous contact with GF is required to commit cells to cell cycle entry. Indeed, 
GF are needed until the cells pass the so called restriction point (in advance G1 phase), after which 
GF can be eliminated and the cells proceed to S phase even in the absence of GF (Garcia et al., 
2006).  However, the continuous presence of GF can be substituted by addition of GF in early and 
late G1 with an intermediate serum deprivation (Jones et al., 2001). We first checked that 
incubation with serum-containing medium for just 9h was sufficient to trigger cell cycle entry (not 
shown).  
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In cells entering the cell cycle synchronously, we confirmed early G1 (1 h) and late G1 (~9 
to 15 h) PI3K activity peaks (Fig. 2A), as determined by examining phosphorylation of the PI3K 
effector PKB (pPKB) (Bouchard et al., 2004). We also examined c-Myc expression levels and 
found that they paralleled the PI3K activity peaks (Fig. 2B). 
 
 
Figure 2. The late G1 PI3K activity peak induces PKB activation and c-Myc expression.  Western blot (WB) 
analysis of the cells in Fig. 1 using anti-phospho-S473-PKB (pPKB), -PKB, -c-Myc and -actin antibodies. 
1.3)  Ras and Tyr kinases activate PI3K in late G1 
It has been extensively examined how induction of the first signalling wave occurs 
immediately after acute cell stimulation (Marques et al., 2008). In contrast, nothing is known 
regarding the molecular events by which the second wave of signalling molecules occurs. Whether 
the mechanisms by which the signalling enzymes are activated during the first and second wave of 
signalling are identical or distinct is thus unknown. Growth factors activate tyrosine kinases (TyrK) 
and Ras needed for cell cycle entry. PI3K activation at the G0/G1 transition is known to be 
triggered following activation by TyrK and Ras activities (Blow & Dutta, 2005; Schmidt et al., 
2002). We thus investigated whether TyrK and Ras were also induced in late G1.  We examined 
TyrK activation using an anti-pTyr antibody in WB, and Ras activity in pull-down assays.  We 
observed that after growth factor addition, total TyrK activity increased transiently at 1 h, and again 
between 9 and 16 h (Fig. 3A).  Some of the Tyr-phosphorylated bands that appeared at 1 h differed 
from those visible at ~9 h, suggesting that more than one TyrK is activated during G1.  Ras 
activation was also observed in early and late G1, as Ras-GTP increased at ~1 h and again at 9-12 h 
post-serum stimulation; the second Ras activity peak was greater than that at early G1 (Fig. 3B). 
 
 
   A)                B) 
        
Figure 3.  PKB activation in late G1 correlates with TyrK and Ras activation.  A) Activation of TyrK in cells 
entering cycle, as determined in WB using anti-p-Tyr antibody.  B) Ras-GTP was examined in whole cell extracts.  Total 
Ras and Ras-GTP were examined by WB. The figure shows representative experiments of at least four with similar 
results. 
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PDGF receptor activation results in recruitment of p85/p110 from cytosol to the plasma 
membrane via p85 SH2 domains binding to phosphotyrosine residues on the PDGF receptor 
(Cantley et al., 1991). To determine whether TyrK or Ras stimulation was necessary for PI3K 
activation in late G1, we used the small molecule inhibitors: herbimycin for TyrK inhibition 
(Serrano et al., 1997) and lovastatin for Ras inhibition (Schorl & Sedivy, 2003), and examined 
the effects on PI3K activity in extracts from synchronous cell cultures. At 4 h post-serum addition, 
treatment with lovastatin, herbimycin, or both resulted in reduced PI3K activity at 7 to 8 h post-
serum addition (Fig. 4).   
 
 
 
 
Figure 4. Ras and TyrK contribute to PI3K activation in late G1. PI3K was immunoprecipitated from cell extracts 
(see Methods) and its activity assayed in vitro.  The inhibitors lovastatin (lov), lovastatin plus mevalonate (lov+mev) or 
herbimycin (herbi) were added to some samples at the time of serum addition (t = 0) or at 4 h post-serum addition, and 
cell extracts collected at the time points indicated.  Lipids were extracted and resolved by TLC. 
As PI3K activity regulates pPKB, c-Myc and cyclin levels, we also examined the effects of 
lovastatin and herbimycin on PI3K effectors.  Lovastatin addition at 0, 4 or 6 h reduced pPKB 
levels at 9 and 12 h after serum stimulation (Fig. 5A), suggesting that Ras activation is involved in 
late G1 PI3K activation.  Addition of mevalonate, a lovastatin substrate, restored PKB 
phosphorylation (Fig. 5A).  Herbimycin also reduced PKB activation at 9 and 12 h (Fig. 5A), 
whereas genistein, an inhibitor with high specificity for EGFR (Uckun et al., 1998), did not affect 
the second PI3K activity peak in late G1 (not shown).  Combination of lovastatin and herbimycin 
treatments yielded a greater reduction in pPKB (Fig. 5A).  
 In conclusion, examination of the PI3K effector PKB confirmed that TyrK and Ras are 
involved in late-G1 PI3K activation. The decrease in pPKB levels correlated with a reduction in 
both c-Myc content and in the number of cells entering S phase at 12 h (Fig. 5A).  We also 
examined the effect of lovastatin and herbimycin on cyclin D3, E and A levels. Inhibition of both 
TyrK and Ras reduced the levels of these cyclins, with a more marked effect on cyclin A (Fig. 5A). 
Since c-Myc-action is critical for Cyclin A expression, we concluded that one of the most 
prominent defects of PI3K inhibition on late G1 was the reduction of c-Myc levels and in turn the 
defective Cyclin A expression. TyrK and Ras thus cooperate to induce the second PI3K activity 
peak, which in turn regulates c-Myc and cyclins levels in G1, as well as S phase entry.  The activity 
of the inhibitors in blocking TyrK and Ras activation was confirmed in WB; herbimycin reduced 
cell phospho-Tyr levels (Fig. 5B), and lovastatin reduced the active Ras fraction, an effect that was 
reversed by mevalonate addition (Fig. 5C). 
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A)     
 
      
B)               C) 
 
Figure 5.  Ras and TyrK contribute to PI3K activation in late G1. A) pPKB levels in serum-starved cells, cells in 
exponential growth, or cells arrested in G0, then serum-released for 9 or 12 h.  Lovastatin (lov), lovastatin plus 
mevalonate (lov+mev) or herbimycin (herbi) were added to some samples at the time of serum addition (t = 0), at 4 h, or 
at 6 h after serum addition.  Cell extracts were examined by WB using anti-pPKB, -PKB, or -c-Myc antibodies.  The 
percentage of cells in G0/G1, S and G2/M phases is indicated.  B, C) The efficiency of the inhibitors was tested in 
samples as in (A) by WB using anti-pTyr (B) or -pan-Ras (C) antibodies.  The slower-migrating inactive Ras form is 
indicated. 
1.4) Late G1 PI3K inhibition reduces c-Myc and cyclin A levels as well as CDK2 activity 
As PI3K activation in late G1 correlates with increased c-Myc expression levels, we 
examined the effect of inhibiting PI3K in late G1 on c-Myc protein levels, as well as on the c-Myc 
effectors cyclin D2 and Cdk4.  Inhibition of PI3K activity markedly reduced c-Myc protein levels 
at 9 to 18 h post-serum addition (Fig. 6).  PI3K/PKB inhibits GSK3 (Chan et al., 2002), a kinase 
that phosphorylates c-Myc at Thr58, thereby triggering c-Myc degradation (Madine et al., 2000).  
PI3K inhibition notably enhanced c-Myc phosphorylation on Thr58, an event that correlated with 
reduction in c-Myc levels (Fig. 6).  The decrease in c-Myc protein levels correlated with 
diminished expression of the Myc transcriptional effectors cyclin D2 and CDK4 (Fig. 6). 
 
 
 
Figure 6.  PI3K inhibition in late G1 reduces c-Myc , cyclin D2 and CDK4 levels.  Extracts were prepared from cells 
entering the cell cycle synchronously.  The PI3K inhibitor Ly294002 was added at 7 h post-serum addition.  Western 
blots show expression of c-Myc, phospho-c-Myc, cyclin D2, CDK4 and actin.  The percentage of cells with sub-G1, 
G0/G1, S or G2/M DNA content is indicated beneath the blots.  
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To examine whether reduced c-Myc protein levels were caused by PI3K inhibition of c-Myc 
transcription or protein stability, we performed Northern blot for c-myc mRNA.  Cells were 
synchronized as above and the PI3K inhibitor Ly294002 was added 7 h after serum stimulation; 
cells were harvested at 9 h.  This analysis showed that late G1 PI3K inhibition induced a reduction 
in c-myc mRNA levels of about 15 ± 5% (at 9 h; mean of three experiments, Fig. 7B), whereas the 
reduction in c-Myc protein was systematically >50% (Fig. 7A). 
 
                            A)                                                B) 
 
Figure 7.  PI3K inhibition in late G1 reduces c-Myc protein but not mRNA levels.  Total RNA and protein extracts 
were prepared from cells entering the cell cycle synchronously.  Ly294002 was added at 7 h post-serum addition; cells 
were harvested at t = 0 and 9 h. Samples were examined in WB (A) and in Northern blot (B) using a c-myc probe or anti-
Myc antibody, respectively (B).  The Northern blot corresponds to two different experiments. 
We further examined the effect of PI3K inhibition in late G1 on c-Myc protein stability in 
35
S-Met pulse-chase assays.  Inhibition of PI3K activity in early G1 (3 h post-serum stimulation) 
blocked protein synthesis (not shown).  For pulse-chase, we synchronized cells, labelled them with 
35
S-Met between 3 to 9 h post-serum addition, and harvested them at 9 h.  At this time, the medium 
was exchanged for non-radiolabelled Met/Cys-rich medium, alone or with Ly294002, and cells 
were collected at 12 and 16 h (Fig. 8).  For the 9 h time point with Ly294002, the inhibitor was 
added 30 min prior to cell harvest.  PI3K inhibition greatly reduced c-Myc stability, an effect that 
was already evident by 30 min after enzyme inhibition (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8.  PI3K activity in late G1 regulates c-Myc protein stability.  Synchronized cells were 35S-Met labelled during 
the first 9 h post-serum addition and medium was changed to unlabelled Met/Cys-rich medium, alone or with Ly294002 
(Ly; 10 M), and cells were collected at 12 and 16 h.  For the 9 h with Ly294002, the inhibitor was added 30 min before 
harvest.  35S-c-Myc was examined by autoradiography.  Quantitative analysis of three experiments is shown. 
To further define the role of the second G1 PI3K activity peak in S phase entry, cells were 
synchronized in G0/G1 and PI3K was inhibited at 7 h post-serum stimulation; we examined the 
consequences for G1 phase cyclin levels at different time points.  Inhibition of late G1 PI3K 
activity greatly reduced cyclin A protein levels at 9 h, whereas cyclin D3 and E levels were more 
affected when Ly294002 was present for prolonged periods (Fig. 9).  The Ras inhibitor lovastatin 
had a greater effect than Ly294002 on reducing cyclin D3 levels (Fig. 5, 9); this is probably due to 
the reported Ras/MAPK dependence for cyclin D synthesis (Jirmanova et al., 2002).  We next 
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tested the effect of PI3K inhibition on CDK2 activity.  The CDK2 substrate retinoblastoma protein 
(Rb) was hyperphosphorylated in late G1 and this phosphorylation was markedly reduced by PI3K 
inhibition (Fig. 9). 
 
 
Figure 9.  Inhibition of PI3K activity in late G1 downregulates cyclin A levels and hypophosphorylation of 
retinoblastoma protein.  Cell extracts as Fig. 6 were examined by WB using anti-c-Myc, -cyclin D3, -E, and –A, as well 
as anti-Rb antibodies.  The percentage of cells in S and G2/M phases is indicated beneath the blots. 
Moreover, both cyclinE/CDK2 and cyclinA/CDK2 kinase activities were consistently 
decreased after PI3K inhibition (Fig. 10 A).  The decrease in cyclin A expression (Fig. 9) paralleled 
the reduction in cyclinA/CDK2 activity.  Nonetheless, PI3K inhibition in late G1 affected 
cyclinE/CDK2 activity more markedly than cyclin E levels.  Considering that we also observed an 
increase in p27
kip1
 expression after PI3K inhibition in late G1 (Fig. 10 B), a possible explanation 
for the defect could be that the increased p27
kip1
 levels resulted in an enhanced association of 
p27
kip1
 to cyclinE/CDK2 complex, thereby reducing its kinase activity.  
 
    A) 
 
               
B)         C)  
 
 
 
 
Figure 10.  PI3K activity in late G1 regulates cyclin E/A-associated CDK2 kinase activity. (A) Downregulation of 
cyclin E/CDK2 and cyclin A/CDK2 kinase activities in cyclin E and cyclin A immunoprecipitates, respectively, from cell 
extracts.  Histone H1 (5 g) served as substrate.  32P-histone was quantitated and the activity represented (in arbitrary 
units).  Mean ± SD of three experiments.  B) Upregulation of p27 protein levels after inhibition of PI3K activity in late 
G1.  C) Scheme representing the cause of downregulation of cyclin E/A-associated kinase activities on the inhibition of 
PI3K activity in late G1.  
We examined whether PI3K inhibition reduced cyclin E/CDK2 activity by enhancing its 
association with p27
kip
.  PI3K inhibition increased the amount of p27
kip
 bound to CDK2 (see 
 p27kip1 
                    0        1      3      6        9      12     16   18   9LY 12LY 16LY 18LY 
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below), which explained the reduction in cyclin E/CDK2 activity by late G1 PI3K inhibition.  
Cyclin E/CDK2 activity is required for minichromosme maintenance protein complex (MCM2) 
loading onto chromatin (Ekholm-Reed et al., 2004; Geng et al., 2003). Accordingly, PI3K 
inhibition in advanced G1 resulted in a notable reduction in the amount of chromatin-bound 
MCM2 (Fig. 11). 
 
 
Figure 11.  Inhibition of PI3K activity in late G1 reduces MCM2 association to chromatin.  Cells entering the cell 
cycle synchronously, treated as in Fig. 6 were fractionated into cytosolic, nuclear and chromatin fractions, which were 
examined in WB using anti-MCM2 and -histone antibodies.  A representative experiment is shown of three with similar 
results.  
1.5) Conditional c-Myc-ER activation rescues S phase entry in PI3K inhibitor-treated cells 
PI3K inhibition reduced cyclin A levels and CDK2 activity.  c-Myc regulates G1 cyclin 
expression, especially that of cyclin A, and the association of p27
kip
 with cyclin/CDK2 (Mateyak 
et al., 1997; Perez-Roger et al., 1997; Vlach et al., 1996).  We thus hypothesized that the main 
function of PI3K activity in late G1 is to regulate c-Myc levels.  To test this possibility, we used a 
c-Myc-oestrogen receptor fusion protein (c-Myc-ER) that translocates to the nucleus after addition 
of an estrogen analogue 4-OHT (Littlewood et al., 1995; Fig. 12A).  We examined whether the S 
phase entry defects induced by late G1 PI3K inhibition were counteracted by c-Myc-ER induction.  
Cells were infected with c-Myc-ER-expressing viruses (Fig. 12B), arrested in G0, and released by 
serum addition.  Some of the cells were treated with 4-OHT alone (at 6.5 h), with Ly294002 (at 7 h 
post-serum addition), or with both. We collected cells at different times and examined S phase 
entry.  
c-Myc-ER
 
induction corrected the defects in S phase entry, cyclin A expression,
 
and Rb 
phosphorylation induced by late-G1 PI3K inhibition (Fig. 12 C). c-Myc-ER expression did not 
trigger S phase entry in the absence of serum (Fig. 12D, E).  After serum addition, c-Myc-ER 
expression caused a slight increase in S phase entry compared to that in control cells, which was 
moderately enhanced by 4-OHT addition (Fig. 12 D, E).  We found no notable differences when 4-
OHT was added at 0 or at 6.5 h (not shown).  Ly294002 treatment reduced the proportion of cells 
in S phase by 50% in both c-Myc-ER and control ER vector-expressing cells (Fig. 12E).  
Nonetheless, c-Myc-ER induction at 6.5 h in cells treated with Ly294002 in advanced G1 (7 h) 
showed almost normal S phase entry levels (85% recovery) compared to Ly294002-treated controls 
(Fig. 12D, F).  Induction of c-Myc-ER failed to compensate for the action of PI3K in S phase entry 
when PI3K was inhibited in early G1 (0 to 4 h post-stimulation; Fig. 12E and not shown).  
Examination of BrdU incorporation confirmed that c-Myc induction at 6.5 h counteracted S phase 
entry defects in cells treated with Ly294002 in advanced G1 (Fig. 12F).  Results were comparable 
using the PI3K inhibitor wortmannin (not shown).  These data suggest that the main function of PI3K 
activity in late G1 is to regulate c-Myc protein levels. 
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A) 
 
 
 
 
 
B)                         C) 
                                          
D)  
 
 
E)       F) 
 
Figure 12. Conditional activation of c-Myc-ER rescues S phase entry blockade induced by PI3K inhibition in late 
G1.  A) Myc-ER, a chimaeric protein of c-Myc fused with the estrogen receptor, Myc-ER complexed with 
Hsp90 is localized in the cytoplasm in the absence of 4-OHT. Following 4-OHT addition, Myc-ER is 
translocated into the nucleus to be activated. B) c-Myc-ER expression was examined in c-Myc-ER-infected NIH3T3 
cells by WB using anti-Myc antibody. C) Synchronized c-Myc-ER-expressing cells were treated with 4-OHT (at 6.5 h), 
Ly294002 (at 7 h), or both simultaneously; cells were collected at different time points (indicated). Cyclin E, cyclin A, 
pRb, and actin levels were examined by WB. D) Cell cycle profiles of c-Myc-ER cells in quiescence (t = 0) or at 18 h 
post-serum addition, alone or in the presence of 4-OHT (200 nM; added at t = 6.5 h) and/or Ly294002 (10 M; added at t 
= 7 h post-serum addition).  The figure illustrates a representative experiment of three performed. E) Percentage of c-
Myc-ER and control cells in S phase.  Cells were treated as in (C).  A sample of cells treated with 4-OHT and Ly294002 
as above at the time of serum addition (t = 0 h) is included.  The figure shows the mean of three experiments.  F) BrdU 
incorporation in c-Myc-ER-infected NIH3T3 cells entering cell cycle synchronously as in (C) and collected at 13 h after 
serum addition.  BrdU (10 M) was present for the last 90 min.  Mean ± SD of three experiments. 
c-Myc  
 
Estrogen Receptor OHT(Estrogen
) 
nucleus 
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1.6)  Expression of a GSK3-resistant c-Myc mutant rescues the cell cycle entry defects 
induced by inhibiting PI3K activity in late G1 
PI3K/PKB inactivate GSK3, an enzyme that targets c-Myc for degradation (Yeh et al., 
2004; Fig. 13).  To confirm that c-Myc stabilization is the main role of PI3K activity in late G1, we 
examined the effect of inhibiting PI3K in cells expressing the c-MycT58A substitution mutant, 
which is resistant to GSK3 action (Hemann et al., 2005). 
 
 
 
 
 
 
 
 
 
 
     
Figure 13.  Mechanism of PI3K mediated c-Myc stabilization.  Activation of PI3K and ERK pathway through Ras. 
Activated PI3K inhibits GSK-3 activity to stop c-Myc phosphorylation at Thr 58. Phosphorylation at Thr 58 targets c-
Myc for proteosomal degradation. 
Cells were transfected with GFP control vector or with cDNAs encoding GFP fused to WT 
c-Myc or c-MycT58A (Fig. 14A).  Transfected cells were sorted, the cell cultures were 
synchronized, released from arrest, and treated with Ly294002 at 7 h after serum addition.  Cells 
were harvested at different time points.  Overexpression of either WT c-Myc or c-MycT58A 
induced apoptosis and cell cycle entry in the absence of serum (Fig. 14B).  Late G1 PI3K inhibition 
reduced cell cycle entry in control cells and, to a lesser extent, in cells overexpressing WT c-Myc; 
nevertheless, c-MycT58A expression largely restored cell cycle entry in cells treated with LY (Fig. 
14B).  
 
A)                                     B) 
 
Figure 14.  Expression of c-Myc T58A and WT c-Myc rescues cell cycle entry defects induced by PI3K inhibition 
in late G1.  A) WT-c-Myc and c-MycT58A expression in NIH3T3 cells, tested in WB using anti-Myc antibody.  B) 
DNA content in representative NIH3T3 cells transfected with a control vector or cDNA encoding WT-c-Myc or              
c-MycT58A.  Cells were arrested by serum deprivation (t = 0) and released by serum addition for 16 h.  Some samples 
were incubated with Ly294002 added 7 h post-serum stimulation.  
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In the previous experiment (Fig. 14), we observed that overexpression of c-Myc (WT or c-
MycT58A) induced apoptosis and cell cycle entry even in the absence of serum. To reduce c-Myc 
expression levels we used infection with virus encoding c-MycT58A, which yield lower expression 
levels than transfection.  Under these conditions, c-MycT58A did not markedly induce cell cycle 
entry in the absence of serum (Fig. 15). Synchronous cultures of infected cells were treated with 
Ly294002 at 7 h after serum addition and harvested at different time points.  PI3K inhibition 
blocked cell cycle entry in controls, but cell cycle entry was nearly normal in cells expressing c-
MycT58A (Fig. 15). Again, expression of c-MycT58A restored S-phase entry in cells treated with 
LY. These results confirm that a stable form of c-Myc substitutes for PI3K action in late G1. 
 
 
      
 
Figure 15. Expression of c-MycT58A rescues cell cycle entry defects induced by PI3K inhibition in late G1. DNA 
content in representative NIH3T3 cells infected with a control virus or a virus encoding c-MycT58A.  Infected cells were 
arrested by serum deprivation, or arrested and then released by serum addition for 9, 12, 16 and 18 h.  Some samples 
were incubated with Ly294002 added 7 h after serum stimulation.  A representative experiment is shown of four with 
similar results.  Percent of cells in G0/G1, S (in bold) and G2/M phases is indicated.  
1.7) c-MycT58A expression rescues cyclin A expression, CDK2 activity, and MCM2 loading 
defects induced by PI3K inhibition in late G1 
To confirm that the primary effect of PI3K activity in advanced G1 is to stabilize c-Myc, we 
tested whether c-MycT58A expression compensated for the cell cycle entry defects induced by late 
G1 PI3K inhibition.  PI3K inhibition moderately affected cyclin D3 and E expression levels (see 
above).  Similarly, c-MycT58A expression did not markedly alter cyclin D3 (not shown) or cyclin 
E levels (Fig. 16).  In contrast, cyclin A levels were greatly reduced by PI3K inhibition in late G1 
(Fig. 16).  c-MycT58A expression increased cyclin A expression in Ly294002-treated cells and 
moderately increased basal cyclin A levels (Fig. 16). Results were similar to c-Myc-ER-expressing 
cells treated with 4-OHT (at 6.5 h), Ly294002 (at 7 h), or both simultaneously (Fig. 12 C). 
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Figure 16. c-MycT58A expression counteracts cyclin A expression induced by PI3K inhibition in late G1.  Control 
and c-MycT58A-expressing cells were arrested in G0, then released and treated with Ly294002 at 7 h post-serum 
addition.  Cells were harvested at different time points (indicated) and extracts examined by WB using anti-cyclin E, -
cyclin A, -actin and -Rb antibodies. 
Moreover, whereas levels of hyperphosphorylated Rb and cyclinE/CDK2 and 
cyclinA/CDK2 kinase activities were reduced by late G1 PI3K inhibition in control cells, they were 
virtually unaffected in c-MycT58A-expressing cells (Fig. 17). 
 
 
 
 
 
Figure 17.  c-MycT58A expression counteracts CDK2 activity defects induced by PI3K inhibition in late G1.  
Cyclin E/CDK2 and cyclin A/CDK2 kinase activity in cyclin E and cyclin A immunoprecipitates, respectively, of cell 
extracts from control and c-MycT58A-expressing cells treated as in Fig. 16.  CDK2 activity was measured as in Fig. 10.  
Cyclin E/CDK2 and cyclin A/CDK2 activity in c-MycT58A-expressing cells was examined by in vitro kinase assays 
performed as in Fig. 10.  Data shown are means ± standard deviation of three experiments. 
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Finally, we examined p27
kip
 binding to the cyclinE/CDK2 complex. Ly294002 treatment 
at 7 h in synchronous cell cultures increased p27
kip1
 association with cyclinE/CDK2 in controls, but 
association was lower and resistant to PI3K inhibition in c-MycT58A-expressing cells (Fig. 18).  
Thus, p27
kip1
-CDK2 association was reduced upon c-MycT58A expression in LY-treated cells.  
 
 
 
Fig. 18.  c-MycT58A expression inhibits p27 binding to the cyclinE/CDK 2 complex.  Synchronized cells in different 
cell cycle phases were lysed and cyclin E was immunoprecipitated from lysates (200 g).  Samples were resolved and 
examined by WB using anti-p27Kip or anti-cyclin E antibody. 
We also examined the result of expressing c-MycT58A on MCM2 loading onto 
chromatin.  In control cells, MCM2 loading was still low at 9 h (similar to that observed at 0 h), 
increased at 12 to 16 h, and was blocked by PI3K inhibition.  In contrast, in c-MycT58A cells, 
MCM2 loading increased by 9 h in c-MycT58A-expressing cells and remained insensitive to late 
G1 PI3K inhibition (Fig. 19).   
 
 
Figure 19.  c-MycT58A expression counteracts the reduced MCM2 chromatin loading induced by PI3K inhibition 
in late G1.  Western blots documenting MCM2 protein levels in different subcellular fractions (as in Fig. 3F) of cells 
treated as in Fig. 6A.  WB using anti-tubulin and -histone antibodies were used as controls of fraction purity. 
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1.8)  Conclusions 
Phosphoinositide 3-kinase (PI3K) is one of the early signalling molecules induced by growth 
factor receptor (GFR) stimulation that is necessary for cell growth and cell cycle entry.  PI3K 
activation occurs at two distinct time points during G1 phase.  The first peak is observed 
immediately following GF addition, and the second in late-G1, before S phase entry.  This second 
activity peak is essential for transition from G1 to S phase; nonetheless, the mechanism by which 
this peak is induced and regulates S phase entry was poorly understood.  We have examined the 
mechanism of activation and the function of PI3K activity in late G1. We conclude that activation 
of Ras and Tyr kinases are required for late-G1 PI3K activation.  Inhibition of late-G1 PI3K 
activity results in low c-Myc and cyclin A expression, impaired Cdk2 activity, and reduced MCM2 
(minichromosome maintenance) loading onto chromatin.  The primary consequence of inhibiting 
late-G1 PI3K was c-Myc destabilization, as conditional activation of c-Myc in advanced G1 as 
well as expression of a stable c-Myc mutant rescued all of these defects, restoring S phase entry.  
These results show that Tyr kinases and Ras cooperate to induce the second PI3K activity peak in 
G1, which mediates initiation of DNA synthesis by inducing c-Myc stabilization. 
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2. MECHANISMS CONTROLLING p110 NUCLEAR LOCALISATION 
2.1) Class IA PI3K isoforms p110 and p110 have distinct intracellular localisation 
The main function of class IA PI3K in cells is thought to be its ability to produce PIP3 at the 
plasma membrane.  Nonetheless, class IA is also found in the nucleus of various cell types (Neri et 
al., 2002).  p110 selectively controls DNA replication, whereas p110 had a minor function in 
this process (Marques et al., 2009).  Since DNA replication occurs in the nucleus, we considered 
that p110 might exhibit a subcellular localisation distinct from that of p110. 
We studied the localisation of p110 catalytic and p85 regulatory subunits in NIH3T3 cells by 
immunostaining with specific anti-p110, -p110, -p85 and -p85 antibodies.  We found that 
p110 catalytic and p85 regulatory subunits localised mainly in the nucleus, whereas p110 and 
p85 subunits concentrated mainly in cytoplasm (Fig. 20A).  We examined the specificity of the 
antibodies used for p110 and p110 immunostaining by transfecting shRNA for p110 and 
p110respectively, which reduced the detection of the corresponding p110 isoforms (Fig. 20B). 
 
A)  
       
B)  
 
 
 
 
 
    
                              
 
Figure 20.  Cellular localisation of different class IA PI3K proteins in NIH3T3 cells.   A) Immunofluorescence 
(indirect) in exponential growing cells, using specific anti-p110, -p110, -p85 and -p85 antibodies developed with 
Alexa488-secondary antibody. B) NIH3T3 cells were cotransfected with red fluorescence protein (RFP) and control, 
p110 or - shRNA; p110 localisation was examined by immunofluorescence. DAPI nuclear staining is shown in insets.  
We also determined p110 localisation in other cell types and found that p110 localizes in 
the nuclei in HeLa, MEF and SAOS-2 cells (Fig. 21).  p110 nuclear localisation is therefore not 
restricted to the murine NIH3T3 cell line, but is also present in many mammalian cells. 
 
                 
Figure 21.  Cellular localisation of PI3K p110 protein in different cells. Indirect immunofluorescence of p110 
staining in HeLa, MEF and SAOS-2 cells, treated as above (Fig. 20 A). 
2.2) p110 localisation in the nucleus is transient and activation-dependent  
These observations suggested that p110 localisation in the nucleus is a phenomenon 
common to various cell types.  Our group described p110 activation at different times during G1, 
which is necessary for cell transit through G1/S (Marques et al., 2008).  Based on our findings, we 
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considered that p110 intracellular localisation might be important for its role in S phase; we thus 
examined p110 localisation and subcellular activity during cell progression through G1. 
Quiescent NIH3T3 cells were stimulated, fixed at different times and stained with anti-
p110 antibody.  Although quiescent cells showed diffuse p110 staining throughout the cell, 30 
min serum stimulation induced its complete nuclear translocation.  At 45 and 90 min post-serum 
stimulation, some p110 returned to the cytoplasm.  At later times  (4.5 h), p110 again began to 
concentrate in the nucleus, with maximum nuclear localisation at 8.5 h post-stimulation (Fig. 22A).  
We prepared cytoplasmic and nuclear subcellular fractions of cells at different times in G1, then 
immunoprecipitated with anti-p85 Ab (as p110 is the only nuclear isoform observed), followed by 
an in vitro PI3K kinase assay using PI as substrate.  In cytoplasmic fractions, PI3K was activated at 
5 min post-stimulation; this activity later returned to basal levels.  In contrast, the second PI3K 
activity peak (Jones et al., 2001) was observed at 7-10 h post-serum stimulation (Fig. 22B).  In the 
nucleus, however, PI3K activation was observed at 30 min post-stimulation, with a second peak at 
8.5 h that remained even at 10 h post-stimulation.  The kinetics of p110 nuclear localisation 
parallels nuclear PI3K activity, suggesting that p110 might enter the nucleus in its active state. 
 
                         A) 
 
                          B) 
 
         
Figure 22.  p110 shows parallel intracellular localisation and activation kinetics during the cell cycle. A) 
Intracellular p110 staining using anti-p110 antibody at different times after serum stimulation of quiescent cells. B) In 
vitro PI3K kinase assay using PI as substrate to detect PI3K activity in cytoplasm and nuclear fractions of cells harvested 
at the indicated times post-stimulation.  After the kinase reaction, the substrate was resolved on thin layer 
chromatography (upper panels).  Anti-tubulin antibody was used to control purity of the two subcellular fractions of these 
samples (tubulin is an exclusively cytoplasmic protein) (lower panels). 
2.3) p110 overexpression results in cytoplasmic retention 
To elucidate the role of PI3K p110 in the nucleus, we transfected p110 into several cell 
lines.  p110 overexpression resulted in cytoplasmic accumulation of this protein in all cell types 
tested (Fig. 23A).  To exclude the possibility that protein overexpression caused an accumulation 
of newly synthesized protein in the endoplasmic reticulum (ER), we inhibited translation using 
cyclohexamide in the last 2-3h of the 24h transfection period.  Despite inhibition of protein 
synthesis, p110 remained cytoplasmic (Fig. 23B).  We also tested the localisation of 
overexpressed p110, p85 and p85.  As predicted, p110 and p85 were overexpressed in 
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cytoplasm, as is the case for endogenous proteins, whereas overexpressed p85 showed diffused 
cytoplasmic and nuclear staining (Fig. 23C). 
A) 
        
 B) 
 
C) 
 
Figure 23.  p110 overexpression results in cytoplasmic localisation as for p110.  A) NIH3T3, HeLa and SAOS-2 
cells were transfected with p110 plasmid and stained with anti-p110 antibody at 48 h post- transfection.  B) p110-
transfected NIH3T3, HeLa and SAOS-2 cells were cyclohexamide-treated (30 g/ml, 3 h) before being fixed for staining.  
Cells were stained with anti-p110 antibody for indirect immunofluorescence.  C) Myc-tagged p110, HA-p85 and 
HA-p85 were transfected individually into NIH3T3 cells and processed for indirect immunostaining using appropriate 
tag-specific antibodies to examine intracellular localisation. 
2.4) p85 promotes p110 nuclear localisation 
The regulation of subcellular localisation has emerged as a major mechanism that governs 
several cell processes (Reynisdottir et al., 1997; Zhou et al. 2001).  Based on the report by 
Geering et al., showing that class IA catalytic and regulatory subunits are obligatory heterodimers 
and are not physiologically available as single subunits (Geering at al., 2007), we determined 
whether regulatory subunits might influence subcellular localisation of the class IA catalytic 
isoforms.  We cotransfected combinations of catalytic p110 and p110 subunits with the 
regulatory p85 and p85 subunits, and found that only the p110/p85 combination showed 
nuclear localisation (Fig. 24A). The p110/p85, p110/p85 and p110/p85 concentrated in 
cytoplasm (Fig. 24A); a fraction of p85 was always seen in the nucleus (possibly in combination 
with endogenous p110). Therefore, p110 bound to either p85 or p85 is cytosolic, whereas 
p110 translocates to the nucleus in association with p85. 
The finding that p110/p85 coexpression caused nuclear localisation, and that this did not 
occur with p110/p85 complexes prompted us to determine the molecular basis for this 
difference.  We examined the sequence homology of p85 and p85 although we did not find a 
clear nuclear localisation sequence (NLS) in p85 we found a basic region between the BCR and 
N-SH2 region in p85 that was not present in p85. To test the role of this sequence in p85 nuclear 
localisation, we constructed a chimera in which we replaced this region in p85 (77-351 aa) with 
the corresponding p85 sequence (Fig. 24B).  We cotransfected this chimera with p110 and 
observed no difference between p110 / p85 and p110 / p85- chimera localisation. The p85-
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 chimera still co-localized with p110 in the nucleus (Fig. 24C).  These results suggest that 
polybasic sequence between BCR and N-SH2 in p85 does not act as a nuclear localisation region. 
 
A) 
                   p110+HA-p85 p110+HA-p85Myc-p110+p85 Myc-p110+p85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B)        C)  
 
 
Figure 24.  Intracellular localisation of p110 and p110 in combination with different regulatory subunits.  A) 
NIH3T3 cells were transfected with p110 in combination with HA-p85 or HA-p85, or with Myc-p110 combined 
with HA-p85 or HA-p85.  In cells cotransfected with p110/p85 or p110/p85, we identified transfected proteins 
using anti-p110 (green), -HA for p85 (red), and -p85 (red).  In cells cotransfected with p110/p85 or p110/p85, 
we identified transfected proteins using anti-Myc tag for p110 (red), -HA for p85 (green), and -p85 (green).  B) 
Scheme of p85-chimera formation.  The p85 region between amino acids 78 to 351was removed and replaced with 
amino acids 77-363 from p85.  C) NIH3T3 cells were transfected with the HA-p85 chimera with the p110 plasmid 
and stained with anti-p110 (green) and -HA antibodies (red). 
2.5)  C2-domain in p110 contains a nuclear localisation sequence 
Since we did not find any NLS in p85, we sought to identify if NLS were present in p110 
that would explain the nuclear localisation of p110/p85 complexes. We identified three putative 
NLS motifs with polybasic residues in p110KVKTKRSTK, RRKMRK and RRH). We 
proceed to substitute their basic residues with non-basic residues KVNTTRSTK (mutant 1), 
RRNMRN (mutant 2) and RGH (mutant 3) (Fig. 25). We did not find any obvious effect of 
mutant 2 and mutant 3 mutations in nuclear localisation of p110 co-expressed with p85 
suggesting that these sequences do not determine the nuclear localisation of p85/p110 
complexes. On the other hand, expression of mutant 1 with p85 could not enter nucleus, 
suggesting that KVKTKRSTK acts as the nuclear localisation of p85/p110 complex. 
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                                                      Mutant1-p110Mutant2-p110      mutant3-p110 
                      KVNTTRSTK         RRNMRN             RGH 
 
Figure 25. NLS motif in p110. Amino acid substitutions were made to generate mutant with non-basic residues (in 
red). p110 and three distinct mutant of p110 were cotransfected with p85 and processed and stained for indirect 
fluorescence with anti-p110. 
2.6)  Preferential association of p110 with p85 compared to p85 
Based on the role of the p85 and p85 regulatory subunits in the distinct cellular 
localisation of p110and p110, we tested whether there is preferential complex formation when 
the regulatory subunits are coexpressed in conjunction with either catalytic subunit (p85+p85 
with p110 or p110).  We fused the SV40 NLS at the p85 N-terminus.  Coexpression of p85-
NLS with p110 or p110 resulted in constitutive nuclear localisation of p110 and p110 (Fig. 
26, upper panel).  In contrast, when p85-NLS+p85 were coexpressed with p110or p110, 
most p110 was nuclear, whereas p110 concentrated mainly in cytoplasm (Fig. 26, lower panel).  
This suggests that p110 associates preferentially with p85 and not p85, and that p110 prefers 
p85 to p85.  We will attempt to confirm this observation biochemically in the future. 
 
Figure 26.  Association of regulatory subunits determines the cellular localisation of catalytic subunits. NIH3T3 
cells were cotransfected with HA-p85-NLS and p110 or Myc-p110 (upper panel), or in triple cortransfections with 
HA-p85-NLS and HA-p85 with p110 or p110 (lower panel). Samples were processed and stained for indirect 
fluorescence using anti-p110 (green) or -Myc tag for p110 (red).  
2.7) p85 shuttling between nucleus and cytoplasm regulates p110 nuclear export 
After determining that p85 facilitates p110 translocation to the nucleus, we sought the 
mechanism for transient nuclear-cytoplasm localisation during cell cycle progression.  p110 was 
found in cytoplasm by 90 min post-serum stimulation in quiescent cells (Fig. 22A). Various means 
of nuclear export have been documented (Kaffman and O’Shea, 1999).  One common mechanism 
is a conserved leucine-rich nuclear export signal (NES) that binds the nuclear export protein CRM1 
(Fornerod et al. 1997; Kudo et al. 1998).  We used leptomycin B to inhibit CRM1 binding to the 
cargo protein, which retains NES-containing protein in the nucleus.  After leptomycin B treatment 
of p110-, p110-, p85- and p85-transfected cells, only p85-expressing cells showed a strong 
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increase in the amount of recombinant protein in the nucleus; p110 also had moderately enhanced 
nuclear localisation (Fig. 27A), suggesting strong CRM1 dependence for nuclear export of p85. We 
examined the effect of leptomycin B on cellular localisation of the p85 chimera (overexpressed) 
and of p65 (a mutant similar to p65; Jiménez et al., 1998). p65 lacks the 562-to-723 C-
terminal fragment. Both the p85 chimera and p65 were found in cytosol and nucleus, and both 
showed increased nuclear localization after leptomycin B treatment (Fig. 27B). As we had 
observed that p85 facilitates p110 nuclear entry, we tested the leptomycin B effect on p110 
localisation when coexpressed with p85. Leptomycin B-mediated inhibition of p85 nuclear 
export led to p110 accumulation in the nucleus (Fig. 27C).  Results were similar after leptomycin 
B treatment when p110 was coexpressed with the p85 chimera or p65 (Fig. 27D).  We 
concluded that p85 has an important role in both nuclear export and import of p110. 
 
A)           p85 alone                                      p85 alone                 p110alone             p110alone                                                 
 
    
   B)        D) 
       
 
  C)  
       
Figure 27. The p85 nuclear export signal regulates p110 intracellular 
localisation dynamics.  A) NIH3T3 cells were transfected with HA-p85, 
HA-p85, p110 or Myc-p110 .  One set of transfected cells was treated 
with leptomycin B (5 ng/ml; 2 h) before fixing and another set was mock-
treated (control). Samples were processed and stained for indirect 
fluorescence using anti-HA for p85 and p85 (red), anti-p110 (green) or 
anti-Myc tag for p110 (red). B) Intracellular localisation of HA-p85 
chimera or HA-p65 (p85-truncated form of) in mock- or leptomycin B-
treated cells using anti-HA antibody for indirect staining. C) Staining with 
anti-HA (p85; red) and anti-p110 (green) in p85/p110 cotransfected 
cells, either mock- (control) or leptomycin B-treated (as above). D) 
p65/p110 were coexpressed and their cellular localisation detected in 
mock- and leptomycin B-treated cells using anti-HA for HA-p65 (red) and 
anti-p110  for p110 (green). 
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2.8) The p85 N-terminal region contains a nuclear export signal 
p85 regulates p110 nuclear export. We next investigated which region in p85 is 
responsible for p85/p110 nuclear export. The p65 mutant lacks the 562-to-723 CT terminal 
fragment of p85 (Jiménez et al., 1998) and localized similarly than p85 (Fig. 28) Replacement 
of the region between BCR and N-SH2 (77-to-351 aa) in p85 for the ones corresponding in p85 
also did not affect nuclear localisation (Fig. 24). Moreover, both the p85 chimaera and p65 
responded to leptomycin treatment implying that they include the potential NES of p85. Then 
neither the 77-to-351 region nor the562-to-723 region contained the NES. 
We generated two additional truncated p85 constructs, one in which the first N-terminal 
41 amino acids were deleted and a second in which the N-terminal 100 amino acids deleted. Both 
the p85 lacking 41 N-terminal amino acids (1p85) and p85 lacking 100 N-terminal amino 
acids (2p85) concentrated predominantly in the nucleus (Fig. 28A).  This indicates that first 41 
N-terminal amino acids of p85 are necessary for its nuclear export.  We examined the effect of 
these truncated p85 forms on p110 localisation after coexpression.  p85 lacking the 41 N-
terminal amino acids remained in the nucleus, whereas p110 localized mainly in cytoplasm.  The 
localisation of p85 lacking the 100 N-terminal amino acids was similar to that of p110 (Fig. 
28B). These data shows that the NES is located within the first 41 NT- residues of 
p110 p85/ p110 complexes. 
We will examine this biochemically in the future.  
         A)                                            B) 
 
Figure 28.  The p85 N-terminal region has a CRM1-dependent nuclear export signal, and p110 intracellular 
localisation varies after its coexpression of distinct truncated p85 forms. A) NIH3T3 cells were transfected with 
truncated p85 constructs alone (1,lacking 41, or 2, lacking 100 N-terminal amino acids). B) cells cotransfected with 
truncated p85/Myc-p110. Cells were fixed after 48 h and processed for indirect immunofluorescence with anti-p85 
(green) and -Myc tag (red) antibodies in 2 p85/myc-p110 transfected cells and with anti-HA (red) and p110 (green) 
in 1HA-p85/p110 transfected samples.  
2.9) p85/p110 associates with PCNA and translocates more efficiently to the nucleus 
Although we identified the NLS in p110 and export domain in p85 that facilitates 
shuttling of p85/p110 complex in and out of nucleus, we were unable to get the overexpressed-
p110 concentrated in the nucleus as we find the endogenous p110.  Our group described a direct 
p110 role in DNA replication (Marques et al., 2009) by regulating PCNA (proliferating cell 
nuclear antigen) loading onto chromatin. Considering that PCNA is a nuclear resident protein, we 
postulated that PCNA might associate with p110 and influence its nuclear localisation. We 
examined p110 association with PCNA. 
To this end, we examined cells in S phase, as most p110 is in the nucleus in this phase (Fig. 
22). Cells were serum starved for 19 h to induce quiescence, then stimulated with 10% FBS for 14 
h to drive the majority of cells into S phase; cells were then harvested and lysed.  We 
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immunoprecipitated p110 and examined the presence of associated PCNA in WB (Fig. 29A); 
PCNA immunoprecipitated with anti-PCNA antibody was used positive control.  
To determine whether the selective association of PCNA with p110 was due to a p110-
specific structural feature or to its subcellular distribution, we modify the subcellular localization of 
p110 by coexpressing it with a p85 molecule-fused to a string NLS. Under these conditions, NLS-
p85 cotransfection with Myc-WT-p110 or -, which increased the nuclear localisation of both 
p110 and  (Fig. 26). Both nuclear p110 and  associated with PCNA, although p110 
association to PCNA was greater than that of nuclear p110 (Fig 29B).  
We also immunoprecipitated p110 and p110 from plasmid-transfected cells using anti-
Myc tag antibody and examined their PCNA association by blotting with anti-PCNA antibody(Fig. 
29C).  PCNA showed higher affinity for p110 than for p110.  These observations led us to 
conclude that PCNA preferentially binds to p110 and this association depends on the 
physiological p110 localisation in the nucleus. Therefore, in addition to its subcellular 
distribution, p110 has a structural advantage for association to PCNA. 
  
 
A) 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
C) 
 
 
 
 
 
 
 
 
Figure 29.  PCNA associates with p110 and coexpression increases its nuclear localisation.  A) Synchronized NIH3T3 cell 
cultures were collected at 14 h post-serum addition and chromatin fractions were obtained.  PCNA or p110 immunoprecipitates 
were analysed in western blot using anti-PCNA antibody.  As controls, protein A was incubated with antibody alone or with lysate 
alone.  Graphs show the percent PCNA signal in p110 and p110 immunoprecipitates, where 100% = signal in PCNA 
immunoprecipitates from a similar amount of lysate.  B, C) NIH3T3 cells were transfected with Myc-p110 or - in combination 
with p85-NLS.  Cells were synchronized at 24 h post-transfection and collected at 14 h post-serum release.  The chromatin fraction 
was immunoprecipitated with anti-Myc-tag (100 g) or -PCNA (800 g) antibodies. p110 or p110 association to PCNA was 
tested in western blot using anti-Myc-tag antibody.  Extracts were also immunoprecipitated with anti-Myc-tag (400 g) or -PCNA 
(100 g) antibodies, then examined in western blot using anti-PCNA antibody.  The graphs show the mean percentage of p110 
bound to PCNA, normalized to p110 levels in p110 immunoprecipitates, or the percentage of PCNA bound to p110 compared to 
PCNA levels in PCNA immunoprecipitates.  
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We then determined whether PCNA affects the cellular localisation of class IA PI3K 
regulatory and catalytic subunits when coexpressed.  p85 localisation to the nucleus increased 
when it was coexpressed with PCNA, whereas p85 remained in cytoplasm when expressed alone 
or with PCNA.  Nonetheless, coexpression of p110 with PCNA did not alter its cytoplasmic 
localisation, whereas p110 coexpression with PCNA increased p110 nuclear translocation (Fig. 
30).  These findings suggest that contributes to determine the nuclear localisation of p110/p85. 
 
 
Figure 30.  Coexpression of PCNA with p110 increases p110 nuclear localisation. RFP-PCNA was cotransfected 
with p85, p85, p110, or p110 (upper panel and lower left panel), PCNA was cotransfected with p85 and 
p110 for indirect fluorescence at 48 h post-transfection using anti-PCNA (red) and anti-p110 
(green).  Only p85 and p110 showed increased nuclear localisation when coexpressed with PCNA. 
2.10) Conclusions 
Nuclear localisation of class IA PI3K was described previously, although the specific isofoms 
that located to the nucleus remained unclear.  Here we determined that of the PI3K ubiquitous 
isoforms p110 and p110, the majority of p110 localizes in the nucleus, whereas p110 is found 
mainly in cytoplasm.  We also determined that during cell cycle progression, p110 shuttles 
between the nucleus and cytosol and that major nuclear concentration occurs in S phase.  The 
increase in nuclear localisation coincided with p110 activation in the nucleus.  These observations 
led us to conclude that p110 kinase activity is important for its nuclear translocation, an aspect 
that requires future analysis.  We dissected part of the mechanism for p110 nuclear translocation, 
and report that p110 does not translocate to the nucleus by itself, but must associate to p85.  In 
addition to its role in nuclear translocation of p110, p85 also controls p110 nuclear exclusion.  
We determined that the first 41 N-terminal amino acids of p85 regulate nuclear export of this 
protein.  In addition, we identified a nuclear localisation sequence in the p110 C2 domain, which 
when mutated inhibits nuclear translocation of the p85/p110 complex.  Finally, we observed that 
p85 was not sufficient for complete nuclear localisation of p110, and that PCNA binds to p110 
and increases p110 nuclear localisation. 
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3. P110 REGULATES DNA REPAIR PATHWAYS 
3.1) Cells with reduced p110 levels undergo apoptosis following ultraviolet radiation 
We previously shown that p110 regulates DNA replication (Marques et al., 2009), we next 
examined p110 control of DNA repair.  To determine the role of p110 in DNA damage 
response, we first examined whether reduced expression of p110 affect the recovery of cells 
following radiation stress. We used p110-specific shRNA. At 30 h post-transfection with p110 
shRNA, we selected the cells transfected with p110 shRNA using puromycin (48 h). Cells were 
then harvested and lysed, then analysed in western blot for p110 and actin.  All three shRNA 
tested reduced the levels of p110 to approximately 60% of those for endogenous p110 (Fig. 
31A). p110 shRNA also reduced p110 expression (Fig. 31A) p110 shRNA, p110 shRNA and 
vector-transfected cells were exposed to UV light and 12 h after UV exposure, we observed a 
greater apoptosis in cultures of p110-depleted cells than in vector-transfected control cells or 
p110-depleted cells.  At 30 h post-UV exposure, more p110-depleted cells were found in sub-G1 
than p110-deleted or control cells (Fig. 31B), suggesting that reduction of p110 levels interferes 
with the cellular mechanisms that correct the DNA damage inducing cell death. 
 
A) 
               
 
B) 
               
Figure 31.  Downregulation of p110, but not of p110 results in cell death following UV exposure.  A) (left panel) 
NIH3T3 cells transfected with vector or three different p110 shRNA were selected with puromycin (2 M; 48 h) at 48 h 
post-transfection; lysates were then analysed for p110 in western blot, (right panel) vector or p110 shRNA transfected 
in NIH3T3 cells, 48 h post transfection cell were lysed and p110 protein levels were determined in western blot using 
anti p110 antibody, actin was used as loading control.  B) Propidium iodide FACS analysis of vector, p110- and 
p110-deleted cells at different times post-UV (80 J/m2) exposure. Percentage of cells in Sub G1 (dead, in Bold), G0/G1, 
S and G2/M phases is indicated. 
3.2) p110-deficient cells show genomic instability 
The recently described conditional p110-/- mouse phenotype and that of inactive p110 
knock-in mice indicate that p110 kinase activity regulates mouse and tumour growth and that 
p110 has a kinase-independent function essential for embryonic development (Jia et al., 2008; 
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Ciraolo et al., 2008). Kinase-independent functions often reflect the ability of a protein to associate 
a necessary partner, as is the case for PI3K in the control of cardiac stress response (Patrucco et 
al., 2004). To this end, we compared metaphases of p110-/- immortalized mouse embryonic 
fibroblasts (MEF) with p110-/- MEF reconstituted with WT-p110 (Jia et al., 2008). Most  p110-
/-
 immortalized cells had aberrant chromosome numbers (Fig. 33), including highly aneuploid cells 
containing 100-150 chromosomes.  Chromosome breaks and non-disjunction figures were also 
observed in almost all p110-deficient metaphase cells analysed. 
 
                            WT                   KO p110                                       
   
 
                                       KO p110                                                  KO p110 
                     
 
 
 
Figure 32. Genomic instability in p110-/- cells.  DAPI staining of wild type and p110-/- immortalized MEF showing 
chromosome breaks and non-disjunction structures (arrowheads). 
3.3) p110 is activated by exposure to UV or ionising radiation 
To determine whether p110 activation is induced following DNA damage, we exposed 
NIH3T3 cells to UV or IR.  NIH3T3 cells were harvested at different time points after UV or IR 
exposure and we examined p110 PI3K activity following immunoprecipitation with anti-p110 
antibody in an in-vitro kinase assay using PI as substrate.  Maximum p110 activation was 
observed at 15 min post-UV exposure, whereas p110 activation peaked at 30 min after IR 
exposure; serum-stimulated (1 h) NIH3T3 cells (Marques et al., 2008) were used as positive 
control for p110 activity (Fig. 33). 
 
 
 
 
Figure 33. p110 is activated by UV or -irradiation. NIH3T3 cells in exponential growth were exposed to UV (30 
J/m2) or -irradiation (6 Gy) and harvested at different times post-irradiation.  Lysates were quantified and an in vitro 
PI3K lipid kinase assay performed using lysates (800 g) from mock, UV- and IR-treated cells, immunoprecipitated with 
anti-p110 antibody and PI as substrate.  As controls, protein A was incubated with antibody alone or with lysate alone.  
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3.4) p110 associates with DNA repair protein in a radiation-dependent manner 
To dissect the mechanism of p110 action after UV and IR exposure, we analysed p110 
association with the DNA repair machinery.  We expressed GST-p110 in the nuclei by fusing 
NLS at the N-terminus of GST-p110. We isolated GST alone and GST-p110 from the nuclear 
fraction using glutathione Sepharose columns, and associated proteins were resolved in SDS-
PAGE. GST-p110-bound fraction-specific bands were excised and analysed by mass 
spectrometry.  The DNA repair protein RAD17 was pulled down with p110 (Fig. 34A).  We then 
tested whether p110 and RAD17 form a complex in intact cells.  NIH3T3 cells were harvested 1 h 
after exposure to mock-, UV- or -irradiation, then fractionated into cytoplasmic and nuclear 
fractions.  p110 and RAD17 interaction was studied in coimmunoprecipitation experiments using 
the nuclear fraction from irradiated NIH3T3 cells. Anti-p110 immunoprecipitates analysed in 
Western blot with anti-RAD17 Ab showed that RAD17 coimmunoprecipitates with p110 (Fig. 
34B).  p110 association with RAD17 was not constitutive, but induced by irradiation (Fig. 34B).  
Both UV- and IR-irradiation induced strong p110-RAD17 association.  The presence of 
p110/RAD17 complexes only in irradiated cells suggests a role for p110 in DNA repair.  We 
also identified RAD9B, RAD50 in the pull-down assay, but did not confirm their association to 
p110 in intact cells. 
A)    B)  
 
Figure 34.  UV and -irradiation induced p110/RAD17 association. A) NIH3T3 cells were transfected with GST or 
GST-p110-NLS. The GST fusion proteins were purified from nuclear extracts in glutathione-agarose columns and 
resolved in SDS-PAGE. Gels were silver-stained, stained differential bands sliced and analysed by mass spectrometry. 
RAD17, RAD9B and RAD50 were identified. B) Anti-RAD17 western blot of anti-p110 or -RAD17 
immunoprecipitates from NIH3T3 cells, untreated or UV- or IR-exposed as indicated.  
3.5) p110 regulates ATR pathway activation after UV exposure 
The observation that p110 binds to RAD17 after irradiation was of interest, as RAD17 is 
one of the first sensor proteins to recognize damaged DNA, and has an important role in functional 
activation of the ATR pathway of DNA repair (Zou et al., 2002).  We studied phosphorylation of 
the ATR effector protein Chk1, which is phosphorylated by ATR after UV exposure.  We also 
examined phosphorylation of p38, as cells undergo apoptosis through activation of the p38 
pathway after UV exposure (Bulavin et al., 1999).  After UV exposure, Chk1 phosphorylation was 
severely affected in p110 shRNA-transfected cells compared to control vector-transfected cells 
(Fig. 35).  We tested whether total Chk1 protein was affected by p110 depletion, and found no 
change in Chk1 levels in p110 shRNA cells compared to controls.  There was no change in p38 
phosphorylation in p110 shRNA-transfected cells after UV radiation, indicating that this pathway 
is not controlled through p110 (Fig. 35).  These findings suggest that apoptosis of p110 shRNA-
transfected cells following UV exposure is not mediated by the p38 pathway, as phospho-p38 
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levels were unaltered in p110 shRNA and control cells.  The reduction in Chk1 (S345) 
phosphorylation nonetheless suggested a defective ATR pathway in p110-depleted cells. 
 
 
Figure 35.  p110 depletion reduces Chk1 phosphorylation.  Three different p110 shRNA or a control vector were 
transfected individually into NIH3T3 cells; after 48 h, cells were puromycin-selected (48 h).  Cells were then plated in 
duplicate; one group was UV-exposed and the other was not-irradiated.  Cells were harvested at 1 h post-treatment, lysed, 
and analysed by western blot using anti p-Chk1(S345), -Chk1 and -p-p38; anti-actin was used as control.  
3.6) p110 affects the ATR pathway by inactivation of its sensor protein 
We examined the mechanism by which p110 regulates activation of the ATR pathway 
following UV or IR treatment of cells, and examined whether p110 kinase activity has a role in 
ATR pathway activation. We treated the cells with a p110 specific inhibitor TGX221 (Jackson et 
al., 2005) and subsequently irradiated them with UV or IR. We found that inhibition of p110 
kinase activity resulted in a defective ATR pathway activation (Fig. 36). The phosphorylation 
defect was more evident in p110 shRNA cells than TGX-treated cells, suggesting that in addition 
to kinase-mediated regulation, p110 might have a kinase-independent role in ATR pathway 
activation.  We examined the phosphorylation state of RAD17, an upstream protein that also acts as 
a sensor protein. RAD17 phosphorylation is required for functional activation of the ATR pathway 
(Lee et al., 2007).  Inhibition of kinase activity or p110 depletion led to RAD17 inactivation, even 
at high radiation doses, actin was used as a protein loading control (Fig. 36A).  This observation 
suggests that p110 is upstream of RAD17 in ATR pathway activation during DNA repair. We 
also examined phospho-RAD17 by immunofluorescence after IR exposure in vector (control)- or 
p110 shRNA-transfected cells (Fig. 36B).  This analysis confirmed the profound defect in RAD17 
phosphorylation in cells expressing reduced p110 levels. 
A) 
                                                
       B) 
3Gy, 15min 
Figure 36.  p110 depletion results in defective activation of the RAD17 sensor protein.  NIH3T3 cells were 
transfected with p110 shRNA or control vector; after 48 h, cells were puromycin-selected (48 h).  A) The p110 shRNA 
or vector-transfected cells that had been DMSO- or TGX21-treated (4 h) were UV- or IR-exposed, and harvested after 1 
h.  Lysates were resolved in SDS-PAGE and probed in western blot with anti p-Chk1 and -p-RAD17 antibodies, with 
anti-actin as loading control.  B) At 48 h post-puromycin selection, vector and p110 shRNA cells were plated on 
coverslips; after 24 h, cells were exposed to IR, fixed after 15 min, and processed for indirect immunofluorescence using 
anti-phospho-RAD17 antibody and Alexa 488-secondary antibody.  
3.7) p110 also regulates activation of the ATM pathway 
After determining the role of p110 in radiation-induced ATR pathway activation, we 
examined whether p110 acts as a general regulator of DNA repair pathways.  Because ATM 
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participates in cellular responses to DNA DSB, we investigated whether activation of the ATM 
pathway is p110-dependent.  We examined ATM pathway activation in p110-depleted, p110 
kinase-inactive (TGX-treated) and control NIH3T3 cells after UV or IR exposure.  Inhibition of 
p110 kinase activity or a reduction in p110 protein reduced ATM phosphorylation at S1981 in 
UV- or IR-treated cells (Fig 37A). Structural maintenance of chromatin 1 (SMC1), Chk2 and 
H2AX protein phosphorylation were downregulated due to inactivation of the ATM pathway (Fig 
35A).  In a complementary experiment, p110 knockdown or inactivation markedly decreased p-
ATM and H2AX accumulation at IR-induced DSB foci (Fig 37B, C).  Together these data 
suggested that, both as a kinase and as a protein, p110 regulates activation of the ATM DNA 
repair pathway. 
 
               A) 
 
               B) 
                 IR 3Gy, 15min 
              C) 
      
Figure 37.  ATM pathway downregulation following p110 deletion.  A) NIH3T3 cells were transfected and selected 
as in Fig. 36.  A) The p110 shRNA or vector-transfected cells that had been DMSO- or TGX21-treated (4 h) were UV- 
or IR-exposed, and harvested after 1 h.  Lysates were resolved in SDS-PAGE and probed in western blot with anti-p-
Chk1, -Chk2, -p-ATM, -p110 and H2AX; actin was used as loading control.  B) At 48 h post-puromycin selection, 
vector and p110 shRNA cells were plated on cover slips; after 24 h, cells were exposed to IR, fixed after 15 min, and 
processed for indirect immunofluorescence using anti-phospho-ATM 1981 antibody and Alexa 488-secondary antibody. 
C) At 48 h post-puromycin selection, vector, TGX treated cells and p110 shRNA expressing cells were plated on cover 
slips; after 24 h, cells were exposed to UV (upper panel) or IR (lower panel), fixed after 15 min, and processed for 
indirect immunofluorescence using anti-phospho-H2AX antibody and Alexa 488-secondary antibody.  
3.8) Rapid p110 translocation to DNA damage sites 
Biochemical fractionation of cells (Mendez et al., 2002) showed that p110 appears in 
chromatin fraction (our data not shown). To elucidate the role of p110 in regulation of DNA 
repair pathways, we examined whether inhibition or deletion of p110 affects translocation of 
DNA damage mediator proteins to the DSB. 
We cotransfected NIH3T3 cells with GFP-p110 and p85-NLS for constitutive 
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translocation of p110 to the nucleus.  Cells were then irradiated by a micro-laser in conditions that 
generate limited DNA strand breaks in defined nuclear volumes.  We followed GFP-p110 protein 
mobility in time by fluorescence after photobleaching at the irradiated portion in individual nuclei.  
GFP-p110 moved to the laser-generated DSB sites, suggesting integration of p110 in the DNA 
repair machinery (Fig. 38A). We also examined the intranuclear localisation of p110 following IR 
irradiation. We observed a dramatic increase in the p110 accumulation at DSB sites in 
comparison with control (non-irradiated) cells (Fig. 38B). The concentration of p110 at specific 
points in mock treated cells could be due to its role in DNA replication, where it is shown to 
associate PCNA (Fig. 29). Accumulation of p110 in IR-induced foci was confirmed by co-
immunostaining with -H2AX (Fig. 38C; Pilch et al., 2003). 
A)                                 
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Figure 38.  p110 mobilizes to UV laser-induced DNA breaks.  A) NIH3T3 cells were cotransfected with GFP-p110 
and p85-NLS; after 24 h, cells were plated and part of the nucleus was micro-irradiated, after which GFP-p110 loading 
was observed under a confocal microscope. B) NIH3T3 cells were exposed to IR (2Gy), fixed after 1hr, and processed 
for indirect immunofluorescence using anti-p110 antibody. C) NIH3T3 cells were exposed to IR (2Gy), fixed after 15 
min, and processed for indirect immunofluorescence using anti-phospho-H2AX (red) and anti-p110green) antibody.  
3.9) p110controls NBS1 immobilisation at DNA damage sites 
To test the importance of the p110-controlled events for the DNA damage response, and to 
elucidate whether p110 is integrated in or operates in parallel to known DNA repair pathways, 
GFP-NBS1 was transfected in WT, KR and KO p110 MEF.  A part of the nucleus in GFP-NBS1-
transfected cells was micro-irradiated using a UV laser, and GFP-NBS1 mobility was examined 
(Bekker-Jensen et al., 2005; Lukas et al., 2003; Lukas et al., 2004).   
NBS1 accumulation at the micro-irradiated zone was slower and less intense in p110-KR 
than in WT cells, whereas the NBS1 mobility defects were more pronounced in p110-KO cells 
(Fig. 39).  These results show that p110 acts upstream in the activation of the ATM pathway in 
response to DNA breaks. 
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Figure 39.  p110-/- MEF showed defective NBS1 mobility at DNA damage sites.  Immortalized WT, KR and KO 
MEF were transfected with GFP-NBS1; after 24 h, cells were plated  A UV laser was applied to part of the nucleus, after 
which GFP-NBS1 mobility to the irradiated site was followed under a confocal microscope.  
3.10) p110 regulates 53BP1 loading at DNA damage sites 
To confirm the role of the p110 pathway in the regulation of DNA repair in live cells, we 
examined the DNA repair protein 53BP1 (an ATM substrate in the homologous DNA repair 
pathway; Wang et al., 2002).  GFP-53BP1 loading at the DNA damage sites was less intense and 
was delayed in samples in which p110 kinase activity had been inhibited using TGX221, as 
compared to control DMSO-treated cells.  Moreover, 53BP1 mobility to the micro-irradiated area 
was absent in p110 knockdown cells (Fig. 40).  These data further supported that p110 is 
essential for activation of DNA damage responses. 
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Figure. 40.  Inhibition of p110 kinase activity resulted in defective 53BP1 loading at DNA damage sites. NIH3T3 
cells were treated as in Fig. 36, cells were also transfected with GFP-53BP1. After 24 h, p110 shRNA or vector-
transfected cells that had been DMSO- or TGX21-treated (4 h) were micro-irradiated using UV laser; the exchange rate 
of the GFP-tagged proteins at the DSB sites was determined by live imaging under confocal.  
3.11) PCNA is a marker for DSB and requires p110 for loading at DNA damage sites 
PCNA is a known DNA replication marker and also has an important role in mismatch and 
nuclear excision repair (Jonsson et al., 1997).  Since we observed a physical association of p110 
with PCNA, and that p110 activates following DNA damage and regulates DNA repair 
machinery, we analysed whether PCNA translocates at the nicks formed using a UV laser scissor. 
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We found that PCNA translocated rapidly to DNA breaks and remained there for long 
periods.  After confirming PCNA loading at DNA nicks, we examined the role of p110 in PCNA 
loading at DNA breaks (Fig. 41).  RFP-PCNA was transfected into control vector- or p110 
shRNA-transfected NIH3T3 cells; we also examined cells in which p110 kinase activity was 
inhibited with TGX221 (20 M).  Cells were passed through a UV laser scissor and RFP-PCNA 
translocation to the damage site was followed. We concluded that p110 kinase regulates PCNA 
localization at damage sites. Moreover expression of p110 protein is critical for PCNA loading at 
DNA damage sites (Fig. 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41.  p110 regulates PCNA loading at DNA damage sites . NIH3T3 cells were transfected and selected as in 
Fig. 36, transfected with RFP-PCNA. After 24 h, The p110 shRNA or vector-transfected cells that had been DMSO- or 
TGX21-treated (4 h) were micro-irradiated using UV laser, the exchange rate of the RFP-tagged-PCNA at the DSB sites 
was determined by live imaging under confocal microscope.  
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3.12) PCNA and NBS1 translocates simultaneously at damaged areas 
Having identified PCNA mobility on micro-irradiated sites, we tested whether it translocates 
to DNA damaged sites in parallel to NBS1 translocation after micro-irradiation induced DSBs.  
Indeed, we found simultaneous translocation of both PCNA and NBS1 at DSB suggesting that 
PCNA acts as a sensor protein at DSB sites.  
                       6´´                               7´´                               8´´ 
GFP-NBS1       
 
RFP-PCNA      
Figure 42.  Identical NBS1 and PCNA translocation kinetics at micro-irradiated sites. NIH3T3 cells were 
transfected with NBS1 and RFP-PCNA. After 48 h, were micro-irradiated using UV laser, the mobility rate of the RFP-
tagged-PCNA and GFP-tagged-NBS1 at the DSB sites was determined under confocal microscope.  
3.13) Conclusions 
After determining the nuclear localization of p110 and its role in regulation of DNA 
replication, we examined whether p110 participates in the regulation of DNA repair pathways, an 
important cell process required for maintaining genomic stability, proliferation and survival.  
p110 knockout mice are embryonic lethal, and recent reports indicated that p110 kinase activity 
regulates mouse growth, as well as tumour development.  A kinase-independent role in embryonic 
development is also described.  The UV exposure of cells with reduced p110 levels resulted in 
apoptosis.  We examined the possibility of greater p38 pathway activation in these cells compared 
to controls.  The similar phospho-p38 levels detected led us to study the DNA repair pathways in 
p110-depleted cells.  p110-deficient cells showed larger numbers of chromosomes and aberrant 
chromosomal breaks, implicating a p110 function in the maintenance of genomic integrity.  We 
further analysed two pathways that regulate activation of DNA damage responses and DNA repair 
machinery, the ATR and ATM pathways.  We observed a defective ATR pathway, with inactive 
Chk1 and reduced p-RAD17 accumulation.  In addition, we found that deletion of p110 also 
resulted in a defective ATM pathway, in which we found downregulation of activation of ATM 
and its downstream effectors.  We also determined the direct role of p110 in regulation of DNA 
repair; p110 activation and its colocalisation with -H2AX at the DNA damage area, implying an 
integrative role for p110 in the aftermath of DNA damage.  We found that p110 regulates the 
mobility of the DSB sensor protein NBS1 at damage sites, and conclude that p110 acts upstream 
of DNA damage sensor proteins.  We also showed that PCNA localizes at the DNA damage area 
with similar kinetics over time as NBS1, and infer that PCNA could be a sensor protein in addition 
to its role in DNA replication and its dependence on p110. 
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CONCLUSIONS 
 
Objective 1. Investigate the mechanism of activation and the function of PI3K activity in late G1 
1.1)  Activation of Ras and Tyr kinases are required for late-G1 PI3K activation and this late-G1 PI3K 
activity regulates c-Myc levels and in turn cyclin A expression, Cdk2 activity, and MCM2 loading 
onto chromatin 
1.2) The primary function of late-G1 PI3K is c-Myc stabilization, as conditional activation of c-Myc in 
advanced G1 as well as expression of a stable c-Myc mutant rescued the defects induced by late G1 
PI3K inhibition and S phase entry 
 
 Objective 2. Investigate the mechanism for p110 nuclear localisation 
2.1)  The majority of p110 is nuclear while p110 is mainly cytosolic. In addition p110 shuttles between 
nucleus and cytosol during cell cycle progression and is mainly nuclear in S phase; p110 increased 
nuclear localisation is coincident with activation of nuclear PI3K activity 
2.2)   p85 association with p110 is required for the localisation of p110 in the nucleus. In addition p85 
also determines p110 exit from the nucleus; the first 41NT-reidues contain the NES of p85 
2.3)   The C2 domain of p110 contains a NLS 
2.4)   p110 associates with PCNA; this complex further increases p110 nuclear localisation 
 
 Objective 3. Investigate the involvement of p110 in DNA repair 
3.1) Reduction of p110 cellular levels interferes with the cellular mechanisms that counteract DNA 
damage; these cells undergo cell death upon UV irradiation. p110 deficiency also induces genomic 
instability 
3.2)  UV and IR activates irradiation p110
3.3)  p110 associates RAD17 in a radiation-dependent manner and regulates ATR and ATM pathway 
activation 
3.4)  p110 translocates to DNA damage sites and controls NBS1, 53BP1 and PCNA recruitment to these 
sites 
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Studies in Caenorhabditis elegans and Drosophila melanogaster have been a useful 
source of knowledge regarding PI3K regulation, as these species have a single class IA PI3K.  Class 
IA PI3K mediates cell growth and metabolism control downstream of the IGF-R (Engelman et al., 
2006).  Due to the many effectors PI3K pathway and to the various growth factors that transmit 
signals through PI3K, its signalling in mammals is more complex.  Of this family, only class I 
PI3K is implicated in cancer; class II and class III PI3K (Vps34p) have no described role in 
oncogenesis.  The distinct roles of the different PI3K classes could be due to their specific substrate 
preference and to the products they catalyze.  In general, overexpression and mutational activation 
of class I PI3K and inactivation of PTEN result in oncogenic cell transformation and cancer 
(Cantley, 2002; Wishart & Dixon, 2002; Bachman et al., 2004; Broderick et al., 2004; 
Campbell et al., 2004; Fruman, 2004; Leslie & Downes, 2004; Cully et al., 2006; Vogt et al., 
2007; Salmena et al., 2008).  The signalling pathways by which activated class IA PI3K isoforms 
control cell growth and contribute to cell transformation are therefore of considerable and 
continuing interest. 
The study of cell cycle regulation is fundamental for understanding the mechanisms of 
cell proliferation.  Cells plated at low cell density in serum-containing medium progress through 
the four cell cycle phases: G1, S, G2 and M.  The initial phase of growth factor-stimulated 
signalling facilitates entry into the cell cycle; the majority of these signalling events do not persist 
much longer than 60 min.  In normal cells, class I PI3K activity is precisely controlled.  Activation 
of transmembrane receptors recruit cytosolic PI3K to the plasma membrane; this relocation is 
mediated by interactions with RTK (Skolnik et al., 1991) or GPCR (Stephens et al., 1994).  The 
PI3K products accumulate within minutes of growth factor stimulation, and return to near-basal 
levels by 30 min.  Fibroblasts nonetheless require 8-10 h of continuous exposure to growth factor 
to pass the restriction point (Pardee, 1989; Stiles et al., 1979). Jones et al. demonstrated that the 
early signalling burst is insufficient for cell cycle progression, and that there is additional growth 
factor input at later times before S phase entry (Jones et al., 2001).  One goal of the studies 
presented here was to further understand the purpose and mechanism of PI3K activation near the 
G1/S transition. 
Class IA PI3K activation in late G1 is required for c-Myc stabilization and S phase entry 
PI3K activation in late G1 is essential for cell cycle entry (García et al., 2006; Jones et 
al., 2001).  Here we examined the signals involved in late G1 PI3K activation and the mechanisms 
by which PI3K controls the G1/S transition. We found that tyrosine kinases and Ras activation are 
both necessary to activate PI3K in late G1 phase.  Specific inhibition of tyrosine kinases or Ras in 
late G1 resulted in downregulation of PI3K-associated lipid kinase activity.  Simultaneous 
inhibition of tyrosine kinase/Ras in late G1 completely abrogated PI3K activity.  The results 
suggest that PI3K activation in late G1 is tyrosine kinase-dependent and is further controlled by 
Ras.  We also demonstrate that c-Myc stabilization is a major function of PI3K activation in the 
late G1 phase, based on the observation that PI3K inhibition in late G1 reduces c-Myc and cyclin A 
levels.  PI3K inhibition in late G1 also increased p27
kip
 expression and reduced cyclinE/CDK2- and 
cyclinA/CDK2-associated kinase activity.  Our results are consistent with observations in c-Myc-
deficient cells, which show similar defects (Vlach et al., 1996; Mateyak et al., 1999).  Oscillations 
in cyclin-dependent kinase (CDK) activities dictate orderly progression through the cell cycle; 
downregulation of CDK activity due to PI3K inhibition abrogated cell cycling.  As PI3K/PKB 
inactivates GSK3, the enzyme that targets c-Myc for degradation (van Weeren et al., 1998; Yeh 
et al., 2004), we hypothesised that late G1 PI3K activation is essential for c-Myc stabilization.  We 
demonstrated this using a c-Myc mutant (MycT58A, Hemann et al., 2005) resistant to GSK3 
action, and by induction of c-Myc in late G1.  MycT58A expression or tamoxifen activation of c-
Myc ER expression in late G1 restored cell cycle entry by counteracting PI3K inhibition in all 
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parameters studied, which included those related to DNA synthesis, cyclin A expression, 
cyclinE/CDK2 and cyclinA/CDK2 activity, as well as p27
kip
 association to cyclinE/CDK2.  PI3K 
activation in late G1 therefore regulates c-Myc protein levels. 
Due to the relatively short half-lives of c-Myc mRNA and protein, c-Myc levels are 
tightly controlled in normal cells.  The average half-life is 20-30 min for c-Myc RNA and 20-40 
min for the protein (Thompson et al., 1998; Ponzielli et al., 2005).  To achieve the c-Myc protein 
expression levels necessary for cell cycle entry (Mateyak et al., 1997), the stability of c-Myc must 
be regulated during G1.  We found that late G1 PI3K activation stabilizes c-Myc, which is further 
supported by our findings using interfering RNA and constitutive active mutants of class
 
IA PI3K 
isoforms (Marques et al., 2008).  Although these tools do not allow distinction
 
between the first 
and second PI3K activity peaks in the G1 phase, they
 
confirm the role of PI3K in cell cycle entry 
and in c-Myc expression
 
control.  Whereas PI3K activation accelerates cell cycle entry
 
and 
increases c-Myc levels, downregulation of PI3K levels reduces
 
S phase entry and c-Myc levels 
(Marques et al., 2008). 
The regulation of c-Myc stability involves the phosphorylation of two key residues, 
Thr58 and Ser62.  MAPK mediates phosphorylation of Ser62, which is necessary for subsequent 
Thr58 phosphorylation by GSK3 (Yeh et al.2004).  Thr58 phosphorylation destabilizes c-Myc 
protein, and represents a major mutation hotspot in Burkitt‟s lymphomas (Hemann et al., 2005).  
Since Ser62 phosphorylation is a prerequisite for Thr58 phosphorylation, c-Myc might be 
phosphorylated in vivo by MAPK in late G1.  The concomitant activation of MAPK and PI3K in 
late G1 supports this possibility.  We also observed an increase in c-Myc phosphorylation at Thr58 
after inhibition of PI3K activity in late G1 phase, which is consistent with previous reports 
(Domínguez-Cáceres et al., 2004). 
Although the main role of PI3K in late G1 appears to be c-Myc stabilization, the 
functions of c-Myc and PI3K are otherwise unrelated.  c-Myc function is linked to its transcription 
factor activity, which is required for its transforming capacity (Ponzielli et al., 2005; Dang et al., 
1999; Amati et al., 1998).  c-Myc regulates transcription by associating to the Max protein (Cole 
& Nikiforov, 2006).  c-Myc/Max-regulated gene expression involves several complex 
mechanisms, including chromatin remodelling due to c-Myc association with TRRAP, an ATM-
related protein that interacts with histone acetyl-transferase (HAT) (Dang, 1999).  c-Myc also 
associates with CREB-binding protein (CBP), providing a link between c-Myc and transcription 
activation.  In addition c-Myc associates with the chromatin remodelling regulators TIP48 and 
TIP49 (Dang, 1999).   Finally, c-Myc interacts with components of the SWI/SNF complex, which 
control transcription through nucleosome repositioning (Dang, 1999).  Local chromatin 
remodelling as well as recruitment of RNA polymerases and transcription elongation factors forms 
part of the mechanism by which c-Myc controls gene expression of its targets (Dang, 1999; 
Pelengaris et al., 2002).  c-Myc regulates a large number of target genes, including all those 
containing E-box consensus binding sites in their promoters; many of these are required for cell 
cycle progression, including cyclins D, E and A (Dang, 1999).  The first c-Myc expression peak 
occurs ~1 h after serum stimulation; since c-Myc promotes cyclin D and E expression (Mateyak 
et al., 1999, and results shown here), this regulation would take place in early G1.  c-Myc is also 
essential for cyclin A expression, as well as for p27
kip
 inhibition (Perez-Rogers et al., 1997; 
Vlach et al., 1996; Mateyak et al., 1999).  Our observations suggest that the second c-Myc 
expression peak (coincident with Rb hyperphosphorylation) is necessary for cyclin A expression 
and p27
kip
 inhibition. 
One intriguing aspect of our observations is that although PI3K activity in late G1 is 
nearly parallel to that of c-Myc, c-Myc and PI3K cooperate in cell cycle entry, at G0 G1 
transition (Jones et al., 2001), suggesting distinct functions in early and late G1.  PI3K-mediated 
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PKB activation is also needed for FoxO TF inactivation.  In an unphosphorylated state, FoxO TF 
inhibit induction of several c-Myc targets, providing a mechanism for the synergistic action of 
c-Myc and PI3K in cell cycle progression (Bouchard et al., 2004).  PI3K activation shortly after 
GFR stimulation might explain this apparent contradiction, as PI3K activity in early G1 is 
essential for cell growth (Álvarez et al., 2003) and for FoxO TF inactivation (Álvarez et al., 
2001).  We found that c-Myc does not compensate the first PI3K activity peak, since inhibition of 
PI3K in early G1 (during the first 6 h) impaired cell cycle entry, even in cells expressing WT or 
T58A c-Myc.  Indeed, c-Myc induction in early G1 after tamoxifen addition did not compensate 
for the loss of PI3K, and resulted in inhibition of cell cycle progression; this was not the case 
when PI3K was inhibited in late G1. It is possible that the action of PI3K at stimulating cell 
growth pathways is not compensated by c-Myc and vice versa. We thus propose that PI3K and c-
Myc cooperate early in G1, but the principal late G1 PI3K activity is to stabilize c-Myc protein 
levels. 
A number of enzymes show discontinuous activation during the G1 phase.  Incubation of 
G0-arrested fibroblasts with PDGF for 30 min, and again at 8 h after serum addition, induces cell 
cycle entry similar to that of continuous PDGF exposure.  Moreover, MAPK activation combined 
with c-Myc overexpression substitutes for the first PDGF pulse, whereas PIP3 addition substitutes 
for the second pulse (Jones et al., 2001).  In view of our findings, we propose that PIP3 addition at 
8 h probably results in c-Myc stabilization and initiation of further downstream events. 
During a normal somatic cell cycle, early G1 signals trigger cell growth as well as cyclin 
D synthesis and stabilization.  MAPK and c-Myc activation are essential for synthesis of cyclin D 
(Mateyak et al., 1999; Jirmanova et al., 2002).  Early G1 PI3K activity is crucial for cell growth 
promotion via the mTOR pathway and for FoxO TF inactivation (Medema et al., 2000; Alvarez et 
al., 2001; Martinez-Gac et al., 2004).  When cyclin D reaches optimal levels and p27
kip
 expression 
decreases, cyclinD/CDK drives Rb phosphorylation, followed by E2F activation, which is 
necessary for cyclin E synthesis (Geng et al., 1996).  This initial signalling wave is transient, 
probably due to the short-lived action of phosphatases; nonetheless, TyrK, Ras, MAPK and PI3K 
are later reactivated and drive CDK2 activation.  During this second signalling wave, the main 
PI3K function is c-Myc stabilization, as PI3K can be replaced by GSK-3-resistant c-Myc.  
Stabilized c-Myc in turn contributes to triggering cyclin A synthesis, p27
kip
 inactivation, and 
cyclinE/CDK2 activation. 
The mini-chromosome maintenance proteins (MCM) are implicated in replication and 
form a complex that is thought to be the replicative helicase in eukaryotic organisms.  The MCM 
complex remains with the replication complex until replication is complete, and several MCM 
proteins are regulated by CDK phosphorylation (Tye, 1999).  Details of MCM regulation differ 
among organisms, but in all cases, several of these proteins are degraded through ubiquitin-
dependent pathways, are excluded from the nucleus, or are otherwise prevented from performing 
their replication function (DePamphilis, 2003).  We hypothesised that, since inhibition of PI3K 
activity in late G1 resulted in downregulation of cyclinE/CDK2 activity, this inhibition would 
affect MCM complex loading on chromatin.  We examined MCM2 protein, as it is defective in 
cyclin E knockout mice (Geng et al., 2003), and tested chromatin loading near the G1/S transition 
while inhibiting PI3K activity.  We found that the late G1 PI3K activity is required for MCM2 
loading, and that all of these events are crucial for DNA synthesis induction.  Our results are 
consistent with the previously reported inactivation of MCM2, which resulted in nuclear export 
(Yamaguchi & Newport, 2003).  This led us to conclude that inhibition of the late PI3K activity 
peak inhibits S phase entry in this manner. 
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Figure 1.  Mechanism of DNA replication inhibition after inactivation of PI3K in late G1.  An early burst of 
signalling results in activation of the PI3K pathway following stimulation of serum-starved cells; signalling continues for 
60-90 min, and then returns to basal levels.  The second wave of signalling is observed around late G1 (7-9 h post-
stimulation); it activates the PI3K pathway, whose primary role is to stabilize c-Myc.  This in turn regulates cyclinA 
expression, Rb hyperphosphorylation and DNA replication.  Inhibition of late G1 PI3K using LY294002 blocks the 
pathway and abrogates G1/S transition. 
After determining the role of PI3K in late G1, we sought to identify the class IA PI3K 
isoform responsible for G1/S transition.  Our group recently reported that both p110 and p110 
are activated in late G1, although the timing differs (Marques et al., 2008).  p110 is activated at 
about mid-G1, whereas p110 is activated near late G1 (G1/S phase entry).  The distinct activation 
times of these isoforms indicates separate roles in the G1-to-S phase transition.  Marques et al. also 
described distinct p110 and p110 requirements during late G1 and S phases.  When p110 and 
p110 constitutive active stable cell lines reached confluence and were released to observe cell 
cycle progression, control and p110 cells were arrested in G1, whereas some p110 cells 
progressed slowly into S phase.  They concluded that p110 has a different role from that of 
p110, as it regulates S phase progression and hence DNA replication (Marques et al., 2009). 
p85 association mediates nuclear translocation of p110 
We explored the basis of the role of p110 in S phase progression.  Using 
immunostaining and immunoblotting of the p85 regulatory subunit, Neri and colleagues showed 
that class IA PI3K localizes in the nucleus of various cell types (Neri et al., 2002).  We found 
distinct intracellular localisation for different p110 and p110 class IA PI3K isoforms of in 
NIH3T3 cells; whereas p110 is concentrated mainly in cytoplasm, most p110 is found in the 
nucleus.  In HeLa and mouse embryonic fibroblasts (MEF), we also observed nuclear localisation 
of p110.  These observations suggest that nuclear p110 is a general phenomenon, irrespective of 
cell type and mammalian species.  A few recent reports document PI3K isoforms in nucleus and a 
distinct role from their cytoplasmic counterparts (Martelli et al., 2007), although the mechanism of 
p110nuclear translocation remains unclear. 
To dissect the role of nuclear p110 and to define its function in DNA replication, we 
used the NIH3T3 cell line and determined the intracellular localisation of p110 at different times 
during G1 phase.  We showed that following cell release from serum starvation, a fraction of p110 
shuttles between the cytoplasm and the nucleus during G1.  In addition, the nuclear kinetics of 
PI3K activation paralleled the nuclear translocation of p110.  p110 nuclear localisation was 
maximal near the G1/S phase transition.  We also found p85 nuclear localisation, whereas the 
p85 regulatory subunit was mainly cytoplasmic. 
While studying the role of nuclear p110, we observed that p110 overexpression 
resulted in its cytoplasmic localisation. In view of this result, we sequenced cDNA for human 
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PIK3CB and murine pik3cb. Although their primary sequences were correct, expression of 
recombinant p110 resulted in cytoplasmic localisation of exogenous protein in murine as well as 
in human cells.  We considered that the continuous transcription and translation of cDNA in cells 
could result in accumulation of de novo synthesised p110 in the polysomes of the endoplasmic 
reticulum.  Moreover, inhibition of protein expression with cyclohexamide 3 h before 
immunofluorescence analysis did not change the cytosolic localisation of recombinant p110.  An 
alternative possibility is that p110 requires association with other cell proteins for its nuclear 
translocation. 
 p110 and p110 are considered obligatory partners of their regulatory p85 subunits 
(Geering et al., 2007). We found that expression of p85, but not of p85 facilitates nuclear 
localisation of p110 but not of p110.  When p85 was expressed alone, it showed slight nuclear 
staining in all transfected cells.  When cells were cotransfected with p85/p110, p85 nuclear 
staining was observed in ~22% of the cells. p110 also localized to the nucleus in these cells, 
showing that p85/p110is the heterodimer that localizes to the nucleus.  When p110 was 
cotransfected with p85 or p85, p110 remained cytoplasmic similarly than p85and most of 
p85. These results were unexpected; although both regulatory subunits are considered to have 
similar roles, p85 subunit and not p85  reproducibly facilitated nuclear translocation of p110, 
but not that of p110.  
p85 binding to p110 might result in conformational changes in the complex, or in 
complex activation; either of these events could promote nuclear translocation.  Another possibility 
is preferential binding of p110 to p85 and of p110 to p85.  We examined this possibility by 
fusing the NLS to p85 and cotransfecting p110 or p110 with p85 and p85-NLS (Fig. 26).  
p85 showed complete nuclear localisation due to the SV40 NLS, which also rendered p110 
nuclear; however, even in this case, a large fraction of p110 remained cytoplasmic, similar to 
p85.  Until further data have been accumulated, we cannot rule out the possibility of preferential 
binding of p85 to p110 or selective exposure of NLS in the p85/p110 complex. 
After determining the localisation of complexes to the nucleus, we searched for classical 
NLS in p85 and p110.  We found a potential polybasic NLS region in p85 and mutated it by 
replacing the basic residues from the same region in p85.  We observed no change in localisation 
of the p85/p110 mutant complex, and the p85 chimera expressed alone also retained its 
intracellular localisation.  In addition, we detected three potential NLS in p110 and mutated them 
with non-basic residues.  Two of these mutations had no effect on nuclear localisation of 
p85/p110 mutant complexes, whereas mutation in the putative NLS in the p110 C2 domain 
inhibited nuclear translocation of the p85/p110 complex.  These observations led us to 
hypothesize that the p85/p110 complex conformation opens up the polybasic region in the C2 
domain to associate the nuclear import machinery for nuclear translocation as a complex (Fig. 2). 
To determine whether p85 or p110 has a nuclear export signal (NES), we examined the 
effect of leptomycin B treatment on p85, p110 or p85/p110 localisation.  Leptomycin B 
alkylates and inhibits CRM1 (a protein required for nuclear export of NES-containing proteins).  
Leptomycin B treatment resulted in constitutive nuclear localisation of transfected p85and in 
partial nuclear retention of p110.  In contrast, p110 and p85 localisation were unchanged after 
leptomycin B treatment; these isoforms did not localize to the nucleus and the inhibitor did not alter 
their localisation.  These results suggested the presence of a NES in p85. We indeed identified the 
NES-containing region in the initial 41 N-terminal amino acids (NT41aa).  Interestingly, when 
p110 was coexpressed with a p85 mutated form that lacked NT41aa, truncated p85 localized 
mainly to the nucleus, whereas p110 was found in cytoplasm.  This shows that the NES is found 
in the first 41 amino acids of p85, but also that this mutation impairs p85/p110
formation.  We also examined the localisation of p110 coexpressed with p85 lacking NT100aa, 
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and detected these complexes distributed throughout the cell.  This implies that the p85 NT41aa 
region could have a role in certain conformational changes in the complex that affect its 
localisation. 
Even when p85 was coexpressed with p110, not all the cells coexpressing these two 
subunits showed as complete a nuclear localisation phenotype as that exhibited by endogenous 
complexes.  We hypothesised that p110 might associate with additional partners.  To identify such 
potential partners, we fused the NLS from SV40 large T-antigen to the p110 C-terminal and 
examined the associated proteins by pull-down assays.  We observed the association of several 
proteins, among them the DNA repair-associated protein RAD17.  RAD17 forms part of the 9-1-1 
complex, which behaves as a clamp loader, similarly to a PCNA trimmer.  We therefore analysed 
the binding of nuclear p110 to PCNA.  As anti-p110 antibody was poorly efficient in 
immunoprecipitation, we performed a reciprocal assay in cells transfected with Myc-p110 or -
p110, which were expressed at levels similar to those of endogenous p110.  A small fraction of 
endogenous PCNA associated to Myc-p110 in the nuclear fraction; PCNA association to p110 
was barely detectable.  These observations were confirmed by immunoprecipitating Myc-tagged-
p110 and -p110; PCNA affinity for p110 was much higher than for p110, suggesting that 
p110 localisation in the nucleus determines its association to PCNA.  In addition, we found that 
PCNA assists p110/p85 nuclear entry.  The p85/p110 complex showed an increase in nuclear 
localisation, whereas cotransfection with PCNA rendered this complex completely nuclear (Fig. 31, 
results). A scheme on the mode of p110 nuclear translocation is presented (Fig. 2). Although 
PCNA does not have a NLS, it is a constitutively nuclear protein.  CDK2 has been suggested to 
control PCNA translocation to the nucleus (Koundrioukoff et al., 2000).  Further study will 
increase understanding of the mechanism or identify other proteins that contribute to p110 nuclear 
translocation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Model explaining possible mechanism of p110 nuclear localisation. Growth factor mediated activation of 
p85/p110 results nuclear localisation aided by C2-domain NLS in p110. The association of PCNA to p85/p110 
further enhances their nuclear translocation. 
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p110 is necessary for genomic stability and for activation of the DNA damage response after 
UV or IR exposure 
Our results indicated that p110 deletion gives rise to genomic instability, with 
chromosome breaks and altered chromosome structures due to aberrant junction.  In addition, we 
found aneuploidy in p110-/- MEF, with an average chromosome number of 100-150.  This led us 
to examine the role of p110 in DNA repair.  Although several molecules that participate in the 
DNA damage response have been identified, the full spectrum of proteins that act in the cell 
response to DNA damage remains to be discovered.  Here we show that p110 is essential for 
correct activation of the DNA repair pathway induced by UV and IR.  DNA damage response 
(DDR) pathways coordinate a multi-step cascade, interactions among a multitude of proteins, 
DNA-protein complexes and checkpoint controls.  Activation of the DNA repair pathway involves 
a complex network of checkpoint signalling molecules downstream of ATM and ATR.  The 
differing requirements for ATM and ATR activation, as well as later differences in signalling 
partnerships remain unclear.  We found radiation-dependent p110 association with RAD17, 
suggesting a specific role for p110/RAD17 complexes in DNA repair.  This hypothesis was 
further strengthened by the observation that in p110 shRNA-transfected cells, UV exposure led to 
cell death (in sub-G1 phase). 
UV-induced activation of p38 MAPK signalling promotes cell death through regulation 
of p53 activity, by directly targeting p53 residues for phosphorylation (Bulavin et al., 1999).  
Nonetheless, comparable levels of p38 pathway activation in control and p110 shRNA-transfected 
cells suggested the involvement of additional signalling pathways regulated by p110 in DNA 
repair.  An increase in p110 kinase activity after UV or IR exposure shows that DNA damage 
induces p110 activity.  Bozulic et al. recently reported PKB activation in response to DNA DSB 
(Bozulic et al., 2008).  They concluded that PKB acts downstream of DNA-PK in DDR, where 
DNA-PK phosphorylates PKB at Ser473; in addition, they reported an increase in phosphorylation 
at Thr308 that is strictly PI3K-dependent.  It is therefore possible that p110 activation regulates 
PKB activation following DSB. 
Deletion of Chk1 results in hyperactivation of initiation of DNA replication (Syljuåsen et 
al., 2005), a phenotype that correlates with hyperactivation of replication origins (Maya-Mendoza 
et al., 2007).  Results were similar in cells in which p110 kinase activity was inhibited, with 
hyperactivation of initiation of DNA replication and defective DNA elongation (Marques et al., 
2009).  In addition, both ATR
-/-
 and p110-/- mice are embryonic lethal, implying that ATR and 
p110 are essential for embryonic development (Brown & Baltimore, 2000; Bi et al., 2002).  As 
these defects were similar in both phenotypes, we postulated that p110 might regulate the ATR 
pathway. 
Our studies indicate impaired activation of the ATR pathway in p110-depleted cells; 
Chk1 and RAD17 phosphorylation was downregulated in these cells following UV or IR exposure.  
We also observed a diminished pRAD17 accumulation and focus formation in both p110-
inhibited and -depleted cells, although the effect was more profound in p110-depleted cells.  This 
could be due to the reported RAD17/9-1-1-mediated activation of ATR, where the RAD17-9-1-1 
complex recruits the ATR-activating protein TopBP1 to DNA damage sites (Kumagai et al., 2006; 
Delacroix et al., 2007; Lee et al., 2007). 
We observed that p110 also regulates ATM autophosphorylation, which in turn controls 
the DDR after IR exposure.  Following exposure of p110-depleted cells to -irradiation, we 
observed defective ATM, Chk2 and SMC1 activation, resulting from the downregulation of 
upstream events in the ATM pathway.  Indeed, IR-induced pATM focus formation was largely 
abolished in p110-depleted cells; the remaining cellular pATM showed diffuse staining and rarely 
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formed distinctive foci. To further analyze whether p110 regulates upstream events in the ATM 
pathway, we examined immobilisation of NBS1 (a regulatory protein that acts early in the ATM 
pathway) at DNA damage areas and found defective migration of this protein.  Formation of the 
MRN complex (Mre11, Rad50 and Nbs1) plays a critical role in DNA damage sensing, signalling 
and repair mechanisms, as well as in maintenance of the chromosomal integrity of the cell (van 
den Bosch et al., 2003; Kanaar & Wyman, 2008).  Our results indicated that defective NBS1 
loading at DNA damage sites in p110-depleted cells inactivated the ATM pathway.  Previous 
studies showed that NBS1 associates with the p110, p110, and p110 catalytic subunits of class 
IA PI3K (Chen Y-C et al. 2008).  We propose that, of these, only the p110/NBS1 complex resides 
in the nucleus.   IR-induced -H2AX focus formation was barely detectable in p110-depleted 
cells.  In cells in which p110 kinase activity was inhibited using TGX221, -H2AX levels 
decreased, although less markedly than in p110-depleted cells.  We thus concluded that p110 is 
necessary for ATM pathway activation at the DNA damage-sensing stage, irrespective of the type 
of radiation exposure.  p110 mobility to the micro-irradiated sites further demonstrated an integral 
role for p110 in the initiation of DNA damage responses. 
p53-binding protein 1 (53BP1) participates in the cell response to DNA DSB, where it 
associates with various DNA repair proteins in a ATM-dependent manner (Wang et al., 2002; 
DiTullio et al., 2002).  In our study, manipulation of the p110 signalling pathway resulted in 
defective 53BP1 recruitment to DNA damage sites.  Translocation of 53BP1 to the damage sites 
was more severely affected in p110-depleted than p110-inhibited cells.  The defect observed in 
GFP-53BP1 immobilisation in UV laser-induced DNA damage is in accordance with a defective 
DDR, as 53BP1 is an early participant in the cell response to DNA DSB (Schultz et al., 2000) and 
contributes to activation of the checkpoint following recruitment (Wang B. et al., 2002). 
PCNA is a major factor in many features of DNA metabolism, such as DNA replication, 
NER (nucleotide excision repair), MMR (mismatch repair) and BER (base excision repair) 
(Jónsson & Hübscher, 1997).  Here we showed rapid PCNA accumulation at UV laser-
microirradiated sites, suggesting a role for PCNA in DSB repair.  Our data are consistent with the 
previous observation that PCNA is needed for filling a single-strand DNA gap (Torres-Ramos et 
al., 1996).  PCNA might therefore be necessary for recruiting DNA polymerases or repair proteins 
to the DNA damage site, and not only for processive replication by DNA polymerases.  In addition, 
Holmes and colleagues suggested that PCNA is a requirement for recruiting recombination proteins 
to DNA repair sites (Holmes & Haber, 1999).  In support of this idea, our live imaging analysis in 
cells showed simultaneous mobilization of PCNA and NBS1 to the DNA damage sites following 
UV-laser treatment.  We examined the effect of p110 on PCNA translocation to DNA damage 
system, and found that inhibition of p110 kinase activity retarded PCNA mobility. Moreover, 
p110 depletion greatly impaired PCNA localisation at DNA damage sites.  We concluded that 
p110 acts as a scaffold to regulate PCNA loading onto chromatin following DNA damage. 
Both p110 and p110 knockout mice are reported to be non-viable.  p110-/- mice die at 
embryonic day E9 (Bi et al., 1999,2002) and p110 kinase-dead (PIK3CAD933A/D933A) knock-in 
mice die at E10 (Foukas et al., 2006).  Like p110-/- mice, p110 kinase-dead heterozygous mice 
(PIK3CA
D933A/D933
) not only show no oncogenic effects, but also in fact have proliferation defects 
(Foukas et al., 2006).  p110 is described as the principal isoform responsible for cell 
hyperproliferation, as many human cancer types show miss-sense mutation hot spots in the p110 
gene (Kang et al., 2005; Samuels & Ericson, 2006).  These results indicate a kinase-dependent 
role for p110.  Although their hypothesis remains to be confirmed, Irarrazabal et al. proposed that 
IR-mediated changes in chromatin structure could activate nuclear PI3K, leading in turn to ATM 
activation (Irarrazabal et al., 2006).  p110-/- mice die very early (E3.5), which has been linked to 
a cell proliferation defect (Bi et al., 2002).   Jia et al. recently reported similar results, with a 
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description of retarded cell growth in p110-/- MEF (Jia et al., 2008).  The p110 kinase-dead 
allele (PIK3CB
K805R/K805R
) (Ciraolo et al., 2008) yields two distinct phenotypes.  Viable mice show 
normal proliferation and high PIK3CB
K805R/K805R
 protein expression; whereas mice with low 
PIK3CB
K805R/K805R
 expression levels were embryonic lethal, demonstrating that p110 acts as a 
scaffold protein rather than as a kinase (Jia at al., 2008). 
The class IA p110 catalytic isoform exhibit point mutations at hot spots in many tumour 
types, supporting the kinase-dependent function of p110 (Kang et al., 2005).  p110 mutations at 
amino acids E542K, E545K and H1047R are considered oncogenic gain-of-function mutations 
(Kang et al., 2005; Zhao at el., 2005).  p110 overexpression is described in some tumours, but no 
mutations were found in the protein, which places in doubt the role of p110 as an oncogene 
(Benistant et al., 2000; Knobbe & Reifenberger, 2003; Zhao et al., 2005).  Zhao et al. showed 
that p110 could be oncogenic, as addition of a myristoylation tag to p110 resulted in cell 
hyperproliferation (Zhao et al., 2005).  It is clear from our studies that p110 regulates both 
branches of the DSB response pathways.  As class I PI3K have both lipid and protein kinase 
activities (Dhand et al., 1994; Foukas et al., 2004; Foukas & Shepherd, 2004), further study will 
help determine the role of p110 (as protein or lipid kinase) after IR/UV-induced activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Proposed model for p110-mediated activation of ATR and ATM pathways in the DNA damage 
response (DDR).  p110 is activated by DNA double strand breaks (DSB), loads itself at the DNA damage sites 
immediately, and helps to recruit DNA sensor proteins NBS1 and PCNA simultaneously; these in turn recruit the apical 
protein kinase ATM, which undergoes autophosphorylation.  Chk2 localizes transiently at DNA damage sites to be 
phosphorylated and activated by ATM.   ATM translocation at damage sites stimulates various mediators, leading to 
Chk2 translocation to the damage area, where it is phosphorylated by ATM.  H2AX phosphorylation further boosts 
accumulation of the DNA damage mediator 53BP1 at the damage site.  Recruitment of p110 can also activate ATR 
pathway, where it regulates RAD17 phosphorylation.  In addition, we propose that PCNA is recruited and might be able 
to replace 9-1-1 complex function, boosting ATR pathway activation and Chk1 phosphorylation. 
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Class IA phosphoinositide 3-kinase (PI3K) are enzymes comprised of
a p85 regulatory and a p110 catalytic subunit that induce formation
of 3-polyphosphoinositides, which activate numerous down-
stream targets. PI3K controls cell division. Of the 2 ubiquitous PI3K
isoforms,  has selective action in cell growth and cell cycle entry,
but no specific function in cell division has been described for. We
report here a unique function for PI3K in the control of DNA
replication. PI3K regulated DNA replication through kinase-de-
pendent and kinase-independent mechanisms. PI3Kwas found in
the nucleus, where it associated PKB. Modulation of PI3K activity
altered the DNA replication rate by controlling proliferating cell
nuclear antigen (PCNA) binding to chromatin and to DNA poly-
merase . PI3K exerted this action by regulating the nuclear
activation of PKB in S phase, and in turn phosphorylation of PCNA
negative regulator p21Cip. Also, p110 associated with PCNA and
controlled PCNA loading onto chromatin in a kinase-independent
manner. These results show a selective function of PI3K in the
control of DNA replication.
C lass IA phosphoinositide 3-kinase (PI3K) is an enzyme thatcontrols cell cycle entry. Mutations in this pathway are
among the most frequent events in human cancer; a mayor
objective in translational biology is to define PI3K isoform-
specific functions. The PI3K are comprised of a p85 regulatory
and a p110 catalytic subunit that mediates formation of
3-polyphosphoinositides (1, 2). There are three class IA p110
catalytic subunits (,  and ), but only p110 and  are
ubiquitous and essential for development (3, 4); enhanced p110
and  activity trigger cell transformation (5). p110 regulates cell
growth and cell cycle entry (6). In the case of p110, the recent
description of p110 conditional knockout mouse phenotype
shows that p110 activity is essential for animal growth and
tumor development (7). Nonetheless, the cellular events selec-
tively controlled by p110 remain unknown.
DNA replication controls the accurate, timely duplication of the
cell genome each time the cell divides. Preparation for replication
requires formation of the origin replication complex (ORC) at the
DNA replication origin. The ORC acts as a scaffold for assembly
of the prereplicative complex that includes Cdc6 and Cdt1, proteins
involved in recruitment of the minichromosome maintenance
(MCM) complex exhibiting helicase activity.WhenMCM is loaded
into the ORC, the pre-RC is licensed to initiate replication (8–12).
After licensing, replication initiation involves formation of the
preinitiation complex, which requires activation of Cdk2 and Dbf4/
Cdc7 kinases (13). These kinases phosphorylate the MCM and
induce binding of DNA polymerase (Pol)/primase, which triggers
primer DNA synthesis (11). Elongation of DNA synthesis requires
subsequent binding of the proliferating cell nuclear antigen
(PCNA), a homotrimeric factor that triggers Pol displacement and
tethers the processive polymerases ( and ) to the DNA template
for rapid, accurate DNA elongation (9, 14). We examine here the
function of p110 and  in DNA replication.
Results and Discussion
The p110 Controls S-Phase Progression. p110 regulates G1 entry
and cell growth (1); both p110 and  regulate late G1 events and
accelerate G1S transition (6); however, no p110-specific func-
tion has been described in cell division. To examine the potential
p110 action in this process, we compared the division rates of NIH
3T3 stable cell lines expressing p110 or  active forms (Fig. 1A).
Active p110 cells divided more rapidly (t1/2 18 h) than active
p110 cells or controls (t1/2 24 h; Fig. 1B). In addition, although
a small fraction of active p110 and  cells enter cell cycle after
serum deprivation (6), only active p110 cells escaped cell contact
inhibition in confluence (Fig. S1A). We also compared synchro-
nous cell cycle progression in these cells. Cells were first serum-
deprived (G0 arrest) and released by serum addition; using this
protocol, NIH 3T3 cells reach S phase at 9 to 12 h postrelease
(15). Active p110 cells were faster in terminating S phase than
control or active p110 cells (Fig. 1C; Fig. S1B), as confirmed by
calculation of S phase duration (4 0.5 h for active p110 cells vs.
5.5–6 h for active p110 cells and 6 h for control cells); three
distinct clones behaved similarly.
We also examined the consequences of reducing endogenous
p110 and  activity using inactive K802R-p110 and K805R-
p110 mutants (KR hereafter) (6). Expression of KR mutants in
exponentially growing NIH 3T3 cells reduced PKB phosphoryla-
tion (pPKB, Fig. 1D) and affected cell division; we were unable to
prepare stable KR-p110 or  lines. We expressed KR mutants by
retroviral infection (95% efficiency), which yielded levels similar to
endogenous p110 proteins (Fig. 1D). Cell division was significantly
slower in KR-p110 cells (Fig. 1E), which remained in S phase for
prolongedperiods (Fig. 1F; Fig. S1C) and showeda longerSphase (6
h control cells; 6–6.5 h KR-p110 cells, 8 h for KR-p110 cells).
p110 expression did not vary appreciably throughout the cell
cycle.Weexamined the consequences of reducing p110 expression
using various shRNA and protocols in NIH 3T3 cells and human
U2OS cells (Methods). Whereas efficient protocols for p110
deletion interfered with cell viability, partial p110 reduction
permitted cell cycle progression studies. To reduce p110 expres-
sion in U2OS cells, we stably transfected pTER-shRNA vectors,
which allow inducible shRNA expression (16). shRNA reduced
p110 and levels even before induction, but reduction was greater
after doxycycline treatment (Fig. 1G). U2OS cells were synchro-
nized at G1/S boundary by double thymidine block and examined
S phase progression after release. We confirmed slower cell cycle
entry in cells with reduced p110 or  levels (6); in addition, only
the cells with reduced p110 levels remained in S phase for
prolonged periods, showing a Gaussian peak at mid-S phase DNA
content at 6–7 h postrelease (Fig. 1G).
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We used the selective inhibitors PIK75 and TGX221 to inhibit
p110 and , respectively (17, 18). We confirmed inhibitor selec-
tivity in NIH 3T3 cells (Fig. S2 A–D). Inhibition using 0.5 M PIK
resulted in complete blockade of S phase entry and triggered
apoptosis (Fig. S2E), showing that p110 is needed for cell survival
(19). p110 inhibition (0.08 M PIK) near S phase permitted cell
cycle entry (Fig. S2F) although it impaired G2/M entry, suggesting
that p110 could be the isoform that acts in mitosis (1). This
treatment nonetheless allowed S phase progression, as indicated by
the increased proportion of S phase cells and displacement of the
S phase population from near-G1 to near-G2 DNA content over
the time course (Fig. S2F). In contrast, selective inhibition of p110
permitted G2/M entry but extended S phase compared with
controls (Fig. S2F).
The p110 Activity Controls DNA Elongation. To compare S phase
progression rates more accurately we BrdU-labeled (1 h pulse)
newly synthesized DNA in exponentially growing cells and
collected cells at various times after BrdU deprivation. While
most BrdU control and KR-p110 cells reached G2/M at 3 to
5 h, the majority of BrdUKR-p110 cells remained in S phase
at 5 h (Fig. S3A). We examined the consequences of impaired
p110 function on DNA elongation with the DNA combing
assay (20, 21). We used PI3K inhibitors, as they permit p110
or  blockade in late G1 without affecting prior events.
G0-synchronized NIH 3T3 cells were serum-released, treated
with PIK 75 (0.08 M) or TGX 221 (30 M) at 7 h, BrdU-
labeled (20 min) at 12 h, then collected to examine the
replication profile (Fig. 2A). For each sample, we analyzed
30 MB of individual DNA fibers (250 kb). TGX-treated
cells showed 43% reduction in the length of BrdU tracks
relative to controls, suggesting that p110 is required for
normal replication fork progression; in contrast, elongation
was not significantly affected by p110 inhibition (Fig. 2A).
Median center-to-center distance between adjacent BrdU
tracks, indicative of the initiation rate, was shorter in TGX-
than in PIK-treated cells or in controls (Fig. 2B), consistent
with cell activation of additional replication origins to com-
pensate slow fork progression (21). The percentage of repli-
cation of individual DNA fibers was lower in TGX- (20.7%)
than in control or PIK-treated cells (33.0 and 32.3%). These
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(B) Control NIH 3T3 cells, active p110 and active p110 cells were seeded at
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examined in Western blot (WB) at 24 h posttransfection. (E) Cell division time for
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(Right).
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results suggest that p110 activity controls replication fork
progression.
The p110 Is Located in the Nucleus and Controls PCNA Binding to
Chromatin. Since DNA replication occurs in the nucleus, we exam-
ined p110 localization. Subcellular fractionation (Methods) and
immunofluorescence analysis showed that the majority of endog-
enous p110, but not of, concentrated in theNIH3T3 cell nucleus
(Fig. 2C). Both the nuclear p110 signal and the mainly cytosolic
p110 signal decreased with selective shRNA (Fig. 2C; Fig. S3B).
A similar distribution was observed in MEF, COS-7, HeLa and
U2OS cells. These results indicate that p110 concentrates in the
nucleus.
We examined the mechanisms by which p110 regulates repli-
cation. One of the first events required to initiate replication is
MCM complex loading on origins (replication licensing, 8,13,22).
We compared MCM loading to chromatin by cell fractionation on
nuclear and chromatin extracts (23). Whereas in control cells,
MCM 2/4 appeared on chromatin fractions in exponential growth,
but not after GF starvation or in confluence, active p110 or 
expression induced a similar and moderate enhancement of MCM
2/4 loading onto chromatin in starving and confluence conditions
(Fig. S3C). Accordingly, KR-p110 or expression induced a slight
reduction in late G1 MCM loading (Fig. 3A). MCM loading onto
chromatin is thus modulated to some extent by p110 and , but is
not selectively controlled by p110.
The p110 Activity Regulates PCNA Loading onto Chromatin. After
replication origin activation, Pol binding to the ORC triggers
primer DNA synthesis; elongation of DNA synthesis requires
subsequent binding of PCNA that tethers the processive poly-
merases Pol and  to the DNA template (9, 14). In control
synchronized NIH 3T3 cells, we observed PCNA appearance in
chromatin extracts (22) as well as PCNA-Pol association at12 h
after GF addition, at the onset of S phase (Fig. 3B). Active p110
cells behaved similarly; in contrast, active p110 expression accel-
erated PCNA binding to chromatin and PCNA-Pol association
(Fig. 3B). Moreover, expression of KR-p110 (Fig. 3C), reduction
of p110 levels with shRNA (Fig. 3D; Fig. S3D) and p110
inhibition (Fig. S3 E and F) diminished PCNA loading onto
chromatin as well as PCNA-Pol association; interference with
p110 only had a modest inhibitory effect. These data show that
p110 controls PCNA binding to chromatin and to Pol, providing
a potential mechanism for DNA elongation impairment after
interference with p110 function.
The p110 Activity Regulates p21Cip Phosphorylation. PCNA loads
Pol  and  to the DNA template for efficient elongation; PCNA
also binds p21Cip through the same region, p21Cip thus impairs
PCNA association to Pol/ (22, 24). We examined PCNA-p21Cip
complex formation in cells with altered p110 activity. Whereas
interference with p110 did not appreciably affect PCNA-p21Cip
complexes, active-p110 reduced (Fig. 3E) and inactive p110 (or
p110 inhibition) increased PCNA-p21Cip association (Fig. 3F, Fig.
S4A). Phosphorylation of p21Cip on T145 and Ser-146 phosphor-
ylation (by PKB and PKC) regulates its dissociation from PCNA
(25–28), nonetheless, in vivo T145 appears to be the critical residue
(27, 28).We confirmed that T145 phosphorylation induced PCNA-
p21Cip dissociation in U2OS cells and NIH 3T3 cells (Fig. 4A);
expression of the phosphomimetic D145-p21Cip mutant reduced
PCNA-p21Cip association increasing PCNA binding to chromatin
(Fig. 4A).
We also examined whether p110 regulates T145 phosphoryla-
tion. Whereas in control cells T145 was phosphorylated near S
phase entry, both p110 shRNAandKR-p110 expression reduced
pT145-p21Cip levels (Fig. 4B; Fig. S4 B–D). In these assays we
observed that interference with p110 activity also resulted in
greater p21Cip expression levels. p21Cip is degraded after its release
from PCNA (29); the higher p21Cip levels in cells with impaired
p110 function might be due to stabilization of p21Cip in complex
with PCNA. Both KR-p110 and p110 shRNA expression in-
creased p21Cip protein stability (Fig. S5A), whereas active p110
reduced p21cip stability (Fig. S5B). p110 activity is thus needed for
p21Cip phosphorylation and dissociation from PCNA.
The p110 Regulates Nuclear PKB. The PI3K effector PKB phos-
phorylates T145-p21Cip (27, 28). We confirmed that PKB phos-
phorylates T145-p21Cip in vitro (Fig. S6A) and examined whether
p110 regulates PKB-mediated T145-p21Cip phosphorylation. We
found that expression of KR-p110 (or p110 inhibition) reduced
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Fig. 3. p110 controls PCNA binding to chromatin and
to DNA Pol. (A) NIH 3T3 cells were infected with KR-
p110- or --encoding viruses, synchronized and col-
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nuclear and chromatin fractions were examined in WB.
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-expressing NIH 3T3 cells were synchronized in G0 and
released for different times. PCNA and p21Cip levels in
p21Cip immunoprecipitates and total PCNA levels in chro-
matin-free extracts were examined in WB. (F) NIH 3T3
cells transfectedwithKR-p110or-wereexaminedas in
E. Chr, chromatin. Percentage cells in S phase indicated
below gels. The circles show the time for S phase entry.
(A–F) One representative experiment of at least three
with similar results.*, P 0.05.
Marque´s et al. PNAS  May 5, 2009  vol. 106  no. 18  7527
M
ED
IC
A
L
SC
IE
N
CE
S
S phase PKB kinase activity in vitro (Fig. S6A andB).Western blot
analysis of pPKB in extracts from synchronized NIH 3T3 cells
expressing KR-p110 or treated near S phase with TGX221
confirmed that p110 regulates S phase pPKB, whereas p110
inhibition had a lesser effect (Fig. 4C); results were similar inU2OS
cells (Fig. S6C). As an alternative approach, we examined pPKB by
immunofluorescence. At 1 h postserum addition (G1 phase) pPKB
concentrated at the cell membrane and was reduced by KR-p110
(Fig. S7A), whereas in S phase pPKB concentrated in the nucleus
and was notably reduced by KR-p110 and p110 inhibition (Fig.
4D; Fig. S7B). Cell fractionation confirmed TGX inhibition of S
phase nuclear pPKB (Fig. S7C).
We examined other PKB substrates in S phase; GSK3 phos-
phorylation was reduced by p110 inhibition, whereas FKHRL1
phosphorylation was p110 activity-dependent (Fig. S7D), as is the
case in G1 phase (6). WB using anti-pPKB substrate Ab showed
that p110 inhibition reduced phosphorylation of some PKB
substrates in S phase cells (such as p21Cip, Fig. S7C), while others
were p110-regulated (Fig. S7D). Results were similar using S
phase U2OS cells treated with PI3K inhibitors and then fraction-
ated (Fig. 4E); this assay also showed that p110 inhibition affected
mainly cytosolic substrates and p110 nuclear substrates, suggesting
that p110 and  control distinct PKB pools. p110 thus governs
nuclear S phase PKB activity. Since p110 is activated at the G1/S
boundary (6), the early timing of phosphorylation of some PKB
substrates or their cytosolic localization might determine a p110
activity requirement for phosphorylation.
Based on p110 regulation of S phase nuclear pPKB-mediated
p21Cip phosphorylation, expression of the phosphomimetic D145-
p21Cip mutant in cells with impaired p110 activity could replace
p110 activity in S phase. BrdU labeling of newly-synthesizedDNA
in exponentially growing cells expressing KR-p110 alone or in
combinationwithD145-p21Cip showed thatD145-p21Cip expression
accelerated S phase progression in KR-p110 cells (Fig. 4F).
D145-p21Cip expression also increased PCNA-Pol association and
reduced PCNA-p21Cip complexes in KR-p110 cells (Fig. S8A).
Accordingly, A145-p21Cip expression corrected PCNA-Pol com-
plexes in active p110 cells (Fig. S8B). Thus, expression of phos-
phomimetic p21Cipmutants corrects the Sphase defects of cells with
altered p110 activity.
PI3K Protein Regulates PCNA Loading onto Chromatin. The recently
described conditional p110/ mouse phenotype and that of
inactive p110 knock-in mice (7, 30) indicate that p110 kinase
activity regulates mouse growth and tumor development and also
that p110 has a kinase-independent function in embryonic devel-
opment. Kinase-independent functions often reflect the ability of a
protein to associate a necessary partner, as is the case for PI3K in
the control of cardiac stress response (31). We examined whether
p110 expression (independent of its kinase activity) regulates
DNA elongation, studying the extent of PCNA binding to chroma-
tin after p110 inhibition or p110 knockdown. To improve p110
deletion, we transfected cells with puromycin-shRNA-encoding
vectors, selected them for 48 h and immediately analyzed these
asynchronous cultures (synchronization requires longer culture
times) before reduction of cell viability. Pulse–chase BrdU analysis
in exponentially growing NIH 3T3 cells showed that p110 inhi-
bition reduced S phase progression, but p110 knockdown had a
greater effect in decelerating S phase (Fig. 5A). PCNA loading onto
chromatin was also reduced by p110 or PKB inhibition, but was
drastically diminished by p110 knockdown (Fig. 5B).
We also analyzed asynchronous cultures of p110/ immortal-
izedmouse embryonic fibroblasts (MEF) reconstituted withWTor
KR-p110 (7). KR-p110MEF progressed through S phase more
slowly than WT p110MEF, although p110/MEF showed the
slowest S phase progression (Fig. 5A). KR-p110 MEF had less
chromatin-bound PCNA than controls, but PCNA loading was
lowest in p110/MEF(Fig. 5B). These results suggest that PCNA
loading onto chromatin and in turn S phase progression rate is
further regulated via a kinase-independent p110 function.
pPKB was little affected by p110 deletion in asynchronous
cultures (7). To define whether p110 controls nuclear PKB in S
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phase in these MEF, we synchronized cells at the G1/S border and
examined them after release. In WT p110-reconstituted MEF,
pPKB was found mainly in the nuclear fraction in S phase;
KR-p110 MEF behaved similarly but had lower nuclear active
pPKB levels (Fig. 5C). Both nuclear pPKB and PKB were unde-
tectable in p110/MEF (Fig. 5C), indicating that p110 expres-
sion might control PKB nuclear entry. Cytosolic pPKB was more
abundant in p110/ MEF, but they expressed lower levels of
PTEN (Fig. 5C); this might represent a compensatory mechanism
for p110 deletion. We also analyzed nuclear/cytoplasmic distribu-
tion of pPKB and PKB inNIH 3T3 cells to further examinewhether
p110 deletion reduces not only nuclear phospho-PKB but also
nuclear PKB, as in MEF. p110 shRNA diminished but did not
completely eliminate nuclear PKB (Fig. S8C). These results do not
demonstrate, but suggest that PKB nuclear entry is facilitated by
p110 expression, an aspect that requires further study. In contrast,
both p110 inhibition and p110 shRNA expression clearly re-
duced S phase nuclear pPKB (Fig. S8C), further confirming the
function of p110 in control of nuclear PKB activity in S phase.
PI3K Protein Associates PKB and PCNA. To determine whether
p110-dependent PKB nuclear activity is due to direct association,
we studied PKB-p110 complex formation in cytosolic and nuclear
fractions. Cells were fractionated as described (32), since the
method used earlier (Fig. 2C) (33) destroys protein–protein inter-
actions. NIH 3T3 cells were cotransfected with HA-gagAKT and
WT-p110 or -, collected at 12 h post-G0 release, and examined.
Although PKB and p110 associated in cytosol, this association was
lower than that of PKB and p110, and was not found in the
nucleus, where only PKB-p110 complexes were observed (Fig.
S9A). We also analyzed association of endogenous proteins in
synchronized NIH 3T3 cells collected at 12 h postserum addition.
WB analysis of the fractions confirmed that p110 was mainly
cytosolic and p110 was more abundant in the nucleus (Fig. 5D).
Although immunoprecipitation concentrated the scarce nuclear
p110 protein, endogenous PKB associated mainly with p110 in
the nuclear fraction (Fig. 5D).
To identify other nuclear proteins that regulate DNA replication
and associate to p110, we performed a pull-down assay using
mammalian GST-p110; we obtained a number of candidate
proteins including PCNA. Immunoprecipitates of endogenous
PCNA from nuclear extracts contained associated endogenous
p110 but not p110 (Fig. 5E); results were similar in a reciprocal
assay (Fig. S9B). To determine whether the selective association of
PCNAwith p110was due to a p110-specific structural feature or
to its subcellular distribution, we inserted a nuclear localization
signal (NLS) in p85 and cotransfected it with myc-WT-p110 or -,
which increased their nuclear localization. Both nuclear p110 and
 associated with PCNA, although p110 association to PCNAwas
greater than that of nuclear p110 (Fig. S9C). Therefore, in
addition to its subcellular distribution, p110 has a structural
advantage for association to PCNA.
Here, we describe a role for p110 in replication fork elongation
in mammalian cells, providing an example of elongation control by
extracellular signal-regulated molecules. The nuclear localization
and function of p110 resembles that of class IV PI3K, which are
recruited to DNA damage sites andmediate cell responses as DNA
repair (34). Although some cell cycle phenotypes were moderate
(Fig. 1), complete p110 elimination interfered with cell survival,
and p110 function was studied in partial p110 deletion condi-
tions. p110 regulated DNA replication through kinase-dependent
and -independent mechanisms. p110 associated with PKB, and
p110 activity regulated nuclear PKB-mediated p21Cip phosphor-
ylation, PCNA release, PCNA binding to Pol and replication
elongation. Interference with p110 activity had a slight inhibitory
effect on p21Cip phosphorylation, and might partially compensate
for p110 activity-dependent functions. In addition, p110 associ-
ated with PCNA and controlled PCNA loading onto chromatin in
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Fig. 5. p110 associates with PKB and PCNA. (A) NIH 3T3 transfected with
control or p110 shRNA were selected with puromycin (2 g/mL, 48 h), then
examined. Other samples were treated with TGX221 or PKB inhibitors for 12 h
before collection. Immortalized p110/ mouse MEF, and p110/ MEF
reconstituted with WT- or KR-p110 were cultured in exponential growth. A
fraction of the cells were pulsed-labeled with BrdU (1 h). Graphs show the
percentage of cells remaining in S phase at each chase time (mean  SD, n 
3). (B) Lysates of cells treated as in A were analyzed in WB to determine PCNA
in the chromatin fraction, as well as PCNA and p110 in the chromatin-free
fraction. Graphs show the percentage of chromatin-bound PCNA normalized
to total PCNA and compared with maximum signal in control NIH 3T3 or in
MEF. (C) Immortalized MEF as inAwere arrested by thymidine treatment, then
released for different times. Cell fractions were examined in WB to test for
pPKB and PKB levels; the latter was then reprobed for PTEN. The graphs show
nuclear pPKB or PKB signal in arbitrary units (AU) (mean  SD, n  3). (D)
Synchronized NIH 3T3 cell cultures collected at 12 h postserum addition were
fractionated. The levels of PKB, p110 and  in these fractions were examined
by WB (Left). Endogenous p110 or  from cytosolic (1500 g) and nuclear
extracts (600 g), or PKB from cytosolic (300 g) and nuclear extracts (200 g)
were immunoprecipitated. We tested for PKB and p85 in p110 immunopre-
cipitates by WB. Controls 1–3, protein A plus each of the antibodies. Graph
shows the percentage of p110-associated PKB signal, compared with maximal
PKB signal (in PKB immunoprecipitates from an equivalent protein amount).
(E) Nuclear fractions were obtained from synchronized NIH 3T3 cells (at 12 h).
PCNA (800 g) or p110 (200 g) immunoprecipitates were tested in WB for
p110. For control 1, protein A was incubated with Ab; control 2, protein A was
incubated with lysate. Graphs show the percentage of p110 signal in PCNA
immunoprecipitates compared with maximal p110 signal (p110 immunopre-
cipitated from an equivalent protein amount). *, P  0.05.
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a kinase-independent manner. Since PCNA loading onto chroma-
tin is essential for DNA duplication, this kinase-independent func-
tion explains the greater division defects in cells with reduced p110
expression. The role of p110 in DNA replication could contribute
to cause the early lethality (E2–3, ref.4) of p110-deficient mice.
Materials and Methods
Complementary DNA and shRNA. pSG5-p110CAAX (active p110), pSG5-HA-
wt-PKB and -gag-PKB were described (5, 35). pCEF2-hp110CAAX (active p110)
was a gift of Dr. Murga (Centro de Biología Molecular/CSIC, Madrid, Spain).
PcDNA-Myc -WT and p21Cip mutants were donated by Dr. Ro¨ssig (28). pcDNA
Myc-S146A/T145A double mutant was generated using Quick Change Site-
Directed mutagenesis (Stratagene). Myc-K802R-hp110 and myc-K805R-hp110
mutants were subcloned into pSG5 and pRV-IRES-GFP for retroviral infection (6).
We used several specific short hairpin RNA (shRNA) directed to human or murine
p110 sequences, each assay was performed at least with two shRNA, with similar
results. These shRNA (6) were subcloned in pBluescript/U6 or in pTER vector; we
used control shRNA that did not reduce p110 or  expression. We also used
Pik3cb shRNA (Origene; Fig. 5). To prepare NLS-p85, the PKKKRKV sequence was
inserted 3 of the p85 sequence.
Cell Lines, Cell Culture, and Retroviral Transduction. Active p110 and active
p110 NIH 3T3 cells lines were described (6). KR-p110 and  mutations were
transduced by transient transfection or retroviral infection. We generated pTER-
p110or pTER-p110U2OS clones according to manufacturer’s protocol (Invitro-
gen); shRNA expression was induced for 2 days (p110) or 5 days (p110) in
medium plus doxycycline (6g/mL, Sigma). NIH 3T3 murine fibroblasts, U20S and
COS7 cells were cultured as described (6). For retrovirus production, Phoenix cells
were transfected using JetPei-NaCl (Qbiogene). MEF were donated by Drs. Zhao
and Roberts (7) (Dana Farber Cancer Institute, Boston, MA).
Cell Cycle, BrdU Labeling, Immunofluorescence, and Dynamic Molecular Comb-
ing. Immunofluorescence and NIH 3T3 G0 synchronization were as reported (15).
Briefly, cells were incubated in serum-free medium (19 h) and released by serum
addition. Cell cycle distribution was examined by DNA staining with propidium
iodide and analyzed by flow cytometry (Beckman-Coulter) using Multicycle AV
(Phoenix Flow Systems). Cells were synchronized at G1/S by double thymidine
block (6) or using aphidicolin (22). To determine cell division time (t1/2), cells were
seeded at similar densities and counted at 24 h intervals. S phase duration was
calculated considering t1/2 (mean of n 6) and the proportion of cells in S phase
in exponential growth (mean of n 12). S phase progression rates were exam-
ined in exponentially growing cultures incubated with 20 M bromodeoxyuri-
dine (BrdU; 1 h), chased at different times and stained with BrdU-FITC Ab (BD
Biosciences), then examined by three-dimensional FACS.
For dynamic molecular combing, synchronized NIH 3T3 cells were treated with
0.08M PIK75 or 30M TGX221 at 7 h postserum addition; 20 min before harvest
(12hpostserumaddition), cellswere treatedwith20MBrdU.Afterharvest, cells
were embedded in LMP agarose plugs (3	 106 cells/plug) and DNA fibers were
purified and stretched on silanized coverslips as described (21). BrdU tracks were
detected with rat monoclonal Ab (clone BU1/75; AbCys) and an Alexa 488-
conjugated secondary Ab (Molecular Probes). DNA fibers were counterstained
with mouse anti-ssDNA (MAB3034, Chemicon) and Alexa 546-secondary Ab
(Molecular Probes). Signals were analyzed with MetaMorph.
Statistical analyses were performed using StatView 512 (Calabasas, CA). Gel
bands and fluorescence intensity were quantitated with ImageJ software. Sta-
tistical significance was calculated using Student’s t test. For DNA combing,
statistical analysis was performed with GraphPad Prism 5.0 (GraphPad Software).
For description of antibodies and reagents, cell lysis, subcellular fractionation,
Western blotting, immunoprecipitation, and kinase assays, see SI Methods.
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Phosphoinositide 3-Kinases p110 and p110 Regulate Cell Cycle
Entry, Exhibiting Distinct Activation Kinetics in G1 Phase

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Phosphoinositide 3-kinase (PI3K) is an early signaling molecule that regulates cell growth and cell cycle
entry. PI3K is activated immediately after growth factor receptor stimulation (at the G0/G1 transition) and
again in late G1. The two ubiquitous PI3K isoforms (p110 and p110) are essential during embryonic
development and are thought to control cell division. Nonetheless, it is presently unknown at which point each
is activated during the cell cycle and whether or not they both control S-phase entry. We found that p110 was
activated first in G0/G1, followed by a minor p110 activity peak. In late G1, p110 activation preceded that
of p110, which showed the maximum activity at this time. p110 activation required Ras activity, whereas
p110 was first activated by tyrosine kinases and then further induced by active Ras. Interference with p110
and - activity diminished the activation of downstream effectors with different kinetics, with a selective action
of p110 in blocking early G1 events. We show that inhibition of either p110 or p110 reduced cell cycle entry.
These results reveal that PI3K and - present distinct activation requirements and kinetics in G1 phase, with
a selective action of PI3K at the G0/G1 phase transition. Nevertheless, PI3K and - both regulate S-phase
entry.
The exposure of quiescent cells to growth factors (GF) ac-
tivates a number of early signaling pathways that trigger cell
cycle entry. Class I phosphoinositide 3-kinase (PI3K) repre-
sents one of the GF-stimulated pathways that regulate G0/G1
and G1/S transitions. There are four class I PI3K enzymes,
composed of a regulatory subunit and a conserved p110 cata-
lytic subunit that triggers phosphatidylinositol (3,4)-biphos-
phate and phosphatidylinositol (3,4,5)-triphosphate (PIP3)
production. Class I PI3K enzymes are further classified as the
GF receptor-controlled class IA enzymes and the G protein-
coupled receptor-regulated p110 (class IB PI3K) (12, 42).
Three genes encode class IA catalytic subunits (p110, p110,
and p110) (12, 14, 42). Class IA enzymes are activated by
tyrosine kinases (TyrK) and Ras and regulate cell growth and
DNA synthesis (5, 14, 17). Of the three class IA catalytic sub-
units, p110 is expressed mainly in hematopoietic cells and
regulates the immune response (30), whereas p110 and - are
ubiquitous and they might control cell division. Mice deficient
in p110 or - isoforms are embryonic lethal, suggesting that at
least in development, these two isoforms have nonredundant
functions (3, 4).
PI3K activity increases within minutes after GF receptor
(GFR) stimulation (first peak) and again in advanced G1 phase
(second peak) (18, 19, 24). PI3K has been implicated in the
induction of cell growth and regulation of Cdk activity. Phar-
macological inhibition of PI3K at the time of GFR stimulation
blocks cell division (2). In addition, enhanced PIP3 production
after GFR binding accelerates cell cycle entry, whereas PIP3
reduction diminishes this process (1). PI3K regulates cell mass
increase by activating p70S6 kinase (p70S6K) and mTOR (9,
10, 23, 34, 35). The upregulation of PI3K activity also enhances
Cdk2 activation (21). The mechanisms by which PI3K controls
Cdk activity include the induction of cyclin D synthesis and
inhibition of cyclin D degradation, an effect mediated by pro-
tein kinase B (PKB)-induced glycogen synthase kinase 3 in-
activation (31, 33, 41). PI3K also regulates cell cycle entry
through PKB-mediated FoxO transcription factor (TF) phos-
phorylation, which reduces FoxO TF-controlled cyclin G2 and
p27INK expression (25, 27). Finally, the late G1 PI3K activity
stabilizes c-Myc, an event required for correct cyclin A expres-
sion and Cdk2 activation (24).
Although it is well established that PI3K activation regulates
progression through early and late G1 phase and cell cycle
entry (18, 24), it is unclear which of the two ubiquitous catalytic
subunits, p110 or -, is activated and whether or not they both
regulate cell cycle entry. Here we analyzed p110 and - ac-
tivation patterns during G1-phase progression, their activation
requirements, and their potential contributions to G1-phase
progression and cell cycle entry.
MATERIALS AND METHODS
Plasmids. pSG5-myc-p110 and -p110CAAX have been described previously
(1). pCEF2-hp110CAAX was a gift from C. Murga (Centro de Biologı´a Mo-
lecular/CSIC, Madrid, Spain). The plasmid pAC-CMV encoding Myc-tagged
full-length wild-type human p110 (hp110) was donated by M. White (Howard
Hughes Medical Institute, Chevy Chase, MD), and His-tagged wild-type hp110
by B. Vanhaesebroeck (Ludwig Institute for Cancer Research, London, United
Kingdom). The mutants myc-K802R-hp110 and myc-K805R-hp110 were gen-
erated by using a QuikChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA) with appropriate oligonucleotides and were subcloned into pSG5 and
pRV-IRES-GFP (for retroviral infection). Julian Downward donated the cDNAs
* Corresponding author. Mailing address: Department of Immunol-
ogy and Oncology, Centro Nacional de Biotecnologı´a/CSIC, Darwin 3,
Cantoblanco, Madrid E-28049, Spain. Phone: (34) 91-585-4849. Fax:
(34) 91-372-0493. E-mail: acarrera@cnb.uam.
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encoding yellow fluorescent protein–N17-Ras and V12-Ras (London Research
Institute, London, United Kingdom). Murine short hairpin RNAs (shRNA) were
subcloned in pBluescript/U6 (39). Human shRNA were cloned in the pTER
vector as described previously (40). The following target sequences were efficient
in reducing target mRNA expression: human/murine p1101 (h/mp1101), 5-
GGCATCCACTTGATGCC; h/mp1102, 5-GGGAGAACCCAGACATCAT
GTCA; h/mp1102, 5-AAAGCTGGACTACTAAAGTGA; h/mp1107, 5-TT
GCTCAGCTTCAGGCGCTGC; hp1107, 5-CTGTGGGGCATCCACTTGA;
and h/mp11015, 5-CTGGAATTTGATATTAATAT. The different  shRNA
and  shRNA gave similar results. For controls, we used shRNA that did not
reduce p110 or - expression. The following sequences were used for controls:
5-GGAATGAACCACTGGAATTT (control ) and 5-CCCAGACATCATG
TCAGAG (control ).
Ab and reagents. Transfections were performed by using Lipofectamine (In-
vitrogen, Carlsbad, CA). Blots were probed with the following antibodies (Ab):
cyclin E (M-20), c-Myc (C-19), p110 (S-19), and p70S6K (C-18) (Santa Cruz
Biotechnology, CA). Anti-cyclin D3, anti-phospho-PKB (anti-p-PKB) (Ser-473),
anti-Myc (9B11), and anti-p-p70S6K (Thr-389) Ab were from Cell Signaling
(Beverly, MA); anti-cyclin A, anti-retinoblastoma protein (anti-RB), and anti-
six-His from BD Biosciences (San Jose, CA); and anti-Akt1/PKB and anti-p-
Thr32-FKHRL1 (p-FoxO3a) from Upstate Biotechnology (Millipore, Billerica,
MA). Anti--actin was from Sigma (St. Louis, MO), anti-Ras was from Onco-
gene (Merck, Germany), and anti-p110 was donated by A. Klippel (Merck,
Boston, MA). [-32P]ATP was from Amersham (United Kingdom); lovastatin
and herbamycin were from Calbiochem.
Cell lines, cell culture, and retroviral transduction. Murine embryonic fibro-
blasts (MEF) were prepared as reported previously (13). The cells were main-
tained in Dulbecco’s modified Eagle’s medium medium supplemented with 10%
fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 100 U/ml penicillin, and
100 g/ml streptomycin. Stable NIH 3T3 p110CAAX (p110*) lines were
previously described (1). NIH 3T3 p110CAAX (p110*) cell lines were pre-
pared by transfecting NIH 3T3 cells with 3 g pCEF2-hp110CAAX plus 1 g
p-Pur (Clontech, Mountain View, CA). We failed to obtain stable cell lines
expressing K802R-p110 and K805R-p110 mutations; analyses using these mu-
tants were performed by transient transfection or retroviral infection (cultured
for 1 week). We expressed pTER-p1107 or pTER-p11015 in U2OS cells as
described previously (40).
Cell cycle and immunofluorescence analysis. Cells were synchronized in G0 by
serum starvation as reported previously (25). Synchronous cell cycle entry was
induced by the addition of serum. Cell cycle distribution was examined by DNA
staining using propidium iodide and analyzed by flow cytometry (Beckman-
Coulter, Fullerton, CA). U2OS cell cultures were synchronized at the G1/S
boundary by double-thymidine block (11) or were synchronized in metaphase
with colcemid (13). For retrovirus production, Phoenix cells were transfected by
using JetPei-NaCl according to the manufacturer’s protocols (Qbiogene, Irvine,
CA). Retroviral infection and immunofluorescence analysis were performed as
described previously (24).
WB, in vitro transcription and translation, immunoprecipitation, and PI3K
assays. Total cell extracts were prepared in radioimmunoprecipitation buffer (20
mM Tris-HCl, pH 8.0, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol,
1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS])
containing protease and phosphatase inhibitors (1 mM Na3VO4, 5 mM NaF, 1
mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, 10
nM okadaic acid). Western blotting (WB) and immunoprecipitation were per-
formed as described previously (25). For PI3K assays, cells were transfected with
empty vector (pSG5) or with a combination of pSG5–myc-tagged p110 and
pSG5–His-tagged p110 and were then synchronized as described above. In
some samples, 10 M lovastatin or 0.3 g/ml herbamycin was added 1 h before
harvest. In vitro transcription and translation and subsequent PI3K activity
analysis were performed as reported previously (17). PI3K was immunoprecipi-
tated by using anti-Myc or anti-six-His Ab; the kinase assays were performed as
described previously (24).
Quantitation of gel bands and statistical analyses. Statistical analyses were
performed by using StatView 512 (Calabasas, CA). Gel bands and fluorescence
intensities were quantitated with ImageJ software and were normalized accord-
ing to the fluorescence intensity of the loading control band. Cell cycle profiles
were analyzed with multicycle AV for Windows (Phoenix Flow Systems, CA).
RESULTS
p110 and - contribute differently to downstream signal-
ing. We investigated specific functions of p110 and - PI3K
catalytic subunits in G1 phase by comparing the consequences
of interfering with their activation for the induction of different
effectors. We examined several PI3K downstream targets, in-
cluding PKB, FoxO3a, and p70S6K. To synchronize the cells,
we arrested immortal nontransformed murine NIH 3T3 cells in
G0 phase by serum deprivation and then released them by
low-density replating in serum-containing medium for different
time periods, as described previously (25). We confirmed that
the PI3K effector PKB is activated at G0/G1, in late G1, and at
M-phase entry (Fig. 1A), as reported previously (7, 38). We
also synchronized human U2OS cells at the G1/S boundary or
in metaphase (Fig. 1B and C), as these cells fail to arrest in G0
FIG. 1. PI3K is activated at S-phase entry in different cell lines. (A) NIH 3T3 cells were arrested in G0; (B and C) U2OS cells were synchronized
at the G1/S boundary (B) or in metaphase (C) and released for different times. Extracts were examined with WB by using the indicated Ab. Cell
cycle distribution was examined in parallel; transits through G1, S, or G2/M are indicated (arrows). Graphs represent the means  standard
deviations of the p-PKB signals in arbitrary units, normalized in comparison to control PKB levels (n 	 3).
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(7, 38). We confirmed PI3K activation at G1/S transition and
M-phase entry in U2OS cells (Fig. 1B and C).
We confirmed the specificities of the p110 Ab used for this
study by transfection of wild-type p110 and p110 under the
control of the simian virus 40 promoter (pSG5 vector) in COS
cells, which gives rise to high levels of overexpression of re-
combinant proteins (Fig. 2A). Anti-p110 Ab selectively de-
tected p110 despite the high expression levels of recombinant
p110; similarly, anti-p110 Ab only detected endogenous and
recombinant p110 (Fig. 2A). To interfere with p110’s cellular
activity, we first used the active p110* (1) and p110* forms,
as well as the kinase-inactive myc–K802R-p110 and myc–
K805R-p110 mutants (see Materials and Methods). The in-
terference activities of the mutants were tested by transient
transfection of these PI3K forms in asynchronous cultures of
NIH 3T3 cells. The expression levels of exogenous p110 were
approximately double those of the endogenous proteins (Fig.
2B). Transient transfection of the mutants showed that K802R-
p110 and K805R-p110 reduced and p110* and -* in-
creased (p110* had a greater effect) the p-PKB cellular levels
(Fig. 2C). Thus, these mutants interfere with endogenous PI3K
pathway activation.
We then examined PKB, FoxO, and p70S6K activities during
early G1 (until 6 h following serum addition) in synchronized
populations of stable p110* and p110* transfectants (see
Materials and Methods). In these cells, the exogenous p110
expression levels were similar to the levels of endogenous
proteins (1) (data not shown). In synchrony, p110*-express-
ing cell lines showed sustained p-PKB activation (1) and
p110*-expressing cells showed a minor increase in basal levels
of p-PKB and an increase in the p-PKB signal at 
4 h (Fig.
2D). We failed to stably maintain cells expressing inactive
mutants; these mutants were transduced by transient transfec-
tion (or infection) of NIH 3T3 cells, which yielded expression
levels similar to those of endogenous proteins (Fig. 2B). The
expression of the K802R-p110 mutant, but not of the K805R-
p110 mutant, reduced p-PKB activation in early G1 (
1 h)
(Fig. 2E), as p110 activity is greater at this point (see below).
We also examined p70S6K activation. In asynchronous cul-
tures, the transient expression of p110-interfering forms de-
creased and p110-activating mutations enhanced (p110* had
a greater effect than p110*) p-p70S6K cellular levels (Fig.
2F). In synchronized populations, however, p110* enhanced
p70S6K activation even in G0, whereas p110* increased
p-p70S6K levels most notably at 
4 h after the addition of
serum (Fig. 2G). This suggested a selective action of p110 at
the first PI3K activity peak; accordingly, the expression of the
K802R-p110 mutant selectively inhibited the initial p-p70S6K
peak (
1 h), whereas the K805R-p110 mutant moderately
reduced late p-p70S6K levels (Fig. 2H). The K805R-p110
mutant did not reduce p70S6K activation at 1 h, probably
because p110 exhibits a notably lower activity than p110 in
early G1 (see below). Quantitation of the gel bands in several
assays confirmed the selective effect of the K802R-p110 mu-
tant on the early p-PKB and p-p70S6K activity peaks following
the addition of GF (Fig. 2E and H). The reduction of p110
and - levels with shRNA yielded consistent results (not
shown). These results indicate that both p110 and p110
modified PKB and p70S6K activation but that only p110
regulated their early G1 (
1 h) activity peaks.
p110 regulates FoxO3a phosphorylation. We also exam-
ined FoxO3a (FKHRL1), whose PKB-dependent phosphory-
lation is required for G0/G1 transition (27). We examined the
consequences of reducing the expression of p110 and - by
using interfering mutants or specific shRNA (see Materials
and Methods). The expression of p110 shRNA only affected
p110 levels; similarly, p110 shRNA reduced only p110, and
not p110, expression (Fig. 3A). p110 shRNA required
FIG. 2. Interference with p110 or - activity differentially affects
downstream signaling cascades. (A) Extracts (30 g) from COS cells
transfected with pSG5, pefBOS-p110, pSG5-p110, or pSG5-p110
were analyzed by WB using anti-p110, anti-p110, or actin Ab. (B, C,
and F) NIH 3T3 cells were transfected with vectors encoding p110*
or p110* or the K802R-p110 (KRp110) or K805R-p110
(KRp110) mutant, and extracts were examined with WB as described
above. (D, E, G, and H) Synchronous p110*- and p110*-expressing
NIH 3T3 clones (D and G) or NIH 3T3 cells transfected with the
K802R-p110 or K805R-p110 mutant (E and H) were lysed, and
extracts (30 g) were examined with WB using the Ab indicated on the
left. Graphs (E and H) show the mean percentages  standard devi-
ations (SD) of the p-Ser-473-PKB (pPKB) or p-Thr-389-p70S6K
(pp70S6K) signals normalized in comparison to those of loading con-
trols and compared to the maximum signal (control cells at 1 h, 100%)
(n	 3). P values compare results for control cells and those expressing
the K802R-p110 mutant at 1 h. (*), P  0.05; Student’s t test. Ctr,
control.
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longer incubation periods than p110 shRNA (minimum 96 h
versus 48 h for p110 shRNA), probably due to the greater
stability of the p110 protein (unpublished data). In control
cells, the p-FoxO3a signal peaked at 1 to 1.5 h and was reduced
by 2 h after GF addition (Fig. 3B). p110 shRNA greatly
decreased p-FoxO3a levels at 1 to 1.5 h, whereas p110
shRNA had only a moderate effect on FoxO3a phosphoryla-
tion (Fig. 3B). Similar results were obtained by using a differ-
ent set of shRNA (see Materials and Methods) or the K802R-
p110 or K805R-p110mutant (Fig. 3C). Control cells showed
two peaks of increased p-FoxO3a content in cells in G1 phase,
an early G1 peak and another peak coincident with the PI3K
activity peak in late G1 (Fig. 3C). Whereas the K802R-p110
mutant significantly reduced p-FoxO3a levels throughout G1,
the K805R-p110 mutant moderately diminished the duration
of the early G1 peak and slightly postponed late G1 FoxO3a
FIG. 3. Selective action of p110 on FoxO3a phosphorylation. (A and B) NIH 3T3 cells were transfected with pB/U6-2 (2) or pB/U6-2 (2)
shRNA; WB was used to analyze p110 or - expression at 48 and 96 h posttransfection (A). A cell fraction was arrested in G0 and incubated for
different times with serum; p-Thr-32-FoxO3a (pFoxO 3a) levels were analyzed with WB (B). The graph represents the mean percentages 
standard deviations (SD) of the signal normalized with those of the actin loading control and compared to the maximum signal in control cells
(100%) (n	 3). (C) Extracts (30 g) from synchronized NIH 3T3 cells transfected with the K802R-p110 or K805R-p110 mutant were examined
with WB as described above. Data were quantitated as described for panel B (n 	 3); arrows indicate S-phase progression. (D) Extracts from
control or stable p110*- or p110*-expressing NIH 3T3 cells synchronized in different phases were examined with WB as described above.
(E) Representative cell cycle distributions of the indicated synchronized cells. x axis represents DNA content, and y axis represents cell number.
Percentages of cells in G0/G1, S, and G2/M are indicated. (*), P  0.05 for comparison of results for control cells with results for cells expressing
p110 shRNA or the K802R-p110 mutant at 1.5 h. Ctr, control.
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phosphorylation. Accordingly, stable p110*-expressing cell
lines exhibited sustained and high p-FoxO3a levels (1) (Fig.
3D), whereas p110* only moderately and transiently in-
creased FoxO3a phosphorylation (Fig. 3D and data not
shown). The more-prominent action of p110 in FoxO TF
control in early G1 was confirmed by examining cyclin D (see
below). Thus, p110 plays a dominant role in FoxO phosphor-
ylation in early G1. The parallel examination of cell cycle
profiles in these assays showed that both the K802R-p110 and
the K805R-p110 mutant reduced cell cycle entry (Fig. 3E);
the levels of inhibition varied in different assays (see below)
but were of similar magnitudes for interference with p110 or
p110. Accordingly, p110*-expressing cells entered cell cycle
earlier (1, 21) (Fig. 3E) and p110*-expressing cells entered
S phase even more efficiently than p110*-expressing cells
(Fig. 3E).
p110 and - control cyclin E and A levels, but only p110
regulates cyclin D. Early signaling pathways promote cell
growth and the expression of G1 cyclins (14). We subsequently
examined the consequences for G1 cyclin expression of inter-
fering with p110 and - activity. Comparison of synchronous
stable p110*- and p110*-expressing cells showed that en-
hanced activation of p110, but not -, increased cyclin D3
levels (Fig. 4A and B). In contrast, both p110*- and p110*-
expressing cells upregulated cyclin E levels even before the
addition of serum, and p110*, but not -*, prolonged cyclin E
expression (Fig. 4A and B). Neither p110* nor -* expression
was sufficient to induce cyclin A expression in G0, but cyclin A
appeared earlier in these cells than in controls, and its expres-
sion was greater and more prolonged in p110*-expressing
cells (Fig. 4A and B). In p110*-expressing cells, the higher
cyclin D3 levels (Fig. 4A) correlated with their greater
p-FoxO3a content (Fig. 3) (1), as p-FoxO3a controls cyclin D
synthesis (36).
We performed a complementary analysis and examined the
effects of interfering with p110 and - expression on G1 cyclin
expression. We examined the effect of reducing p110 and -
expression levels by shRNA in murine NIH 3T3 cells (not
shown) and human U2OS cells synchronized at the G1/S bor-
der (Fig. 5). hp110 shRNA selectively reduced p110 expres-
sion, and p110 shRNA acted only on p110 (Fig. 5A). None-
theless, p110, but not -, shRNA reduced cyclin D3
expression (Fig. 5B and C). In contrast, both shRNA (for
p110 or -) delayed the expression of cyclins E and A (Fig. 5B
and C). Thus, p110 and p110 regulate the expression of
cyclins E and A, but only p110 controls cyclin D levels.
p110 and - control late G1 c-Myc levels and RB phosphor-
ylation. Late G1 PI3K activation stabilizes c-Myc (24); we at-
tempted to determine which of the two ubiquitous isoforms
regulated c-Myc levels in late G1. Stable p110*- and p110*-
expressing NIH 3T3 cell lines, as well as NIH 3T3 cells infected
with retroviruses expressing the K802R-p110 or K805R-
p110 mutant, were synchronized as described above. The
control cells exhibited two peaks of increased c-Myc levels
(Fig. 6A and B), as reported previously (24). In p110*-ex-
pressing cells, the c-Myc levels were higher and peaked earlier
but the cells still showed the two peaks of c-Myc expression
(Fig. 6A and B). p110* expression also moderately enhanced
c-Myc stability, but only in late G1 (Fig. 6A and B). The effect
of p110* at increasing c-Myc levels is consistent with its ac-
tion on FoxO TF, since FoxO TF represses c-Myc expression
(8); it also concurs with the higher cyclin A levels observed in
these cells, as c-Myc regulates cyclin A expression (26). None-
theless, both p110* and p110* prolonged c-Myc stability in
late G1. Interference with either p110 or - postponed or
reduced, respectively, the c-Myc expression levels in late G1
(Fig. 6C and D), suggesting that both isoforms control c-Myc
levels in advanced G1, although they do so differently.
FIG. 4. Enhanced p110 and - activities upregulate G1 cyclins.
(A) Levels of cyclins D3, E, and A, as well as actin levels, were
examined by WB in synchronous cultures of stable p110*- or p110*-
expressing NIH 3T3 cells. Transits through S phase are indicated
(arrows). Ctr, control. (B) The graphs represent the mean percentages 
standard deviations (SD) of the signals for cyclins normalized with
those of loading controls and compared to the maximum signal (100%)
in wild-type cells (n 	 3). P values (P  0.05) for the data from some
time points are indicated by asterisks. Gray asterisks show comparisons
between control and p110*-expressing cells; black asterisks show
comparisons between control and p110*-expressing cells. Cy, cyclin.
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We also examined the consequences of interfering with
p110 and - activities for the phosphorylation of RB, a major
Cdk2/cyclin substrate (37). In synchronized NIH 3T3 control
cells, RB was hyperphosphorylated at 
12 h after GF addition
(Fig. 7A). Both p110* and -* expression affected RB phos-
phorylation, which was observed at low levels even in quiescent
cells; in late G1, p110* and -* also increased and accelerated
(p110* more so) the appearance of hyperphosphorylated RB
(Fig. 7A). Accordingly, interference with p110 or - activity
by the expression of the K802R-p110 or K805R-p110 mu-
tant delayed RB phosphorylation (the K805R-p110 mutant
had a greater effect) (Fig. 7B), suggesting that both p110 and
- activities regulate RB phosphorylation.
Distinct activation kinetics of p110 and - during G1
phase. The distinct contributions of p110 and - to early G1
events suggested that p110 and - might present different
FIG. 5. p110 and - control expression of G1 cyclins. (A and B)
Expression levels of p110 and p110 in extracts of U2OS cells trans-
fected with pTER-p1107 (7) and pTER-p11015 (15) shRNA (for
48 and 96 h, respectively) (A), and a fraction of the cells was synchro-
nized at the G1/S boundary, and expression levels of cyclins D3, E, and
A were examined by WB at different times after serum addition (B).
The percentages of cells in S phase are indicated. (C) Graphs show the
mean percentages  standard deviations (SD) of the signals for each
cyclin compared to the maximum signal in wild-type cells (100%),
normalized with the signals for loading controls (n 	 3). P values (P 
0.05) for data at the 0 time point, prior to release, are shown by
asterisks. Gray asterisks show comparisons between control and p110
shRNA-expressing cells; black asterisks show comparisons between
cells expressing p110 shRNA and cells expressing control shRNA.
Ctr, control; Cy, cyclin; Thy, thymidine.
FIG. 6. p110 and - regulate c-Myc levels. (A and B) Stable NIH
3T3 cells expressing p110* or p110* (A) or NIH 3T3 cells infected
with viruses expressing the K802R-p110 or K805R-p110 mutant
(B) were arrested in G0 and incubated for different times after serum
addition; c-Myc expression levels were analyzed by WB. Graphs show
the mean percentages  standard deviations (SD) of the c-Myc signals
compared to the maximum signal in wild-type cells at 12 h after GF
addition (100%) and normalized with the signals of loading controls
(n	 3). Transits through S phase are indicated (arrows). P values (P
0.05; Student’s t test) for comparisons of data at 9 and 12 h are shown
by asterisks. Gray asterisks show comparisons between control and
p110 mutant-expressing cells; black asterisks show comparisons be-
tween controls and p110 mutant-expressing cells.
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activation kinetics. To determine the PI3K isoform(s) activated
in early and late G1, we examined NIH 3T3 cells that permit
the synchronization of the cultures in G0 phase (25). To isolate
p110 and -, we could not use p85 Ab as it brings down both
catalytic subunits, nor we could use anti-p110 and - Ab,
since most of them reduce PI3K activity (unpublished obser-
vations). Thus, to evaluate specific isoform activation through
G1 phase, we cotransfected NIH 3T3 cells simultaneously with
cDNA encoding wild-type p110 and - fused to two different
tags. Recombinant Myc-tagged p110 and His-tagged p110
were expressed at slightly above basal levels (Fig. 8A). p110
and p110 were efficiently immunoprecipitated by using Myc-
tagged or His-tagged Ab, as determined by WB using the
specific p110 or p110 Ab, respectively (Fig. 8B). Moreover,
p110-p85 and p110-p85 complexes were at similar levels, as
estimated by comparison of the amounts of p85 present in
p110 and p110 immunoprecipitates (Fig. 8B, bottom).
We immunopurified p110 and - with the corresponding
anti-tag Ab and tested their enzyme activities in vitro. After the
addition of serum, p110 activated early, at 5 to 10 min fol-
lowing serum addition; this activity increased at 1 h and then
diminished to basal levels, increasing again at 
7 h (Fig. 8C).
p110 exhibited modest activity peaks at 1 and 4 h and a
maximum activity at
8 h after the addition of serum (Fig. 8C).
In NIH 3T3 cells, part of p110, but not p110, localizes in the
nuclei (our unpublished results); nuclear PI3K activity peaked
at 
8 h after the addition of serum, confirming maximum
endogenous p110 activity in late G1 (not shown). We checked
that similar amounts of p85 were associated with either p110
or p110 at different time points (Fig. 8D). Therefore, most
PI3K activity in early G1 corresponds to that of p110; p110
exhibits another minor peak by 4 h. In late G1, both p110 and
- are activated and p110 exhibits its maximum activity.
p110 and - have different activation requirements. The
different activation kinetics of p110 and - suggested that
they exhibit distinct activation requirements. Since TyrK and
Ras regulate class IA PI3K activation (17), we tested whether
the p110 and - activities in G1 phase were affected by treat-
ment with inhibitors of TyrK (herbamycin) and Ras (lova-
statin). We first checked the selective action of these inhibitors
in reducing p-Tyr or active Ras levels (24 and data not shown).
Herbamycin treatment, but not treatment with lovastatin,
reduced p110 activity at 7 min. Both herbamycin and lova-
statin inhibited p110 activation at 1 and 7 h (Fig. 8C). This
suggests that the first increase in the activity of p110 is TyrK
dependent, but TyrK and Ras contribute to p110 activation at
1 and 7 h. In contrast, the modest p110 activity at 1 h was
sensitive to lovastatin, but not to herbamycin, although both
inhibitors blocked later p110 activation peaks (at 4 and 8 h)
(Fig. 8C and F). The results of these assays illustrate the
distinct activation requirements for p110 and - activities.
The maximum p110 (at 1 h) and p110 (at 8 h) activities,
nonetheless, were herbamycin and lovastatin sensitive, suggest-
ing that TyrK and Ras activation contribute to optimal p110
and p110 activities.
To confirm the distinct activation requirements of p110
and p110, we examined whether the response of purified
p85-p110 complex to activated TyrK and Ras is similar to that
of p85-p110 (17). We used Tyr-phosphorylated platelet-de-
rived growth factor receptor (PDGF-R) peptide and purified
active Ras in vitro; this analysis confirmed that the Tyr-phos-
phorylated peptide activates p110, that active Ras alone ex-
erts a moderate activation effect, and that Ras synergizes with
p-Tyr phosphopeptides to enhance p110 activity (Fig. 9B and
C) (17). In contrast, although p110 activity also increased
with the phosphopeptides and with active Ras and together
they induced a greater activation effect (Fig. 9B and C), there
was a consistent difference between p110 and p110 activa-
tion. Whereas p110 responds better to Tyr phosphopeptides
than to V12-Ras alone, Ras consistently induced a greater
activating effect than phosphopeptides on p110 (Fig. 9B and
C). These assays confirmed the TyrK activation requirement
for p110 induction (17) and demonstrated the greater intrin-
sic Ras dependence for p110 activation.
Since p110 activation is greater than that of p110 in early
FIG. 7. p110 and - control RB phosphorylation. (A and B) Sta-
ble NIH 3T3 cells expressing p110* or p110* or infected with viruses
encoding the K802R-p110 (p110) or K805R-p110 (p110) mutant
were treated as described in the Fig. 6 legend; RB expression levels
were analyzed by WB. Graphs represent the mean percentages 
standard deviations (SD) of the signals for p-RB (pRB) compared to
the maximum p-RB signal in wild-type cells at 15 h (100%) (n 	 3).
Quantitation was as described in the Fig. 6 legend. (*), P  0.05.
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G1 (at 7 min to 1 h), we compared the binding of p110 and -
to PDGF-R at early time points. Both isoforms associated with
the PDGF-R at 7 min after the addition of serum (not shown),
arguing against a selective binding of p110 as the cause for its
selective activation at this point. To gain insight into the mech-
anisms of p110 and - activation in early G1, we considered
the greater Ras dependence of p110 in vitro and postulated
that the activation of p110 in vivo might also rely more on
active Ras than that of p110 does. To determine the relative
Ras dependence for p110 and -, we examined the sensitiv-
ities of p110 and - to interference with Ras activation in-
duced by the coexpression of N17-Ras with Myc-tagged ver-
sions of p110 and -. Whereas the first p110 activity peak at
7 min decreased only partially in the presence of N17-Ras
(approximately one-third), p110 activation, which was lower
than that of p110, occurred later and was drastically reduced
(more than 90%) following the expression of N17-Ras (Fig. 9D
and E). These observations show that both in vitro and in vivo,
the activation of p110 is more Ras dependent than that of
p110. Considering that Ras activation is moderate at 1 h and
maximal in late G1 (24), the greater Ras dependence of p110
explains its activation kinetics in G1 phase.
Interference with p110 or - expression/activity results in
cell cycle entry defects. During the course of the experiments
using synchronized populations, we noticed that cells express-
ing p110* and -* showed an earlier S-phase entry (Fig. 3E,
4, 6A, and 7A). Accordingly, the expression of K802R-p110
and K805R-p110 mutants (Fig. 3E, 6B, and 7B) or the re-
duction of p110 and - levels by shRNA in U2OS cells (Fig.
5B) induced a delayed G1/S transition. We also interfered with
p110 or - expression in NIH 3T3 cells by using p110 or -
shRNA, as described above. p110 shRNA selectively reduced
p110 expression and p110 shRNA diminished only p110
levels (Fig. 10A). Despite partial reductions in p110 and -
expression, both shRNA delayed S-phase entry (Fig. 10A).
We also examined cell cycle entry by the incorporation of
bromodeoxyuridine (BrdU). Interference with endogenous
p110 and - kinase activity in COS cells by the transfection of
the inactive K802R-p110 or K805R-p110 mutants reduced
BrdU incorporation (Fig. 10B). We also analyzed primary
FIG. 8. p110 and - show distinct activation kinetics. (A) WB analysis of total p110 and p110 levels in NIH 3T3 cells transfected with empty
vector or with cDNA encoding Myc-tagged p110 plus His-tagged p110; expression levels of recombinant proteins are within the range of
expression of endogenous p110. (B) NIH 3T3 cell extracts as described for panel A were immunoprecipitated (IP) using anti-Myc-tagged or
anti-His-tagged Ab. WB showed p110 or - expression and the amount of p85 in complex with p110. (C) NIH 3T3 cells transfected with
Myc-p110 plus His-p110 were incubated (24 h), arrested in G0, and released in serum alone or with herbimycin or lovastatin at the indicated
times. p110 or - was immunoprecipitated as described for panel B, and kinase activity was assayed in vitro. (D) Immunoprecipitates as described
for panel C were resolved by SDS-polyacrylamide gel electrophoresis, and associated p85 was assayed by WB. (A to D) Each assay result shown
is representative of five assays with similar results. (E and F) Graphs show the mean percentages  standard deviations (SD) (n  4) of p110
and - activities (as shown in panel C) compared to the activity of p110 at 1 h (100%). The double-ended arrow in panel E indicates the time
point for which the P value was calculated. (*), P  0.05; Student’s t test. Ctr, control; , present; , absent.
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cells. Homozygous deletion of p110 or - causes embryonic
lethality (3, 4). We thus examined MEF from p110 and -
heterozygous mice. Since G0 arrest by serum deprivation or
growth to confluence is inefficient in MEF, we analyzed S-
phase entry by measuring BrdU incorporation in exponentially
growing cultures. Both heterozygous deletions reduced the
fraction of BrdU-positive cells compared to the BrdU-positive
fraction of wild-type fibroblasts (Fig. 10C). These results dem-
onstrate that both p110 and - control cell cycle entry.
DISCUSSION
The activation of PI3K is essential for cell division. We
examined which one of the two ubiquitous PI3K isoforms
(p110 and -) regulates cell cycle entry. We describe results
showing that p110 activated before p110 at the G0/G1 tran-
sition exerts a selective action in inducing G1 entry events. In
fact, the first activity peak of p110 had already occurred at 5
to 10 min following the addition of GF and it required TyrK
activation; p110 further increased its activity at 
1 h in a
TyrK- and Ras-dependent manner and activated again in ad-
vanced G1. In contrast, p110 displayed low activity in early
G1, with a moderate increase at 
1 h; Ras induction was
essential for p110 activation. p110 displayed another low
activity peak in mid-G1 and maximal activation in late G1.
p110 and - activate in a sequential manner in late G1. This
concurs with their distinct sensitivities to TyrK and Ras since,
also in late G1, the activation of TyrK precedes that of Ras,
which is maximal at this point (24). In agreement with the
greater activation of p110 in early G1, this isoform regulated
early G1 events (such as cyclin D levels and FoxO phosphory-
lation) more than p110 did. Nonetheless, interference with
either p110 or p110 reduced S-phase entry, showing that
both isoforms control the G13S transition. p110 and - reg-
ulated the expression of c-Myc and cyclins E and A, RB phos-
phorylation, and, in turn, S-phase entry.
The critical role of p110 and - in the control of cell
division was taken into account during the preparation of the
cell lines for this study. We used stable cell lines expressing low
levels of p110* and p110*, since the transient overexpres-
sion of high levels of p110* impairs progression through the
G2/M phases (1). p110*-expressing cells entered cell cycle
faster than controls, and p110*-expressing cells divided at a
lower half-life than both p110*-expressing cells and controls.
For the analysis of the consequences of reducing the p110
and p110 activities, we had to use transient transfection or
infection, as cell lines of kinase-inactive mutants or shRNA
were unstable, showing that p110 and p110 activities control
cell survival and/or division.
An open question regarding the select functions of class IA
PI3K isoforms is how the specificities of the different isoforms
are acquired, as p110 catalytic subunits produce the same lipid
products and all class IA p110s associate with p85 molecules,
which bring p110 to activated receptors (42, 12). p110’s spec-
ificity seems related to its tissue-specific expression pattern
(30). However, in the case of p110 and -, they are ubiquitous
and still they exhibit distinct functions in development (3, 4)
and cell division (Fig. 2 and 3). The observations presented
here illustrate mechanisms for the p110 and - functional
FIG. 9. Activation of p110 requires Ras. (A) Control vector or
cDNAs encoding V12-Ras or p85 combined with p110 or p110 were
transcribed and translated in vitro and then analyzed by SDS-poly-
acrylamide gel electrophoresis. (B) The activities of purified p85/p110 or
p85/p110 complexes were assayed in vitro, alone or in the presence of
a PDGF-R phosphopeptide (pp) at the indicated close (M), V12-
Ras, or both. The panels show the results of representative experi-
ments (n 	 3). (C) The graphs compare PIP3 spot intensities for three
experiments (as in panel B) to maximum p110 or - activities (pp 
VRas [V12-Ras], 100%) (n 	 3). Double-ended arrows indicate the
two values being compared. (D) NIH 3T3 cells were transfected with
empty vector or cotransfected with cDNAs encoding p85 and Myc-
p110 or Myc-p110. p85-p110 cDNAs were transfected alone or with
a vector encoding N17-Ras. After 36 h, cells were synchronized in G0
and released by serum addition for different times. p110 or p110 was
immunopurified, and their activities assayed in vitro. We examined the
amount of p85 in the p85-p110 complexes by WB (middle panels). The
different samples expressed similar N17-Ras levels (bottom), as deter-
mined by WB. , present; , absent; IP, immunoprecipitate.
(E) Graphs compare the mean percentages  standard deviations
(SD) of p110 and - activities of three different assays as described
for panel C to the activity of p110 or p110 at 1 h (100%), normalized
in comparison with the p85 loading control. (*), P  0.05. V-Ras/
VRas, V12-Ras; N-Ras/ 17N-Ras, N17-Ras.
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specificities that are delimited by the different activation re-
quirements determining when these isoforms are activated.
The phenotype of mice expressing a Ras-resistant p110
mutant supports the observation that, physiologically, p110
activity is partially independent of Ras. These mice present a
number of defects, including reduced cell proliferation and
diminished Ras-dependent tumor formation (15); however,
they exhibit a milder phenotype than p110-deficient mice (3).
This shows that despite the fact that K227A p110 is not
activated by Ras, it still exerts some of the p110 actions in
vivo (15). Interestingly, the expression of wild-type p110, -,
and - is sufficient to induce chicken embryo fibroblast focus
formation; in contrast, p110 requires an activating mutation
to trigger transformation (20). The crystal structure analysis of
the inter-Src homology 2 domain of p85 in complex with the
N-terminal part of p110 suggests that activation by Tyr ki-
nases releases p110 from the inhibition exerted by p85; it is
possible that the p85-mediated p110 structural constraint is
stronger in the case of p110 (16, 29). The H1047R mutant
activates p110; following the additional K227E mutation, this
mutant no longer binds Ras but contributes to cell transfor-
mation. In contrast, wild-type p110 loses its transforming
activity when Ras binding is impaired (20). It is possible that in
the absence of Ras binding, p110 simply exhibits low enzy-
matic activity, since we show that purified p110 shows a
higher Ras dependence for activation than p110 (Fig. 9). In
this regard, although late G1 p110 activation was greatly in-
hibited by the addition of herbamycin at 7 h (Fig. 8C), this
treatment reduced late G1 Ras activity (not shown). Future
studies will attempt to determine which residues in the p110
Ras-binding site determine the greater Ras dependence of
p110.
Whereas the results of our studies support the existence of
activation specificities for p110 and -, downstream of p110
and - we find that they are both capable of regulating the
same substrates. In fact, both the mutants interfering with
p110 and those interfering with p110 affected PKB and
p70S6K activities, illustrating that these p110 isoforms have the
potential of regulating the same effectors. The distinct kinetics
of p110 activation in early G1 phase explains the specific
function for p110 at this point. In fact, in synchronized cells,
p110 selectively controlled the first activation wave of PKB
and p70S6K and, in turn, FoxO3a phosphorylation and the
expression of its effector, cyclin D. Since p110’s activity was
low in early G1, interference with its kinase activity affected
PKB and p70S6K activities at this point only slightly, although
it modulated their activities at later time points (Fig. 2). In
contrast, in late G1, both p110 and p110 exhibited remark-
able increases in activity and regulated c-Myc and cyclin E and
A levels, as well as RB phosphorylation. Therefore, both the
p110 and - isoforms controlled cell cycle regulators at the
G1/S boundary, offering a mechanism for the involvement of
these isoforms in the control of cell cycle entry.
The expression of p110 shRNA inhibits carcinoma cell
growth (28), supporting the role of p110 in cell division.
Selective interference with p110 inhibited the early activation
of the cell growth regulator p70S6K (Fig. 2). Since cell cycle
entry cannot occur without cell growth (35), p110 mutations
FIG. 10. Interference with p110 or - results in cell cycle defects. (A) NIH 3T3 cells were transfected with the indicated shRNA; at 48 or 96 h
posttransfection, cells were collected and lysates (30 g) examined by WB using anti-p110, anti-p110, and antiactin Ab (left panels). A fraction
of the cells were synchronized, and cell cycle distribution examined at indicated times. The proportion of cells in S phase is represented (mean 
standard deviation) (n 	 3) (right panels). P values for comparisons of the data at 12 h are shown. (B) COS cells were transfected with cDNA
encoding the K802R-p110 or K805R-p110 mutant; at 24 h posttransfection, the cells were incubated with BrdU (1 h). The percentages of cells
incorporating BrdU were examined by immunofluorescence (IF) (means  standard deviations) (n	 3). (C) Heterozygous (HET/Het) p110 and
p110 MEF were screened by specific PCR (left). We show percent BrdU incorporation in exponentially growing heterozygous MEF compared
to that in wild-type (WT) MEF from littermate embryos. (*), P  0.05; Student’s t test. Ctr, control; 1 and 2, mice 1 and 2; KO, knockout.
2812 MARQUE´S ET AL. MOL. CELL. BIOL.
 at Centro Nacional de Biotecnología - Biblioteca on April 27, 2009 
m
cb.asm
.org
D
ow
nloaded from
 
in human cancer might facilitate G0 exit by upregulating pro-
tein synthesis and inhibiting FoxO TF-controlled cell cycle
inhibitors. Later in the cell cycle, p110 and - contribute to
enhancing c-Myc stability and Cdk2 activation (24). p110 is
thus a potential target for cancer treatment; nonetheless, the
inhibition of p110 interferes with glucose metabolism (22).
Alternatively, interference with p110 might also be consid-
ered a promising approach, since although no activating mu-
tations in p110 in human cancer have been described, the
overexpression of the wild-type p110 does promote cell trans-
formation (20). In fact, shRNA for p110 show an antiprolif-
erative effect in tumor cell lines (6, 32) and interference with
p110 blocks S-phase entry (Fig. 10).
Altogether, we report that p110 and - are activated with
distinct kinetics during G1 phase, as they respond differently to
the activation of TyrK and Ras. p110 primarily controls early
G1 events, such as FoxO TF inactivation and cyclin D expres-
sion, whereas both p110 and - regulate later G1 events and
G0/G1 transition.
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AbstrACt
Although cell lipids were initially envisioned as structural components of the cell, 
their essential contribution to initiation and regulation of cell responses is now clearly 
established. Among the different lipids that regulate cell responses, those produced by 
class I phosphoinositide 3‑kinase (PI3K), phosphatidylinositol (3,4)P2 (PIP2) and phospha‑
tidylinositol (3,4,5)P3 (PIP3), have concentrated much attention in recent years. PIP2 and 
PIP3 are involved in cell division and survival control, and mutations in the PI3K pathway 
are linked to autoimmunity and cancer. Here we discuss two novel observations: a PI3K 
function in the late‑G1 phase of the cell cycle and the contribution of the p85 PI3K regula‑
tory subunit in the control of cytokinesis.
The	phosphoinositide	3-kinases	(PI3K)	are	a	family	of	enzymes	that	phosphorylate	the	
3-position	 in	 the	 inositol	 ring	of	membrane	phosphoinositides.	The	 family	 is	 classified	
according	to	sequence	homology	and	substrate	specificity	into	three	different	types:	class	I,	
class	II	and	class	III.	Class	I	PI3K	produce	PIP2	and	PIP3	rapidly	and	transiently	following	
receptor	stimulation.	These	enzymes	are	further	subdivided	in	class	IA	PI3K,	activated	by	
receptor-activated	 tyrosine	 kinases	 (Tyr	K),	 and	 class	 IB	 PI3K,	 activated	 by	G	protein-	
coupled	receptors.	The	class	IB	PI3K	catalytic	subunit	is	encoded	by	a	single	gene,	p110g,	
and	 is	 regulated	 by	 two	 subunits,	 p101	 and	 p87.1,2	 For	 class	 IA,	 three	 different	 genes	
encode	regulatory	subunits	(p85a,	p85b	and	p55g)	that	have	different	alternative	splice	
forms;	there	are	also	three	catalytic	subunits	(p110a,	p110b	and	p110d).	We	will	focus	on	
class	IA	p85/p110	enzymes,	as	they	are	clearly	involved	in	control	of	cell	division.
2
Growth	factor	addition	to	quiescent	cells	triggers	a	number	of	early	signaling	cascades,	
including	activation	of	Tyrosine	kinases	(Tyr	K),	Ras,	and	phospholipase	C,	among	others.	
Tyr	K	and	Ras	 trigger	class	 IA	PI3K	activation.
3	PIP2	and	PIP3	act	as	docking	sites	 for	
proteins	containing	plescktrin	homology	(PH)	domains,	such	as	protein	kinase	B	(PKB	
or	Akt),	phosphoinositide-dependent	kinase	(PDK1),	and	some	GTPase	exchange	factors	
(GEF).	These	enzymes	subsequently	activate	secondary	effectors	including	small	GTPases,	
the	 target	 of	 rapamycin	 (mTOR),	 glycogen	 synthase-3	 kinase	 (GSK3b),	 ribosomal	 S6	
kinase	 (p70S6K),	 etc.	 PI3K/PKB	 also	 regulate	 transcription	 factors	 such	 as	 c-Myc	 and	
FoxO.2	 By	 inducing	 these	 cascades,	 PI3K	 controls	 cell	 responses	 including	 survival,	
motility	and	division.
Symmetrical	cell	division	is	the	process	in	which	DNA	and	protein	content	duplicate	
to	give	rise	to	two	daughter	cells	with	conserved	genetic	content	and	cell	size.	This	process	
requires	induction	of	protein	synthesis	(highly	active	during	the	G1	phase)	and	of	DNA	
replication,	controlled	by	the	Cyclin-dependent	kinases	(Cdk).	PI3K	regulates	cell	growth	
though	 effectors	 such	 as	 mTOR	 and	 p70S6K,	 which	 control	 protein	 synthesis.	 PI3K	
regulates	 the	 nuclear	 cell	 cycle	 by	 controlling	 the	 stability	 of	 Cdk	 regulatory	 proteins	
including	GSK3b,	 c-Myc,	Cyclin	D	and	p27kip.	 In	addition	 to	affecting	G0/G1	 transi-
tion,	PI3K	activates	again	 in	 late-G1,	an	event	 required	 for	S	phase	entry.
4	The	 second	
G1	PI3K	activity	peak	parallels	activation	of	other	signaling	molecules	including	Tyr	K,	
MAPK	and	Ras,	some	of	which	are	required	for	late-G1	PI3K	activation.
3,5,6	In	fact,	the	
prolonged	 exposure	 to	 growth	 factors	 required	 for	 cell	 cycle	 entry	 and	 commitment	 to	
completion,	can	be	replaced	by	two	short	mitogens	pulses	at	G0	→ G1	and	late-G1	(~8	h	
after	the	first	pulse).4
We	recently	reported	that	expression	of	c-Myc	substitutes	for	the	late-G1	PI3K	activity	
peak,	 resulting	 in	 ~80%	 recovery	 of	 G1-S	 transition.
5	 Increased	 c-Myc	 protein	 levels	
correlates	with	PI3K	induction	in	early-G1	and	late-G1	of	the	cell	cycle.	It	is	nonetheless	
puzzling	that	late-G1	PI3K	can	be	replaced	by	c-Myc,	as	PI3K	and	c-Myc	have	otherwise	
unrelated	functions.	In	contrast	to	the	functions	described	for	PI3K,	the	role	of	c-Myc	is	
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linked	to	its	transcription	factor	activity,	required	for	its	transforming	
capacity.7-9	c-Myc	regulates	 transcription	 in	complex	with	the	Max	
protein.	c-Myc/Max-regulated	gene	expression	involves	several	mech-
anisms	that	include	chromatin	remodeling	as	well	as	recruitment	of	
RNA	polymerases	and	transcription	elongation	factors.8,10
The	requirement	for	c-Myc	for	cell	cycle	entry	is	based	on	several	
observations.	 Under	 certain	 conditions,	 c-Myc	 alone	 drives	 cell	
cycle	 entry	 and	 G1	 phase	 progression.
11,12	 c-Myc	 overexpression	
shortens	 G1	 phase	 promoting	 Cyclin	 D	 transcription	 and	 p27
kip	
downregulation,	which	enhances	Cyclin	D-associated	kinase	activi-
ties	in	early-G1;
9	c-Myc	also	regulates	Cyclin	E	and	A	expression	in	
late-G1.
8	Accordingly,	c-Myc	depletion	leads	to	lengthening	of	G1	to	
almost	double	the	time	compare	to	wild	type	cells.13
c-Myc	cooperates	with	Ras	and	PI3K	to	trigger	cell	 transforma-
tion.14	 In	 nontransformed	 quiescent	 cells,	 expression	 of	 c-Myc	
and	of	active	Mek1	(an	activator	of	MAPK)	synergize	with	PIP3	to	
promote	cell	cycle	entry,	but	Mek1	and	PIP3	are	insufficient	for	the	
cells	to	enter	S	phase,	showing	that	c-Myc,	MAPK	and	PI3K	regulate	
different	events	in	cell	cycle.4	Accordingly,	we	find	that	inhibition	of	
PI3K	activity	during	 the	 first	6	h	 following	growth	 factor	addition	
is	not	compensated	by	c-Myc	induction,	confirming	that	PI3K	and	
c-Myc	exhibit	nonredundant	functions	in	early-G1.
5
Despite	 their	 different	 functions,	 we	 find	 that	 c-Myc	 expres-
sion	reconstitutes	S	phase	entry	(~80%)	when	PI3K	is	 inhibited	in	
late-G1.	 Expression	 of	 c-Myc	 mRNA	 is	 regulated	 by	 Src	 kinases,	
Ras/Raf	 signaling,	 and	 positive	 feedback	 regulation,	 as	 in	 the	 case	
of	 E2F-1-induced	 c-Myc	 expression.15-17	 Nonetheless,	 as	 c-Myc	
mRNA	and	protein,	both	have	very	short	half-lives	(~20–30	min),9	
c-Myc	must	be	stabilized	during	G1	to	guarantee	its	function.
18	The	
PI3K/PKB/GSK3b	 cascade	 controls	 c-Myc	 stability	 function.19,20	
Regulation	 of	 c-Myc	 stability	 involves	 phosphorylation	 of	 two	 key	
residues,	 T58	 and	 S62.	 MAPK	 mediates	 S62	 phosphorylation,	
required	 for	 subsequent	 T58	 phosphorylation	 by	 GSK3b,	 which	
targets	c-Myc	for	degradation	(reviewed	in	ref.	19).	Phosphorylation	
of	T58,	which	 is	 regulated	 by	 the	PI3K	pathway,	 is	 a	 key-destabi-
lizing	 event,	 as	 it	 represents	 a	major	mutation	hotspot	 in	Burkitt’s	
lymphomas.20	 Thus,	 besides	 the	 role	 of	 PI3K	 at	 G0–G1	 entry,	
the	 second	 G1	 PI3K	 activity	 peak	 is	 essential	 for	 c-Myc	 stabiliza-
tion,	which	 in	 turn	affects	Cyclin	A	expression,	Cdk2	activity,	and	
licensing	of	the	DNA	replication	complex.5
Apart	from	contributing	to	the	initiation	of	cell	division,	PI3K	is	
an	essential	manager	of	cell	survival	by	regulating	PKB	(reviewed	in	
ref.	21).	PI3K	also	 regulates	 cell	migration.22	PI3K	activity-depen-
dent	c-Rac	activation	and	p85-regulated	Cdc42	activation	are	both	
essential	events	for	remodeling	the	Actin	cytoskeleton.	Remarkably,	
this	 p85	 function	 in	 cytoskeletal	 remodeling	 is	 also	 important	 for	
cytokinesis	(see	below).
Following	S	phase	entry,	PI3K	exhibits	basal	activity	during	S-G2	
phases.23,24	PI3K	activates	again	at	mitosis	entry,	which	contributes	
to	 trigger	 Cdk1	 activation	 and	 mitosis	 initiation.25-27	 As	 mitosis	
progresses,	however,	PI3K	activity	 reduces;	 reaching	basal	 levels	by	
the	 time	 cells	 are	 ready	 to	 divide	 their	 cytosol.27	We	 found	 that	
deletion	 of	 p85a,	 the	 ubiquitous,	 most	 abundant	 p85	 regulatory	
isoform,	 impairs	cytosolic	 separation.27	As	 in	 the	case	of	migrating	
cells,22	 p85	 appears	 to	 control	 Cdc42	 activity	 in	 cytokinesis,	 as	
well	 as	 its	 localization	 to	 the	 cleavage	 furrow.27	 Defective	 Cdc42	
localization	 to	 the	 cleavage	 furrow	 in	 p85a-deficient	 cells	 results	
in	 impaired	 Septin	 2	 localization	 and	 defective	 cytokinesis	 (20%	
of	 these	 cells	 are	 binucleated,	 ref.	 27).	 Cdc42-controlled	 Septin	
action	in	cytokinesis	was	described	in	Saccacharomyzes cerevisae,28,29	
but	not	 in	mammals.	In	fact,	 in	mammals,	 the	Septins	and	Cdc42	
regulate	microtubule-to-chromosome	attachment	in	metaphase,30-33	
making	difficult	to	examine	posterior	cell	cycle	defects.	At	 least	 for	
the	Septins	their	cytokinesis	function	in	mammals	was	envisioned	by	
microinjection	of	anti-Septin	2	antibodies	as	well	as	using	shRNA	for	
the	Septin	MSF.34,35	We	found	that	metaphase	is	unaffected	by	p85	
deletion,	 suggesting	 that	Cdc42	and	Septin	2	actions	 in	 this	phase	
are	 virtually	 p85-independent.	 In	 contrast,	 the	 role	 of	Cdc42	 and	
Septin	2	 in	controlling	cytosolic	 separation	 involves	p85a,	making	
possible	 to	unmask	 the	 function	of	p85a →	Cdc42	→	Septin2	 in	
cytokinesis,	without	 apparent	 effects	 in	metaphase.	 p85a	 regulates	
this	pathway	through	the	simultaneous	binding	of	Cdc42	and	Septin	
2	via	the	N-terminal	Bcr	region	and	a	C-terminal	region	(around	the	
SH2-iSH2	domains),	respectively.27	This	action	of	p85	is	restricted	
to	 vertebrates,	 as	 the	 invertebrate	 PI3K	 regulatory	 subunit	 lacks	
the	N-terminal	 SH3-Bcr	 region	 (i.e.,	Drosophila	 Acc	Nº	Y12498).	
We	 suggest	 that	p85	brings	Cdc42	 to	 the	 cleavage	 furrow	 through	
microtubules,	 an	 aspect	 that	 remains	 to	 be	 studied.	 Once	 in	 the	
cleavage	furrow,	Cdc42	may	contact	a	GTP	exchange	factor	such	as	
ECT-2,36	which	localizes	in	this	position;	this	would	explain	the	local	
activation	of	Cdc42.	Cdc42	activation	in	the	furrow	then	fosters	the	
changes	in	Septin	polymerization	that	regulate	cytosolic	division.
Formation	of	a	Septin	ring	is	essential	for	cytosolic	separation	in	
the	budding	yeast	S. Cerevisae	as	it	regulates	new	membrane	forma-
tion;	Septin	ring	formation	in	this	organism	is	regulated	by	Cdc42	
activation	and	deactivation	cycles.28,29	We	show	that	Septins,	regu-
lated	by	Cdc42,	are	also	 important	 in	mammalian	cytokinesis,	but	
their	action	remains	to	be	examined.	The	Rho	GTPase	controls	Actin	
polymerization	in	the	cleavage	furrow;37	it	is	therefore	possible	that	
Cdc42	and	Rho	cooperate	for	cytoskeletal	reorganization	in	cytoki-
nesis,	as	they	do	during	wound	healing.38
It	 is	 now	 clearly	 established	 that	 symmetrical	 division	 begins	
by	 growth	 factor-triggered	 activation	 of	 early	 signaling	 molecules.	
Early-G1	PI3K	activity	 is	 crucial	 for	cell	growth.
23,24	as	well	 as	 for	
inactivation	 of	 the	 FoxO	 transcription	 factors.39,40	 In	 addition,	
PI3K,	 c-Myc	 and	MAPK	 trigger	 Cyclin	D	 synthesis	 and/or	 stabi-
lization.9,10,14,41-43	When	Cyclin	D	 reaches	 optimal	 levels	 and	 cell	
cycle	entry	inhibitors	expression	decrease,	Cyclin	D/Cdk	complexes	
drive	 phosphorylation	 of	 retinoblastoma	 protein	 (Rb),	 facilitating	
E2F-mediated	 Cyclin	 E	 synthesis.44	 The	 initial	 signaling	 wave	 is	
transient,	probably	due	to	the	action	of	phosphatases	on	Tyr	K,	Ras,	
MAPK	and	PI3K.	Nonetheless,	 these	enzymes	reactivate	 in	 late-G1	
and	they	enhance	Cdk2	activity	through	upregulation	of	c-Myc	and	
other	events.44	During	this	second	signaling	wave,	PI3K	is	necessary	
for	 c-Myc	 stabilization.	 c-Myc	 in	 turn	 triggers	Cyclin	A	 synthesis,	
reduces	 p27kip	 binding	 to	 Cdk2	 complexes,	 and	 increases	 Cyclin	
E/Cdk2	and	Cyclin	A/Cdk2	activities.	All	of	these	events	are	essential	
for	DNA	synthesis	induction,	explaining	why	PI3K	activity	require-
ment	in	late-G1	for	S	phase	entry.
PI3K	activity	 is	basal	during	S-G2	phases;	which	 contributes	 to	
correct	 activation	 of	 Forkhead	 transcription	 factors	 in	 G2	 phase,	
required	for	mitosis	progression.23	PI3K	reactivates	at	mitosis	entry,	
when	 it	 regulates	 Cdk1	 activation,25,26	 however	 PI3K	 activity	
decreases	during	mitosis	progression,	and	reach	basal	 levels	 in	 telo-
phase.	In	this	phase,	the	action	of	the	p85	PI3K	regulatory	subunit	
contributes	to	Cdc42	activation	in	the	cleavage	furrow,	Septin	accu-
mulation	at	this	site	and	subsequent	execution	of	cytokinesis.27	Thus,	
PI3K,	and	most	likely	other	signaling	pathways,	not	only	regulate	G0	
phase	exit	and	G1	progression,	but	also	later	phases	of	the	cell	cycle,	
contributing	to	promote	the	complex	process	of	cell	division.
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Phosphoinositide 3-kinase (PI3K) is one of the early-signaling molecules induced by growth factor (GF) receptor
stimulation that are necessary for cell growth and cell cycle entry. PI3K activation occurs at two distinct time points
during G1 phase. The first peak is observed immediately following GF addition and the second in late G1, before S
phase entry. This second activity peak is essential for transition from G1 to S phase; nonetheless, the mechanism
by which this peak is induced and regulates S phase entry is poorly understood. Here, we show that activation of
Ras and Tyr kinases is required for late-G1 PI3K activation. Inhibition of late-G1 PI3K activity results in low c-Myc
and cyclin A expression, impaired Cdk2 activity, and reduced loading of MCM2 (minichromosome maintenance
protein) onto chromatin. The primary consequence of inhibiting late-G1 PI3K was c-Myc destabilization, as
conditional activation of c-Myc in advanced G1 as well as expression of a stable c-Myc mutant rescued all of these
defects, restoring S phase entry. These results show that Tyr kinases and Ras cooperate to induce the second PI3K
activity peak in G1, which mediates initiation of DNA synthesis by inducing c-Myc stabilization.
Exposure of quiescent cells to growth factors (GF) activates
a number of early-signaling cascades involved in triggering cell
cycle entry (32). Class IA phosphoinositide 3-kinase (PI3K) is
a heterodimer composed of a p110 catalytic subunit and a p85
regulatory subunit, which induces phosphatidylinositol(3,4)P2
[PtdIns(3,4)P2] and PtdIns(3,4,5)P3 formation. Class IA PI3K
is one the GF-stimulated pathways that trigger S phase entry
(12, 19); it is activated by Tyr kinases (Tyr-K) and Ras (15) and
aids in initiating cell division by inducing cell growth and ac-
tivating protein kinase B (PKB) (12). PKB inhibits glycogen
synthase kinase 3 (GSK3) and FoxO transcription factors,
which in turn control cell cycle regulators (1, 22, 25, 37, 41). In
addition, the expression of a constitutively active PI3K mutant
augments Cdk2 activity (19). PI3K activity increases not only
within minutes of GF receptor stimulation (first peak), but also
in advanced G1 phase (second peak) (1, 17, 38). Late-G1 PI3K
activity is essential for S phase entry (18, 38), but its mecha-
nism of action remains unknown.
c-Myc also regulates cell cycle entry (3, 23, 34), and its levels
are frequently increased in human cancers (30). c-Myc controls
the expression of a large number of genes, including cyclin D
and E and more markedly cyclin A (9, 24). c-Myc also controls
Cdk kinase activity by regulating p27kip expression and its
association with cyclin E/Cdk2 and cyclin A/Cdk2 (29, 42).
c-Myc is very unstable; its stability must be precisely regulated
during the cell cycle. Phosphorylation-dependent regulation of
c-Myc stability involves two key residues, T58 and S62. S62
phosphorylation is mediated by microtubule-associated pro-
tein kinase (MAPK) and that of T58 by GSK3, which targets
c-Myc for degradation (43).
DNA replication requires the establishment of a replica-
tion fork. This is initiated by formation of a prereplication
complex (pre-RC) that assembles when the origin replica-
tion complex is bound to the DNA replication origin, and
minichromosome maintenance proteins (MCM2 to MCM7)
load onto chromatin via a Cdt1- and Cdc6-dependent mech-
anism (4, 8, 21, 27). Binding of MCM to the origin is re-
stricted to late mitosis and to the end of G1 (in cells exiting
G0); following MCM loading, the origin replication complex
is “licensed” for replication (21).
Activation of Cdk2 (cyclin E/Cdk2 and cyclin A/Cdk2) and
Ddk (Cdc7) kinases at the G1-S boundary initiates replication
by recruiting Cdc45 and DNA polymerases to the origin (27).
The helicase activity of the MCM complex is then required to
unwind the DNA double helix (4, 8, 27). Cdc7 and Cdk2
functions are not completely defined, although many initiation
components have consensus phosphorylation sites for these
kinases (27). Cyclin E/Cdk2 is crucial for loading of MCM2
onto chromatin, as it cooperates with Cdc6 in pre-RC assem-
bly; cells lacking cyclin E fail to form the pre-RC on exit from
G0 (11, 13). In addition, cyclin A/Cdk2 activates initiation of
replication and blocks pre-RC reassembly (7).
Here, we examined the mechanism involved in PI3K activa-
tion in late G1 and its role in S phase entry. To distinguish the
first and second PI3K activity peaks, NIH 3T3 cells were driven
into quiescence by serum deprivation and then released into
G1 by serum addition. This protocol allows synchronous cell
cycle progression through G1 and entry into S phase at approx-
imately 9 to 12 h after serum stimulation. We show that Ras
and Tyr-K activation are responsible for PI3K activation in late
G1. Inhibition of the late-G1 PI3K activity peak did not mark-
edly affect cyclin E levels but reduced c-Myc and cyclin A
levels, Cdk2 activity, and loading of MCM2 onto chromatin.
Here, we present evidence that the primary role of PI3K ac-
tivity in late G1 is c-Myc stabilization.
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MATERIALS AND METHODS
Plasmids and reagents. The retroviral vectors encoding wild-type (WT) c-Myc–
internal ribosome entry site–green fluorescent protein (GFP) or T58Ac-Myc–inter-
nal ribosome entry site-GFP (14) were kindly provided by S. Lowe (Cold Spring
Harbor Laboratory, NY). pBabePuro encoding c-MycER (20) was generously
donated by G. Evan (Cancer Research Institute, University of California at San
Francisco, CA). Antibodies to c-Myc (C-19), cyclin E (M-20), and estrogen
receptor alpha (ER) (MC-20) were obtained from Santa Cruz Biotechnology;
anti-pan-Ras and --tubulin were from Oncogene Research; anti-p-PKB(473)
was from Cell Signaling Technologies; and anti-cyclin D3, -p27Kip, and -MCM2
were obtained from BD Biosciences. Anti-Rb antibody was from Zymed Labo-
ratories, anti-phospho(T58/S62)-c-Myc and anti-c-Myc (9B11) were from Cell
Signaling Technologies, and anti-cyclin A and -phosphotyrosine were from Up-
state Biotechnology. Monoclonal anti--actin antibody was from Sigma and
anti-histone from Chemicon International. Horseradish peroxidase-conjugated
secondary antibodies were purchased from Dako Cytomations. Enhanced chemi-
luminescence, L-[35S]methionine, [-32P]dCTP, and [-32P]ATP were from Am-
ersham Biosciences. Lovastatin, herbimycin, and Ly294002 were from Calbio-
chem.
Cell lines and cell cycle analysis. NIH 3T3 and Phoenix cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL) supplemented
with 10% (vol/vol) fetal bovine serum (FBS), 2 mM glutamine, 10 mM HEPES,
100 U/ml penicillin, and 100 g/ml streptomycin in a humidified atmosphere (5%
CO2, 37°C). To monitor the G0-to-S transition accurately, we established a
standard time course protocol for all experiments. Exponentially growing cells
were seeded into dishes and rendered quiescent by incubation in DMEM-0.1%
FBS (19 h). Under these conditions, cells exhibited a G0 phenotype, examined as
previously described (22). Quiescent cultures were rinsed with serum-free me-
dium, and synchronous cell cycle entry was stimulated by readdition of serum
(10% final concentration). Some samples were harvested immediately before
serum addition (time zero). Cells were harvested at various times after serum
stimulation. DNA synthesis was studied by DNA staining with propidium iodide
and analyzed with a flow cytometer (Beckman-Coulter) as described previously
(1) or by bromodeoxyuridine (BrdU) incorporation.
BrdU incorporation. Cells were incubated with 10 M BrdU for 90 min and
harvested at indicated time points by using trypsin-EDTA (see Fig. 4). Cells were
washed twice with phosphate-buffered saline (PBS)-1% FBS and fixed in ice-cold
80% methanol overnight. Cells were then washed twice and resuspended in PBS
containing 1% FBS and 0.1 mg/ml RNase (30 min, room temperature). To
extract histones and denature cellular DNA, we incubated cells with 1.5 N HCl
and 0.5% Triton X-100 (30 min, room temperature). For direct immunofluores-
cence staining, cells were incubated (1 h) with fluorescein isothiocyanate-conju-
gated anti-BrdU antibody (Becton Dickinson). After being washed (in PBS-1%
FBS), cells were resuspended in 500 l PBS (containing 0.1 mg/ml RNase, 0.1%
NP-40, and 5 g/ml propidium iodide) and analyzed by flow cytometry.
Pulse-chase assay. NIH 3T3 cells were incubated in DMEM-0.1% FBS for
19 h (as described above), and then the medium was replaced with Met-free
RPMI medium (Gibco) containing 10% dialyzed FBS for 9 h, with 0.75 mCi
[35S]Met (each p100 dish) included for the last 6 h. At 8.5 h after serum addition,
some of the samples were treated with Ly294002 (10 M). After the 9-h incu-
bation period described above (pulse), the [35S]Met-containing medium was
washed and replaced by DMEM-10% FBS containing 200 M of cold Met and
Cys alone or with Ly294002 (10 M) and maintained until 12 h and 16 h after
serum addition (chase).
Inhibitor treatments and retroviral transduction. To activate c-MycER, we
added 4-hydroxytamoxifen (4-OHT) (200 nM; Sigma) 6.5 h after serum stimu-
lation. In some cases, cells were treated with 0.1% dimethyl sulfoxide (control),
lovastatin (10 M), herbimycin (2 M), or Ly294002 (10 M). When samples
were collected at time zero, inhibitors were added 30 min before serum addition;
otherwise, inhibitors were added after 4, 6, or 7 h after serum stimulation.
Phoenix cells were transfected using Jet Pei-NaCl (Poly plus transfection)
according to the manufacturer’s protocols; after 10 h, cells were washed and
placed in DMEM-10% FBS. Retroviral gene transduction was performed as
described previously (35). Infected NIH 3T3 (c-MycER) cells were selected for
2 days in medium containing 2 g/ml puromycin (Sigma).
Cell lysis, immunoprecipitation, PI3K assay, WB, pull-down assay, subcellu-
lar fractionation, Northern blotting, and Cyclin/Cdk kinase assays. Lysates were
prepared in Triton X-100 lysis buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 1%
Triton X-100) containing protease and phosphatase inhibitors (1 mM Na3VO4,
5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, and 10
g/ml leupeptin). Immunoprecipitation, PI3K assays, and Western blotting
(WB) were performed as described previously (15). For the PI3K assay, the cells
were transfected with pSG5-myc-tagged-p110 (15), and the cells were synchro-
nized 24 h later, as described above; PI3K was immunoprecipitated using anti-
Myc-tag antibody. Ras-GTP was purified from cell extracts on Sepharose-Gex2T-
RBD (the Ras-binding domain of Raf-1). Briefly, NIH 3T3 cells were harvested,
lysed with glutathione S-transferase fluorescent in situ hybridization buffer (50
mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 2 mM MgCl2, 1% [vol/vol]
NP-40, 5 mM NaF, 10% [vol/vol] glycerol, 1 mM phenylmethylsulfonyl fluoride,
1 g/ml aprotinin, and 10 g/ml leupeptin). Protein concentration, examined
using the Micro bicinchoninic acid assay (Pierce), was normalized, and lysates
were incubated (1 h, 4°C) with glutathione-Sepharose beads precoupled with
glutathione S-transferase–RBD. Beads were washed three times in lysis buffer,
and bound Ras-GTP was solubilized in 30 l Laemmli buffer. Ras-GTP content
was analyzed by WB. Total cell extracts, nuclear extracts, and chromatin fractions
were isolated as described previously (26). Northern blot and cyclin/Cdk kinase
assays were performed as described previously (22, 26, 35).
RESULTS
PI3K activity in late G1 induces PKB activation that corre-
lates with increased c-Myc protein levels. PI3K is activated in
late G1; this activity peak is essential for S phase entry, since
late-G1 PI3K inhibition blocks S phase entry and PtdIns
(3,4,5)P3 addition in late G1 induces cell cycle entry in the
absence of serum (17, 18). To study the role of PI3K in late G1,
NIH 3T3 cells were driven into quiescence by serum depriva-
tion and then released into G1 by serum addition. Cells were
committed to enter S phase at about 9 h after serum addition,
with no further GF requirement (not shown). S phase began
between 9 and 12 h after serum addition (Fig. 1A). In cells
entering the cell cycle synchronously, we detected early-G1 (1 h)
and late-G1 (9 to 15 h) PI3K activity peaks (Fig. 1B), as
determined by examining the phosphorylation of the PI3K
effector PKB (p-PKB) (1). c-Myc expression levels paralleled
the PI3K activity peaks (Fig. 1C).
Ras and Tyr kinases activate PI3K in late G1. PI3K activa-
tion at G0-to-G1 transition is dependent on Tyr-K and Ras
activities (6, 15); Ras is also activated in late G1 (38). We
examined Tyr-K activation by WB using an anti-pTyr antibody
and Ras activity by pull-down assays. After GF addition, total
Tyr-K activity increased transiently at 1 h and again between 6
and 16 h (Fig. 1D). Some of the Tyr-phosphorylated bands that
appeared at 1 h differed from those visible at 9 h, suggesting
that more than one Tyr-K is activated during G1 (Fig. 1D).
Ras-GTP increased at 1 h and again at 9 to 12 h after serum
stimulation (Fig. 1E).
To determine whether Tyr-K or Ras stimulation is required
for late-G1 PI3K activation, we used small molecule inhibitors
and examined the effects on p-PKB and c-Myc levels. Addition
of the Ras inhibitor lovastatin (10) at 0, 4, or 6 h after serum
stimulation reduced p-PKB levels at 9 and 12 h (Fig. 2A),
suggesting that Ras activation is involved in late-G1 PI3K ac-
tivation. Addition of mevalonate, a lovastatin substrate, re-
stored PKB phosphorylation (Fig. 2A). Herbimycin, a Src
Tyr-K inhibitor (39), also reduced PKB activation at 9 and 12 h
(Fig. 2A), whereas genistein, an inhibitor with high specificity
for the epidermal GF receptor (40), did not affect the second
G1 PI3K activity peak (not shown). Combination of lovastatin
and herbimycin treatments yielded a larger p-PKB reduction
(Fig. 2A). The decrease in p-PKB levels correlated with a
reduction in both c-Myc content and S phase entry at 12 h (Fig.
2A). The activities of the inhibitors in blocking Tyr-K and Ras
activation were confirmed by WB; herbimycin reduced phos-
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pho-Tyr cellular content (Fig. 2B), and lovastatin reduced the
active-Ras fraction, an effect that was reversed by mevalonate
addition (Fig. 2C).
To confirm that late-G1 PI3K activation requires Tyr-K and
Ras, we examined PI3K activity in extracts from synchronous-
cell cultures (as described above). Addition of lovastatin, her-
bimycin, or both at 4 h after serum addition resulted in reduced
PI3K activity at 7 to 8 h after serum addition (Fig. 2D). As
PI3K activity regulates cyclin levels (see below), we also exam-
ined whether lovastatin and herbimycin affected cyclin D3, E,
and A levels. Tyr-K and Ras inhibition reduced the levels of
these cyclins, most markedly those of cyclin A (Fig. 2E). Thus,
Tyr-K and Ras cooperate in the induction of the second PI3K
activity peak, which in turn regulates c-Myc and G1 cyclin
levels as well as S phase entry.
Late-G1 PI3K inhibition reduces c-Myc and cyclin A levels
as well as Cdk2 activity. As late-G1 PI3K activation correlates
with increased c-Myc expression levels, we examined the con-
sequences of inhibiting late-G1 PI3K on c-myc mRNA levels by
Northern blotting. Cells were synchronized as described above,
and the PI3K inhibitor Ly294002 was added at 7 h after serum
stimulation; cells were harvested at 9 h. This analysis showed
that late-G1 PI3K inhibition induces a reduction of c-myc
mRNA levels of about 15%  5% (at 9 h, the mean value for
three experiments) (Fig. 3A), whereas c-Myc protein reduction
was systematically greater than 50%. In fact, late-G1 PI3K
inhibition markedly reduced c-Myc protein levels at 9 to 18 h
poststimulation (Fig. 3A and B).
PI3K/PKB inhibits GSK3 (41), a kinase that phosphory-
lates c-Myc at Thr 58, thereby triggering Myc degradation (43).
PI3K inhibition notably enhanced Thr 58-c-Myc phosphoryla-
tion, an event that correlated with c-Myc level reduction (Fig.
3B). The decrease in c-Myc protein levels correlated with the
diminished expression of the Myc-transcriptional effectors cy-
clin D2 and Cdk4 (Fig. 3B). c-Myc stability was further exam-
ined in pulse-chase assays. Inhibition of PI3K activity in early
G1 (3 h after serum stimulation) blocked protein synthesis (not
shown). Thus, for pulse-chase, we synchronized cells, labeled
them with [35S]Met between 3 and 9 h after serum addition,
and harvested them at 9 h. At this time, the medium was
replaced with nonradiolabeled Met/Cys-rich medium, alone or
with Ly294002, and cells were collected at 12 and 16 h (Fig.
3C). For the sample treated with Ly294002 at the 9-h time
point, the inhibitor was added 30 min before cell harvesting.
PI3K inhibition greatly reduced c-Myc stability, an effect that
was already evident 30 min after enzyme inhibition (Fig. 3C).
To further define the role of the second G1 PI3K activity
peak in S phase entry, cells were synchronized in G0/G1 and
PI3K was inhibited at 7 h after serum stimulation; we examined
the consequences for G1-phase cyclin levels at different time
points. Inhibition of late-G1 PI3K activity greatly reduced cy-
clin A protein levels at 9 h, whereas cyclin D3 and E levels were
FIG. 1. Late-G1 PI3K activity peak induces PKB activation that correlates with Tyr-K and Ras activation. (A) DNA content cell cycle profiles
of NIH 3T3 cells arrested in G0 by serum deprivation and then released for different periods (indicated) to allow synchronous cell cycle entry.
Percentages of cells in G0/G1, S (in bold), or G2/M phases are indicated. (B and C) WB analysis of the cells used for panel A, using
anti-phospho-S473-PKB (p-PKB), -PKB, -c-Myc, and -actin antibodies. (D) Activation of Tyr-K in cells entering cycle entry as examined by WB
using anti-p-Tyr antibody. (E) Ras-GTP content was examined in cell extracts prepared as described for panel D. Total Ras and Ras-GTP were
examined by WB. The figure shows data representative of at least four experiments with similar results.
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more affected when Ly294002 had been present for prolonged
periods (Fig. 3D). The Ras inhibitor lovastatin had a greater
effect than Ly294002 in reducing cyclin D3 levels (Fig. 2E and
3D); this is likely due to the Ras/MAPK dependence for cyclin
D synthesis (16).
We next tested the effect of inhibiting PI3K on Cdk2 activity.
The Cdk2 substrate retinoblastoma protein (Rb) was hypo-
phosphorylated following late-G1 PI3K inhibition (Fig. 3D).
Consistently, both cyclin E/Cdk2 and cyclin A/Cdk2 activities
decreased after PI3K inhibition (Fig. 3E). The decrease in
cyclin A expression paralleled the reduction of cyclin A/Cdk2
activity. Nonetheless, late-G1 PI3K inhibition affected cyclin
E/Cdk2 activity more markedly than cyclin E levels. We thus
examined whether PI3K inhibition reduced cyclin E/Cdk2 ac-
tivity by enhancing its association with the Cdk2 inhibitor
p27kip. PI3K inhibition increased the amount of p27kip bound
to Cdk2 (see below), explaining the reduction of cyclin E/Cdk2
activity by late-G1 PI3K inhibition. Cyclin E/Cdk2 activity is
required for loading of MCM2 onto chromatin (11, 13); PI3K
inhibition in advanced G1 resulted in a notable reduction in the
amount of chromatin-bound MCM2 (Fig. 3F).
Conditional c-Myc-ER activation rescues S phase entry in
PI3K inhibitor-treated cells. PI3K inhibition reduced cyclin A
levels and Cdk2 activity. c-Myc regulates G1 cyclin expression,
especially that of cyclin A, and the association of p27kip with
cyclin/Cdk2 (24, 29, 42). We thus hypothesized that the main
function of late-G1 PI3K activity may be to regulate c-Myc
levels. To test this possibility, we used a c-Myc–estrogen re-
ceptor fusion protein (c-Myc-ER) that translocates to the nu-
cleus after addition of an estrogen analogue such as 4-OHT
(20). We examined whether the S phase entry defects induced
by late-G1 PI3K inhibition were counteracted by c-Myc-ER
induction. Cells were infected with c-Myc-ER-expressing vi-
ruses (Fig. 4A), arrested in G0, and released by serum addition.
Some of the cells were treated with 4-OHT alone (at 6.5 h),
with Ly294002 (at 7 h after serum addition), or with both. We
collected cells at different times and examined S phase entry.
c-Myc-ER expression did not trigger S phase entry in the
absence of serum (Fig. 4B and C). After serum addition, c-
Myc-ER expression caused a slight increase in S phase entry
compared to that in control cells, which was moderately en-
hanced upon 4-OHT addition (Fig. 4C). We found no notable
FIG. 2. Ras and Tyr kinases contribute to late-G1 PI3K activation. (A) p-PKB levels in serum-starved cells, cells in exponential growth, or cells
arrested in G0 and then released in the presence of serum for 9 or 12 h. Lovastatin (lov), lovastatin plus mevalonate (lovmev), or herbimycin
(herbi) was added to some samples at the time of serum addition (time zero) or at 4 or 6 h after serum addition. Cell extracts were examined by
WB using anti-p-PKB, -PKB, or -c-Myc antibodies. The percentages of cells in G0/G1, S, and G2/M phases are indicated. (B and C) The efficiencies
of the inhibitors were tested in samples prepared as described for panel A by WB using either anti-p-Tyr (B) or anti-pan-Ras (C) antibodies. The
slower-migrating, inactive Ras form is indicated. (D) PI3K was immunoprecipitated from cell extracts (see Materials and Methods) and its activity
assayed in vitro. Inhibitors were added at 4 h after serum addition and cell extracts collected at the indicated time points. (E) Extracts of the cells
used for panel A were examined by WB using anti-cyclin-D3, -E, and -A antibodies. (A to E) Data for one representative experiment (Exp) of four
with similar results.
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differences when 4-OHT was added at 0 or 6.5 h (not shown).
Ly294002 treatment reduced the proportion of cells in S phase
by 50%, in both c-Myc-ER- and control ER vector-expressing
cells (Fig. 4C). Nonetheless, c-Myc-ER induction at 6.5 h in
cells treated with Ly294002 in advanced G1 (7 h) showed al-
most normal S phase entry levels (85% recovery) compared
to what was found for Ly294002-treated control cells (Fig. 4B
and C). Induction of c-Myc-ER failed to compensate for the
action of PI3K in S phase entry when PI3K was inhibited in
early G1 (0 to 4 h poststimulation) (Fig. 4C and data not
shown). Examination of BrdU incorporation confirmed that
c-Myc induction at 6.5 h counteracts S phase entry defects in
cells treated with Ly294002 in advanced G1 (Fig. 4D). Com-
parable results were obtained using the PI3K inhibitor wort-
mannin (not shown). These data suggest that the main function
of late-G1 PI3K activity is to regulate c-Myc protein levels.
Expression of a GSK3-resistant c-Myc mutant rescues the
cell cycle entry defects induced by inhibiting late-G1 PI3K
activity. PI3K/PKB inactivate GSK3, an enzyme that targets
c-Myc for degradation (43). To confirm that c-Myc stabiliza-
tion is the main role of PI3K activity in late G1, we examined
the effect of inhibiting PI3K in cells expressing the c-MycT58A
substitution mutant, which is resistant to GSK3 action (14).
Cells were transfected with GFP control vector or with
cDNAs encoding GFP fused to wild-type (WT) c-Myc or
c-MycT58A (Fig. 5A). Transfected cells were sorted, and cul-
tures were synchronized, released from arrest, and treated with
Ly294002 at 7 h after serum addition. Cells were harvested at
different time points. Overexpression of either WT c-Myc or
c-MycT58A induced apoptosis and cell cycle entry in the ab-
sence of serum (Fig. 5B). Late-G1 PI3K inhibition reduced cell
cycle entry in control cells and to a lesser extent in cells over-
expressing WT c-Myc; c-MycT58A expression, however, largely
restored cell cycle entry (Fig. 5B). To reduce c-Myc expression
levels, cells were infected with viruses encoding c-MycT58A.
Under these conditions, c-MycT58A did not significantly induce
cell cycle entry in the absence of serum (Fig. 5C). Synchro-
nous-cell-infected cultures were treated with Ly294002 at 7 h
FIG. 3. Late-G1 PI3K inhibition reduces c-Myc and cyclin A expression as well as Cdk2 activity. (A) Total RNA and protein extracts were
prepared from cells entering the cell cycle synchronously. Ly294002 was added at 7 h after serum addition; cell harvesting was at 0 and 9 h. Samples
were examined by Northern blotting (see Materials and Methods) or by WB, using a c-myc probe or anti-Myc antibody, respectively. The Northern
blot corresponds to two different experiments (Exp.). (B) Cell extracts were prepared from cells entering the cell cycle synchronously. Ly294002
was added at 7 h after serum addition. Western blots show the expression of c-Myc, phospho-c-Myc, cyclin D2, Cdk4, and actin. The percentages
of cells with sub-G1, G0/G1, S, or G2/M DNA content are indicated. (C) Synchronized cells were [
35S]Met labeled during the first 9 h after serum
addition, and then the medium was replaced with nonlabeled Met/Cys-rich medium alone or with Ly294002 (10 M), and cells were collected at
12 and 16 h. For the sample treated with Ly294002 at 9 h, the inhibitor was added 30 min before harvesting. [35S]c-Myc was examined by
autoradiography. Quantitative-analysis data for three experiments are shown below the blots. (D) The cell extracts used for panel B were examined
by WB using anti-c-Myc, -cyclin-D3, -E, -A, and -Rb antibodies. The percentages of cells in S and G2/M phases are indicated. (E) Cyclin E/Cdk2
and cyclin A/Cdk2 kinase activities in cyclin E and cyclin A immunoprecipitates, respectively, from cell extracts prepared as described for panel
B. Histone H1 (5 g) was used as a substrate. 32P-histone was quantitated, and the activities are represented (in arbitrary units [a.u.]). Data show
means  standard deviations for three experiments. (F) Cells entering the cell cycle synchronously, treated as described for panel B, were
fractionated into cytosolic, nuclear, and chromatin fractions and were examined by WB using anti-MCM2 and anti-histone antibodies. Panels A
to D and F show data for one representative experiment of three with similar results.
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after serum addition and harvested at different time points.
PI3K inhibition blocked cell cycle entry in control cells, but cell
cycle entry was nearly normal in cells expressing c-MycT58A
(Fig. 5D). These results indicate that a stable form of c-Myc
substitutes for PI3K action in late G1.
c-MycT58A expression rescues cyclin A expression, Cdk2 ac-
tivity, and MCM2 loading defects induced by late-G1 PI3K
inhibition. To confirm that the primary effect of PI3K activity
in advanced G1 is to stabilize c-Myc, we examined whether
c-MycT58A expression compensated for the cell cycle entry
defects induced by late-G1 PI3K inhibition. PI3K inhibition
moderately affected cyclin D3 and E expression levels (see
above). Similarly, c-MycT58A expression did not markedly alter
cyclin D3 (not shown) or cyclin E levels (Fig. 6A). In contrast,
cyclin A expression levels were greatly reduced upon late-G1
PI3K inhibition (Fig. 6A). c-MycT58A expression increased cy-
clin A expression in Ly294002-treated cells and moderately
increased basal cyclin A levels (Fig. 6A). Moreover, whereas
hyperphosphorylated Rb levels, cyclin E/Cdk2, and cyclin
A/Cdk2 kinase activities were reduced by late-G1 PI3K inhibi-
tion in control cells, they were virtually unaffected in
c-MycT58A-expressing cells (Fig. 6A to C). As c-Myc controls
the levels of Cdk2 bound to p27kip (29, 42), we tested whether
p27kip-Cdk2 association was affected by c-MycT58A expression.
Ly294002 treatment at 7 h in synchronous-cell cultures in-
creased the association of p27kip with cyclin E/Cdk2 in con-
trols, but association was lower and resistant to PI3K inhibition
in c-MycT58A-expressing cells (Fig. 6D). Similar results were
obtained using c-Myc-ER-expressing cells treated with 4-OHT
(at 6.5 h), Ly294002 (at 7 h), or both simultaneously (Fig. 6E
and data not shown). In fact, c-Myc-ER induction corrected
the defects in S phase entry, cyclin A expression, and Rb
phosphorylation induced by late-G1 PI3K inhibition (Fig. 6E).
We also examined the consequences of expressing c-MycT58A
on the loading of MCM2 onto chromatin. In control cells, MCM2
loading was still low at 9 h (similar to that observed at 0 h),
increased at 12 to 16 h, and was blocked by PI3K inhibition. In
contrast, in c-MycT58A cells, MCM2 loading increased by 9 h and
remained insensitive to late-G1 PI3K inhibition (Fig. 7).
DISCUSSION
Activation of PI3K in late G1 is essential for cell cycle entry
(1, 12, 17). We examined the signals involved in late-G1 PI3K
activation and the mechanisms by which this event controls the
G1-to-S transition. We report that tyrosine kinase and Ras
FIG. 4. Conditional activation of c-Myc-ER rescues S phase entry blockade induced by late-G1 PI3K inhibition. (A) c-Myc-ER expression was
examined in NIH 3T3 c-Myc-ER-infected cells by WB using anti-Myc antibody. (B) Cell cycle profiles of c-Myc-ER cells in quiescence (time zero)
or at 18 h after serum addition, alone or in the presence of OHT (200 nM; added at 6.5 h after serum addition) and/or Ly294002 (10 M; added
at 7 h after serum addition). The figure shows results for one representative experiment of three performed. (C) Percentages of c-Myc-ER and
control cells in S phase. Cells were treated as described for panel B. Data for a sample of cells treated with OHT (200 nM) and Ly294002 (10 M)
at the time of serum addition (time zero) are included. Data shown are mean values for three experiments. (D) BrdU incorporation in NIH 3T3
c-Myc-ER-infected cells entering the cell cycle synchronously as in panel B and collected at 13 h after serum addition. BrdU (10 M) was present
for the last 90 min. Data shown are means  standard deviations for three experiments.
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activation are required to induce the PI3K/PKB pathway in
late G1. Since PI3K/PKB inactivates GSK3, the enzyme that
targets c-Myc for degradation (41, 43), we hypothesized that
late-G1 PI3K activation may be essential for c-Myc stabiliza-
tion. We observed that PI3K inhibition in advanced G1 de-
creases c-Myc and cyclin A levels, reduces cyclin E/Cdk2 and
cyclin A/Cdk2 activity, and increases the fraction of p27kip
bound to cyclin E/Cdk2; c-Myc-deficient cells show these de-
fects (23, 24, 42). Moreover, c-Myc induction in late G1 and the
expression of a c-Myc mutant (c-MycT58A) (14) that does not
require PI3K/PKB for stabilization counteract the cell cycle
entry defects induced by PI3K inhibition in late G1, including
those related to DNA synthesis, cyclin A expression, cyclin
E/Cdk2 and cyclin A/Cdk2 activity, and the association of
p27kip with cyclin E/Cdk2. We conclude that c-Myc stabiliza-
tion is a major role for PI3K activation in late G1.
c-myc mRNA and protein both have very short half-lives (20
to 30 min). To achieve the c-Myc expression levels required for
cell cycle entry, c-Myc stability must be regulated during G1 (9,
30); we show that late-G1 PI3K activation stabilizes c-Myc.
This conclusion is further supported by our in-progress studies
using interfering RNA and constitutive active mutants of class
IA PI3K isoforms. Although these tools do not allow distinc-
tion between the first and second PI3K activity peaks in G1,
they confirm the role of PI3K in cell cycle entry and in c-Myc
expression control. Whereas activation of PI3K accelerates cell
cycle entry and increases c-Myc levels, decrease of PI3K levels
reduces S phase entry and c-Myc content (not shown).
Phosphorylation-dependent regulation of c-Myc stability in-
volves two key residues, T58 and S62. MAPK mediates S62
phosphorylation, which stabilizes c-Myc, but is required for
subsequent T58 phosphorylation by GSK3, which then in-
FIG. 5. Expression of c-Myc T58A rescues cell cycle entry defects induced by late-G1 PI3K inhibition. (A) WT c-Myc and c-MycT58A expression
in NIH 3T3 cells, tested by WB using anti-Myc antibody. (B) DNA content in representative NIH 3T3 cells transfected (Transf.) with a control
vector or cDNA encoding WT c-Myc or c-MycT58A. Cells were arrested by serum deprivation (time zero) and released by serum addition for 16 h.
Some samples were incubated with Ly294002 added 7 h after serum stimulation. (C and D) DNA content in representative NIH 3T3 cells infected
with a control virus or a virus encoding c-MycT58A. Infected cells were arrested by serum deprivation (C) or first arrested and then released by
serum addition for 9, 12, 16, and 18 h (D). Some samples were incubated with Ly294002 added 7 h after serum stimulation. (A to D) Data
representative of one experiment of four with similar results. Percentages of cells in G0/G1, S (in bold), and G2/M phases are indicated.
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duces c-Myc degradation (43). T58 phosphorylation nonethe-
less appears to be the key destabilizing event, as it represents
a major mutation hot spot in Burkitt’s lymphomas (14). Since
S62 phosphorylation is a prerequisite for T58 phosphorylation,
c-Myc might also be phosphorylated in late G1 by MAPK, as
we observed concomitant activations of MAPK and PI3K at
this point (not shown).
c-Myc function is linked to its transcription factor activity,
which is required for its transforming capacity (3, 9, 30). c-Myc
regulates transcription by association with the Max protein.
Gene expression regulated by c-Myc/Max involves several
mechanisms that include chromatin remodeling as well as re-
cruitment of RNA polymerases and transcription elongation
factors (9, 28). c-Myc regulates the expression of a number of
target genes, including cyclins D and E and, to a large extent,
cyclin A (30). The first c-Myc expression peak in G1 occurs at
1 h after serum stimulation. Since c-Myc promotes cyclin D
and E expression (24), the first c-Myc expression peak may
trigger the expression of these cyclins in early/mid-G1. Later
on, c-Myc is essential for cyclin A expression, as well as for
inhibiting the association of p27kip with Cdk2 complexes (24,
29, 42). The kinetics of cyclin A expression, its reduction follow-
ing c-Myc destabilization (by late-G1 PI3K inhibition), and the
association of p27kip with cyclin E/Cdk2 complexes suggest that
the second c-Myc expression peak regulates cyclin A induction
and Cdk2 activity by controlling its association with p27kip (29,
42).
Although late-G1 PI3K action is nearly identical to that of
FIG. 6. c-MycT58A expression counteracts the cyclin A expression, Cdk2 activity, and MCM2 chromatin loading defects induced by late-G1 PI3K
inhibition. (A) Control and c-MycT58A-expressing cells were arrested in G0 and then released and treated with Ly294002 at 7 h after serum addition.
Cells were harvested at different time points (indicated) and extracts examined by WB using anti-cyclin E, -cyclin A, -actin, and -Rb antibodies.
(B) Cyclin E/Cdk2 and cyclin A/Cdk2 kinase activities in cyclin E and cyclin A immunoprecipitates, respectively, of cell extracts from control and
c-MycT58-expressing cells treated as described for panel A. Cdk2 activity was measured as described in the legend to Fig. 3. (C) Cyclin E/Cdk2 and
cyclin A/Cdk2 activities in c-MycT58A-expressing cells were examined by in vitro kinase assays performed as described for panel B. Data shown are
means  standard deviations for three experiments. (D) The cells used for panel A were lysed, and cyclin E was immunoprecipitated from lysates
(200 g). Samples were resolved and examined by WB using anti-p27Kip or anti-cyclin E antibody. (E) Synchronized c-Myc-ER-expressing cells
were treated with 4-OHT (at 6.5 h), Ly294002 (at 7 h), or both simultaneously; cells were collected at different time points (indicated). Cyclin E,
cyclin A, pRb, and actin levels were examined by WB. (A, B, D, and E) Data for one representative experiment of three with similar results.
Percentages of cells in S and G2/M phases are indicated.
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c-Myc, PI3K and c-Myc have otherwise unrelated functions
and appear to cooperate for cell cycle entry (17), suggesting
distinct functions. PI3K/PKB activation is required for inacti-
vation of FoxO transcription factors, which inhibit the expres-
sion of several c-Myc targets, providing a mechanism for the
cooperative action of c-Myc and PI3K in early G1 (5). In fact,
inhibition of PI3K in early G1 (during the first 6 h) impaired
cell growth and cycle entry, and this blockade was not coun-
teracted by c-Myc-ER induction (Fig. 4C). In early G1, PI3K
regulates cell growth, FoxO transcription factor inactivation,
and GSK3 inhibition, events that in turn control cyclin D
levels (1, 2, 22, 25, 31, 33, 36). Nonetheless, Tyr-K and Ras are
reactivated in mid-/late G1, driving PI3K activation (Fig. 2).
We show that the main role of late-G1 PI3K activity is to
stabilize c-Myc. Stabilized c-Myc in turn triggers cyclin A syn-
thesis, reduces the binding of p27kip to Cdk2 complexes, and
induces cyclin E/Cdk2 (which regulates MCM2 loading) and
cyclin A/Cdk2 activities. These events are crucial for DNA
synthesis induction, explaining the requirement for PI3K ac-
tivity in late G1 for cell cycle entry.
ACKNOWLEDGMENTS
We thank J. Leo´n and S. Man˜es for continuous advice, L. Roman for
checking RNA stability, S. Lowe for the c-MycT58A cDNA, G. Evan for
c-MycER plasmid, and C. Mark for editorial assistance.
A.K. received a predoctoral fellowship associated with a project
financed by the Fundacio´n Ramo´n Areces, and M.M. received a pre-
doctoral FPU fellowship from the Spanish Ministry of Education and
Science. This work was financed in part by grants from the AICR
Foundation, the Fundacio´n Ramo´n Areces, the European Union
(QLRT2001-02171), and the Spanish DGCyDT (SAF2004.05955). The
Department of Immunology and Oncology was founded and is sup-
ported by the Spanish National Research Council (CSIC) and by
Pfizer.
REFERENCES
1. Alvarez, B., A. C. Martinez, B. M. Burgering, and A. C. Carrera. 2001.
Forkhead transcription factors contribute to execution of the mitotic pro-
gramme in mammals. Nature 413:744–747.
2. A´lvarez, B., F. Garrido, J. A. Garcia-Sanz, and A. C. Carrera. 2003. Phos-
phoinositide 3-kinase activation regulates cell division time by coordinated
control of cell mass and cell cycle progression rate. J. Biol. Chem. 278:26466–
26473.
3. Amati, B., K. Alevizopoulos, and J. Vlach. 1998. Myc and the cell cycle.
Front. Biosci. 3:250–268.
4. Blow, J. J., and A. Dutta. 2005. Preventing re-replication of chromosomal
DNA. Nat. Rev. Mol. Cell Biol. 6:476–486.
5. Bouchard, C., J. Marquardt, A. Bras, R. H. Medema, and M. Eilers. 2004.
Myc-induced proliferation and transformation require Akt-mediated phos-
phorylation of FoxO proteins. EMBO J. 23:2830–2840.
6. Chan, T. O., U. Rodeck, A. M. Chan, A. C. Kimmelman, S. E. Rittenhouse,
G. Panayotou, and P. N. Tsichlis. 2002. Small GTPases and tyrosine kinases
coregulate a molecular switch in the phosphoinositide 3-kinase regulatory
subunit. Cancer Cell 1:181–191.
7. Coverley, D., H. Laman, and R. A. Laskey. 2002. Distinct roles for cyclins E
and A during DNA replication complex assembly and activation. Nat. Cell
Biol. 4:523–528.
8. Cvetic, C. A., and J. C. Walter. 2006. Getting a grip on licensing: mechanism
of stable Mcm2-7 loading onto replication origins. Mol. Cell 21:143–144.
9. Dang, C. V. 1999. c-Myc target genes involved in cell growth, apoptosis and
metabolism. Mol. Cell. Biol. 19:1–11.
10. del Real, G., S. Jimenez-Baranda, E. Mira, R. A. Lacalle, P. Lucas, C.
Gomez-Mouton, M. Alegret, J. M. Pena, M. Rodriguez-Zapata, M. Alvarez-
Mon, A. C. Martinez, and S. Manes. 2004. Statins inhibit HIV-1 infection by
down-regulating Rho activity. J. Exp. Med. 200:541–547.
11. Ekholm-Reed, S., J. Mendez, D. Tedesco, A. Zetterberg, B. Stillman, and
S. I. Reed. 2004. Deregulation of cyclin E in human cells interferes with
prereplication complex assembly. J. Cell Biol. 165:789–800.
12. Garcı´a, Z., A. Kumar, M. Marques, I. Cortes, and A. C. Carrera. 2006.
Phospho-inositide 3-kinase controls early and late events in mammalian cell
division. EMBO J. 25:655–661.
13. Geng, Y., Q. Yu., E. Sicinska, M. Das, J. E. Schneider, S. Bhattacharya,
W. M. Rideout, R. T. Bronson, H. Gardner, and P. Sicinski. 2003. Cyclin E
ablation in the mouse. Cell 114:431–443.
14. Hemann, M. T., A. Bric, J. Teruya-Feldstein, A. Herbst, J. A. Nilsson, C.
Cordon-Cardo, J. L. Cleveland, W. P. Tansey, and S. W. Lowe. 2005. Evasion
of the p53 tumour surveillance network by tumour-derived MYC mutants.
Nature 436:807–811.
15. Jime´nez, C., C. Hernandez, B. Pimentel, and A. C. Carrera. 2002. The p85
regulatory subunit controls sequential activation of phosphoinositide 3-ki-
nase by Tyr kinases and Ras. J. Biol. Chem. 277:41556–41562.
16. Jirmanova, L., M. Afanassieff, S. Gobert-Gosse, S. Markossian, and P.
Savatier. 2002. Differential contributions of ERK and PI3K to the regulation
of cyclin D1 expression and to the control of the G1/S transition in mouse ES
cells. Oncogene 21:5515–5528.
17. Jones, S. M., and A. Kazlauskas. 2001. Growth-factor-dependent mitogen-
esis requires two distinct phases of signalling. Nat. Cell Biol. 3:165–172.
18. Jones, S. M., R. Klinghoffer, G. D. Prestwich, A. Toker, and A. Kazlauskas.
1999. PDGF induces an early and a late wave of PI 3-kinase activity, and only
the late wave is required for progression through G1. Curr. Biol. 9:512–521.
19. Klippel, A., M. A. Escobedo, M. S. Wachowicz, G. Apell, T. W. Brown, M. A.
Giedlin, W. N. Kavanaugh, and L. T. Williams. 1998. Activation of phos-
phatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cel-
lular changes characteristic of oncogenic transformation. Mol. Cell. Biol.
18:5699–56711.
20. Littlewood, T. D., D. C. Hancock, P. S. Danielian, M. G. Parker, and G. I.
Evan. 1995. A modified oestrogen receptor ligand-binding domain as an
improved switch for the regulation of heterologous proteins. Nucleic Acids
Res. 23:1686–1690.
21. Madine, M. A., M. Swietlik, C. Pelizon, P. Romanowski, A. D. Mills, and
R. A. Laskey. 2000. The roles of the MCM, ORC, and Cdc6 proteins in
determining the replication competence of chromatin in quiescent cells. J.
Struct. Biol. 129:198–210.
22. Martı´nez-Gac, L., M. Marque´s, Z. Garcı´a, M. Campanero, and A. C.
Carrera. 2004. Control of cyclin G2 mRNA expression by forkhead tran-
scription factors: a novel mechanism for cell cycle control by phosphoinosi-
tide 3-kinase and forkhead. Mol. Cell. Biol. 24:2181–2189.
23. Mateyak, M. K., A. J. Obaya, S. Adachi, and J. M. Sedivy. 1997. Phenotypes
FIG. 7. c-MycT58A expression counteracts the reduced MCM2
chromatin loading induced by PI3K inhibition in late G1. Western blots
documenting MCM2 protein levels in different subcellular fractions (as
shown in Fig. 3F) of cells treated as described in the legend to Fig. 6A
are shown. WB analyses using anti-tubulin and -histone antibodies
were used as controls for fraction purity.
9124 KUMAR ET AL. MOL. CELL. BIOL.
 at Centro Nacional de Biotecnología - Biblioteca on April 7, 2009 
m
cb.asm
.org
D
ow
nloaded from
 
of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombi-
nation. Cell Growth Differ. 8:1039–1048.
24. Mateyak, M. K., A. J. Obaya, and J. M. Sedivy. 1999. c-Myc regulates cyclin
D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple
independent points. Mol. Cell. Biol. 19:4672–4683.
25. Medema, R. H., G. J. Kops, J. L. Bos, and B. M. Burgering. 2000. AFX-like
Forkhead TF mediate cell-cycle regulation by Ras and PKB through p27kip1.
Nature 404:782–787.
26. Me´ndez, J., and B. Stillman. 2002. Chromatin association of human origin
recognition complex, Cdc6, and minichromosome maintenance proteins dur-
ing the cell cycle: assembly of prereplication complexes in late mitosis. Mol.
Cell. Biol. 20:8602–8612.
27. Nishitani, H., and Z. Lygerou. 2002. Control of DNA replication licensing in
a cell cycle. Genes Cells 7:523–534.
28. Pelengaris, S., M. Khan, and G. Evan. 2002. c-MYC more than just a matter
of life and death. Nat. Rev. Cancer 2:764–776.
29. Perez-Roger, I., D. L. Solomon, A. Sewing, and H. Land. 1997. Myc activation
of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and
inhibition of p27Kip1 binding to newly formed complexes. Oncogene 14:
2373–2381.
30. Ponzielli, R., S. Katz, D. Barsyte-Lovejoy, and L. Z. Penn. 2005. Cancer-
therapeutics: targeting the dark side of Myc. Eur. J. Cancer 41:2485–2501.
31. Ryves, W. J., and A. J. Harwood. 2003. The interaction of glycogen synthase
kinase-3 (GSK-3) with the cell cycle. Prog. Cell Cycle Res. 5:489–495.
32. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:
211–225.
33. Schmidt, M., S. Fernandez de Mattos, A. van der Horst, R. Klompmaker,
G. J. Kops, E. W. Lam, B. M. Burgering, and R. H. Medema. 2002. Cell cycle
inhibition by FoxO transcription factors involves downregulation of cyclin D.
Mol. Cell. Biol. 22:7842–7852.
34. Schorl, C., and J. M. Sedivy. 2003. Loss of protooncogene c-Myc function
impedes G1 phase progression both before and after the restriction point.
Mol. Biol. Cell 14:823–835.
35. Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe. 1997.
Oncogenic ras provokes premature cell senescence associated with accumu-
lation of p53 and p16INK4a. Cell 88:593–602.
36. Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: positive and negative
regulators of G1-phase progression. Genes Dev. 13:1501–1512.
37. Shin, I., F. M. Yakes, F. Rojo, N. Y. Shin, A. V. Bakin, J. Baselga, and C. L.
Arteaga. 2002. PKB/Akt mediates cell-cycle progression by phosphorylation
of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat.
Med. 8:1145–1152.
38. Stacey, D., and A. Kazlauskas. 2002. Regulation of Ras signaling by the cell
cycle. Curr. Opin. Genet. Dev. 12:44–46.
39. Taylor, C. C. 2000. Platelet-derived growth factor activates porcine thecal
cell PI3K-Akt/PKB and Ras-extracellular signal-regulated kinase-1/2 kinase
signaling pathways via the platelet-derived growth factor- receptor. Endo-
crinology 141:1545–1553.
40. Uckun, F. M., R. K. Narla, T. Zeren, Y. Yanishevski, D. E. Myers, B.
Waurzyniak, O. Ek, E. Schneider, Y. Messinger, L. M. Chelstrom, R.
Gunther, and W. Evans. 1998. In vivo toxicity, pharmacokinetics, and anti-
cancer activity of Genistein linked to recombinant human epidermal growth
factor. Clin. Cancer Res. 4:1125–1134.
41. Van Weeren, P. C., K. M. de Bruyn, A. M. de Vries-Smits, J. van Lint, and
B. M. Burgering. 1998. Essential role for protein kinase B (PKB) in insulin-
induced glycogen synthase kinase 3 inactivation. Characterization of domi-
nant-negative mutant of PKB. J. Biol. Chem. 273:13150–13156.
42. Vlach, J., S. Hennecke, K. Alevizopoulos, D. Conti, and B. Amati. 1996.
Growth arrest by the CDK inhibitor p27Kip1 is abrogated by c-Myc. EMBO
J. 15:6595–6604.
43. Yeh, E., M. Cunningham, H. Arnold, D. Chasse, T. Monteith, G. Ivaldi,
W. C. Hahn, P. T. Stukenberg, S. Shenolikar, T. Uchida, C. M. Counter, J. R.
Nevins, A. R. Means, and R. A. Sears. 2004. A signalling pathway controlling
c-Myc degradation that impacts oncogenic transformation of human cells.
Nat. Cell Biol. 6:308–318.
VOL. 26, 2006 LATE-G1 PI3K ACTIVITY STABILIZES c-Myc 9125
 at Centro Nacional de Biotecnología - Biblioteca on April 7, 2009 
m
cb.asm
.org
D
ow
nloaded from
 
